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Vitamin D deficiency is common in individuals diagnosed with HIV and is known for its 
detrimental health effects. Its recognition as a potent immune-modulator with possible 
immune health implications in HIV disease progression was the main impetus for this 
study. The association between Vitamin D and CD4 count falls short of being consistent 
and is too weak to allow conclusions. Similarly, the literature is inconsistent with regard 
to the impact of Vitamin D supplementation on CD4. This observational, retrospective 
chart review study aimed to explore the relationship between Vitamin D deficiency and 
CD4 count/percent, and to evaluate whether changes in Vitamin D levels after 
supplementation corresponds with significant changes in CD4 count/percent in a cohort 
of African American, HIV-infected men who attended an HIV clinic in southeast 
Michigan (N = 70). The conceptual framework was based on the role of Vitamin D in 
regulating the immune responses through Vitamin D nuclear receptors on the CD4 cells. 
It postulated that an increase in Vitamin D level might enhance immune function, 
promote cellular anti-inflammatory state, and decelerate CD4 destruction. Data analysis 
included descriptive statistics, bivariate correlation, logistic and linear regression, t test, 
repeated measures ANOVA, and ANCOVA. Findings of the study did not support the 
hypotheses of significant correlation between Vitamin D and CD4 count (p = 0.458) and 
percent (p = 0.776), or of any impact of supplementation on CD4 count (p = 0.216) and 
percent (p = 0.918). Social change implications include providing health professionals, 
researchers, and policymakers with knowledge to tailor health promotion interventions 
aiming to reduce Vitamin D deficiency in favor of improving the overall health of HIV 
patients, especially high-risk groups such as African American HIV-infected patients.  
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Chapter 1: Introduction to the Study 
Background 
Despite years of invaluable medical advances, and after more than 3 decades 
since the onset of the HIV/AIDS epidemic, HIV infection rates are still on the rise 
without indication of slowing down. Epidemiological trends have shown a quadruple 
increase in the number of people living with HIV from 1990 until the end of 2011, from 8 
million to 34 million infected individuals globally (United Nations Programme on 
HIV/AIDS [UNAIDS], 2012; World Health Organization [WHO], 2011). HIV infection 
affects the lives of 1.1 million individuals in the United States (Centers for Disease 
Control and Prevention [CDC], 2012a). By the end of the year 2009, there were about 
480,000 individual living with AIDS in the United States (CDC, 2012b). The AIDS death 
toll globally reached 1.7 million people in 2011 (WHO, 2011). In the United States, 
AIDS has so far killed more than 600,000 individuals since the beginning of the 
HIV/AIDS epidemic in the 1980s (CDC, 2012a). Even with unceasing advances in the 
field of HIV/AIDS testing, prevention, and management still more than 2.5 million 
individuals worldwide were diagnosed with HIV infection in the year 2011 alone (WHO, 
2011). Nevertheless, the health efforts yielded at least a 20% reduction in the number of 
newly diagnosed HIV cases in 2001 due to the expanding availability and accessibility to 
treatment with antiretroviral therapy (ART) in many parts of the world (UNAIDS, 2012; 
see Table 1). Despite the current medical care and disease prevention achievements, the 
statistics on HIV are still alarming and reveal the need to tackle risk factors that might 
affect high-risk HIV patients and influence their disease course. 
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In the United States, the trends in HIV incidence (new infections) over the recent 
years have been steady at 50,000 cases per year, and the majority of cases are among 
high-risk subpopulations such as in men who have sex with men (MSM), followed by 
young African American adults (CDC, 2012a, 2012b). Between 1991 and 2008, the 
national HIV surveillance data showed that males constituted 75% of the 1.1 million 
people living with HIV, of which 65.7% were MSM (CDC, 2011a). At the other end, 
women accounted for 25% of all AIDS cases in the United States in 2011 and for 20% of 
total HIV incidence in 2010, of which more than 80% were due to heterosexual activity, 
especially among African American women (with a 20 times higher incidence rate as 
compared to other racial groups; CDC, 2012c).  
 
Table 1 
HIV/AIDS Statistics, Global and in the United States 
HIV/AIDS Epidemiological Distribution Estimates 
People living with HIV/AIDS globally 34 million (50% women) 
People living with HIV/AIDS in the U.S. 1.1 million (20-25% women) 
Global AIDS death toll since the epidemic 30 million 
Global AIDS death toll in 2011 1.7 million (25% decrease from 2005 rate 
of 2.3 million deaths) 
Death toll from AIDS in the U.S. from 1980s to 
present 
600,000 
Global newly diagnosed HIV cases in 2011  2.5 million (20% lower than 2001) 
Annual newly diagnosed HIV cases in the U.S. 
(steady in recent years) 
50,000  
 
Note. Data for HIV/AIDS epidemiological trends globally and in the United States from UNAIDS 




The national trends in HIV/AIDS show a persistent racial disparity in the related 
mortality and morbidity statistics: More African Americans are affected compared to 
other racial and ethnic groups (AIDS/HIV Program-Wisconsin Department of Health 
Services, 2012). African Americans constitute about 44% of all HIV infected people in 
the United States (CDC, 2012b). Between 2005 and 2008, data from 37 states indicated 
that African Americans accounted for 50.3% of all the HIV cases diagnosed compared to 
whites who accounted for 29.4% of all HIV diagnoses in that period (CDC, 2011b).  
In view of the high burden of HIV worldwide and nationwide, more researchers in 
recent years have evaluated the role of different factors that can influence the course of 
HIV infection, especially those that contribute to HIV disease progression. In this 
context, Vitamin D has been identified in the literature as one of the highly prevalent risk 
factors with potential physiologic and metabolic mechanisms capable of influencing the 
HIV disease process (Viard et al., 2011; Villamor, 2006). Particularly, a deficiency in 
Vitamin D constitutes a major contributing factor for a series of negative health outcomes 
(Giusti, Penco, & Pioli, 2011; Holick, 2004, 2006; Holick & Chen, 2008; Villamor, 
2006). In these last 2 decades, there has been a great undertaking to examine the role of 
Vitamin D deficiency in relation to HIV. Major researchers on HIV-infected individuals 
from the United States (Adeyemi et al., 2011; Crutchley et al., 2012; Dao et al., 2011; 
Egan et al., 2008; Murphy et al., 2012; Overton & Yin, 2011; Rodriguez, Daniels, 
Gunawardene, & Robbins, 2009; Tseng et al., 2009), Africa (Mehta et al., 2010, 2011), 
and Europe (Bang et al., 2010; Mueller et al., 2010; Van Den Bout-Van Den Beukel et 
al., 2008; Viard et al., 2011) have indicated that Vitamin D deficiency was more 
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prominent among HIV populations and ranged from a prevalence of 45% to 87% as 
compared to the general population. More importantly, several studies and meta-analyses 
on HIV patients have also concluded that Vitamin D deficiency could be a key culprit 
associated with faster occurrence of poor health outcomes (e.g., opportunistic infections, 
chronic diseases, or multiple organ systems complications) and higher susceptibility for 
HIV disease progression towards AIDS or death (Campbell & Spector, 2012; Dao et al., 
2011; Giusti et al., 2011; Griffin & Arnold, 2012; Mehta et al., 2011; 2010; Spector, 
2011; Sudfeld et al., 2012; Vescini et al., 2011; Viard et al., 2011; Villamor, 2006).  
Based on the aforementioned research, there has been a growing interest recently 
for exploring the mechanism through which Vitamin D influences the course of HIV 
infection (Overton & Yin, 2011). Since Vitamin D is quite well known for its classical 
role in calcium absorption and bone metabolism, most published studies on Vitamin D 
and HIV have focused on its associations with bone diseases (e.g., osteoporosis, 
osteomalacia, and osteopenia) or with HIV metabolic complications (Adams & Hewison, 
2010; Villamor, 2006). However, the mere discovery of the presence of Vitamin D 
receptors (VDRs) in many tissues throughout the body and in the immune cells (e.g., T 
lymphocytes, macrophages, and dendritic cells) initiated a series of studies about the 
physiological mechanism through which Vitamin D could exert its modulatory effects on 
the immune system. Initially, these studies focused on Vitamin D in relation to 
tuberculosis, respiratory infections, autoimmune diseases, some diarrheal diseases, and 
thereafter to HIV (Holick, 2007; Norman, 2012; Villamor, 2006). This discovery 
highlighted a new, nonclassic outlook on Vitamin D and reintroduced it to the scientific 
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platform as an immune modulator capable of influencing and regulating immune 
responses and actions (Hart, Gorman, & Finlay-Jones, 2011; Khoo et al., 2012; Lang, 
Samaras, Samaras, & Aspinall, 2013; Miller & Gallo, 2010; Walker & Modlin, 2009; 
White, 2008). So far, the exact immunologic mechanism has proven to be very complex 
and has not been fully described. In the context of HIV, Vitamin D—besides its anti-
inflammatory and antimicrobial role—is mostly considered for its immune modulator 
effects; it targets immune cells (especially CD4 T lymphocytes), influences their cellular 
differentiation and proliferation, and regulates hormone secretion at the cellular level 
(Giusti et al., 2011; Kamen & Tangpricha, 2010; Spector, 2010). The next sections 
present an overview on Vitamin D and how it influences the immune system in HIV. 
Overview on Vitamin D  
Vitamin D has been misidentified as a vitamin for a long time, but it is in reality a 
steroid hormone (sterol) as per its molecular structure, 1,25-hydroxyVitamin D3 
(Norman, 1998, 2012). There are two types of Vitamin D: D2 and D3 (White, 2008); 
Vitamin D refers to both or either type. Vitamin D2 is synthetic and comes from diet, 
specifically from sun-exposed yeasts or plant sterols (ergosterols) while D3 is 
synthesized in the skin. Both are used in food and vitamin supplements, but D2 is used 
mostly in prescriptions (Holick, 2007). By definition, Vitamin D status can be obtained 
by measuring the blood level of the main circulating metabolite of Vitamin D, 25-
hydroxyVitamin D or 25(OH)D, with normal level set point at 30 ng/μL and above 
(indicating sufficiency), and levels of 20–29 ng/μL and below 20 ng/μL indicating 
Vitamin D insufficiency and deficiency, respectively (Holick, 2003, 2007; Wacker & 
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Holick, 2013). Therefore, for the sake of this study, Vitamin D deficiency was designated 
by 25(OH)D level < 30 ng/μL. 
Exposure to sunlight is responsible for about 90% of Vitamin D synthesis in the 
skin (Holick, 2003; 2004), and the remaining 10% comes from nutrition. It takes 10 to 15 
minutes of whole body sun exposure in the summer to produce and release 10,000 to 
20,000 IU of Vitamin D into blood circulation, providing, therefore, more Vitamin D 
than the nationally recommended Vitamin D dosage of 600 IU per day (Hollis, 2005). 
Holick (as cited in Hollis, 2005, p. 318) argued that excessive sun exposure never leads to 
Vitamin D intoxication because the body naturally adapts and regulates the 
overproduction by inactivating some of the biological precursors of Vitamin D.  
It is hard to self-assess sufficiency in Vitamin D intake because it depends on 
many factors such as age, lifestyle, sunscreen use, clothing, race/skin pigmentation, 
genetics, geographic area and latitude, degree and amount of sunlight exposure (cloud 
coverage or smog), diet, and existing health conditions (Hollis, 2005; Neri, Miller, & 
Potter, 2012; Rosen, 2011). Besides the intensity and quantity of sunlight exposure and 
the influence of seasons and latitude on UVB penetration to the skin (and consequently 
on Vitamin D production), skin color pigment melanin (UVB light filter or blocker), is 
yet a predetermined and irreversible factor that blocks Vitamin D skin synthesis and 
places African Americans at higher risk for Vitamin D deficiency as compared to fair 
skinned people (Egan et al., 2008; Hannan et al., 2008; Holick & Chen, 2008; Murphy et 
al., 2012; Tseng et al., 2009). It is estimated that people with dark skin, such as African 
Americans, need between 10–12 times more UVB light radiation exposure (sunlight) as 
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compared to people with fair skin in order to produce the same amount of Vitamin D 
(Hollis, 2005).  
Dark-skinned people living in highly sunny areas, such as the equator or Africa, 
are less likely to suffer from Vitamin D deficiency because of adequate and extensive sun 
exposure; however, they tend to develop Vitamin D deficiency once they live in a 
northern climate with limited sun exposure (Hollis, 2005). On the other hand, full-body 
exposure to ambient sunlight in northern climates with latitudes above 40 degrees during 
wintertime does not warrant sufficient cutaneous production of Vitamin D (Hollis, 2005; 
Kimlin, 2004). In winter, even in southern geographical areas with high latitude, the 
amount of UVB radiation in sunlight is not adequate to promote skin production of 
Vitamin D (Holick, 2003, 2004, 2007). Overall, at any latitude and under normal 
exposure to sun throughout the year (without Vitamin D supplementation), African 
Americans rarely reach Vitamin D sufficiency and only experience a negligible increase 
in their Vitamin D levels between winter and summer months (Harris, 2006). Hall et al. 
(2010) estimated that African Americans— assuming low sun exposure— need between 
2100 and 3100 IU/day of Vitamin D in all seasons to achieve sufficiency. 
Findings from NHANES surveys between 2001 and 2004 indicated more than 
90% prevalence of Vitamin D insufficiency/deficiency, 25(OH)D < 30 ng/μL, among 
African Americans as compared to other subpopulations; the same surveys also showed 
that the prevalence of insufficiency in the general population (adolescents and adults) 
approached 77% irrespective of race and ethnicity (Ginde, Liu, & Camargo, 2009). 
Beyond the genetic, racial, geographical, and seasonal differences, African Americans 
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tend to have an insufficient intake of foods containing Vitamin D (e.g., milk and dairy 
products, fish, eggs, and fortified orange juice) and below national Vitamin D dietary 
recommendation as shown in national surveys (NHANES) findings, the fact that 
amplifies their risk for Vitamin D deficiency even further as compared to the general 
population (Dawson-Hughes, 2004; Ginde et al., 2009; Harris, 2006; Holick, 2007). 
Moreover, obesity and high body mass index (BMI) that are very common among 
African Americans influence Vitamin D levels; there is an inverse relationship (or 
negative correlation) between BMI and Vitamin D levels, whereby obese people with 
high BMI (greater than 30 or 40 kg/m2) tend to be Vitamin D deficient (Lagunova, 
Porojnicu, Lindberg, Hexeberg, & Moan, 2009). Some researchers have suggested that in 
addition to the socioeconomic factors that contribute to obesity in general, structural 
environmental factors such as the proximity of fast food restaurants to place of residence 
increases further the risk of obesity and high BMI (Reitzel et al., 2013). Such findings 
may complicate the challenge of correcting Vitamin D deficiency in this population and 
the need to rectify nutritional recommendations.  
Several studies have pinpointed serious concerns about the lack of effective, 
nationally targeted, nutritional supplement Vitamin D recommendations for Vitamin D 
(Bischoff-Ferrari, Giovannucci, Willett, Dietrich, & Dawson-Hughes, 2006; Garrett-
Mayer, Wagner, Hollis, Kindy, & Gattoni-Celli, 2012; Holick & Chen, 2008; Hollis 
2005; Vieth et al., 2007); some researchers have argued that the dietary allowance (RDA) 
of 600 IU per day recommended by the Institute of Medicine (IOM, 2011) for Vitamin D 
deficient adults is mediocre and incapable of sufficiently raising Vitamin D level to 
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optimal levels and sustaining it in the blood for a considerable period of time (Bischoff-
Ferrari et al., 2006; Ginde et al., 2009; Hollis, 2005). Consequently, Garrett-Mayer et al. 
(2012) and Hollis (2005) supported the Endocrine Society Clinical Practice Guidelines 
(Holick et al., 2011) that encourage the use of supplementation not less than 4000 IU/day 
to remedy the deficiency epidemic, close the gap in racial disparity, and improve the 
general health of high-risk population groups.  
African Americans with HIV, in every context, are at a greater disadvantage than 
other racial groups; many HIV studies revealed a significant correlation between black 
race and high prevalence of Vitamin D deficiency (Adeyemi et al., 2011; Cervero et al., 
2013; Crutchley et al., 2012; Dao et al., 2011; Mueller et al., 2010; Stein et al., 2011; 
Wasserman & Rubin, 2010; Welz et al., 2010; Yin, 2012). Besides the previously 
discussed non-HIV factors that can contribute to Vitamin D deficiency, there are several 
HIV factors that can alter Vitamin D absorption, activation, or metabolism secondary to 
the course of HIV infection, the coexisting clinical conditions, and to the highly active 
antiretroviral treatment (HAART) side effects (Cozzolino et al., 2003). However, the 
main focus of this study remained on the influence of Vitamin D on the immune function 
as depicted by immune cells (mainly CD4) and viral load.  
Overview on Vitamin D and CD4 Cells in HIV 
CD4 T cells and immune response. CD4 cells are the primary targets of HIV. 
They represent the body’s first defense against pathogens, initiating antimicrobial or 
antiviral responses (Sant & McMichael, 2012). The CD4 cells subdivide or differentiate 
into two major T helper subsets (also known as effector cells responsible for killing 
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pathogens): Th1 and Th2 (BMJ, 2000); they also differentiate into T regulatory cells 
(Tregs), which have a main function to control immune suppression mechanism, mainly 
suppressing T-cell reproduction (Gunville, Mourani, & Ginde, 2013; Hewison, 2010). 
Upon pathogen invasion, Th1 takes over the role of intracellular defense, while Th2 is in 
charge of extracellular defense. Th1 senses foreign antigens on the surface of infected 
cells, instigates CD4 T cellular proliferation, and mounts a vast immune response through 
releasing cytokines, the hormonal messengers that sense danger and mediate immune 
responses upon detection of foreign agents in the body (British Medical Journal, 2000).  
During HIV infection, the viruses go to the lymph nodes where the immune cells 
(mainly CD4 T lymphocytes and B lymphocytes) are programmed to recognize and 
destroy foreign invaders. Once the immune cells are alerted, they activate and reproduce 
rapidly to fight the infection through initiating a cell-mediated defense mechanism, 
secreting cytokines, and later through launching humoral or antibody-mediated immune 
response (i.e., antibodies secretion by B lymphocytes; Kestens, 2005). However, with the 
buildup of viral load, and due to the ever-changing mutation of the genetic make-up and 
structure of the proteins (antigens) on the envelope of the viruses (thus, creating different 
strains), the latter baffle the immune system’s memory, build viral reservoir, and escape 
the antibodies’ counterattack; eventually, this leads to gradual destruction of CD4 cells 
by highly replicating HIV and exhaustive immune activation (Kestens, 2005).  
In HIV infection, immune responses are driven by T helper subsets activities. 
There are two types of immune responses: cell-mediated or humoral/antibody-mediated 
(Kestens, 2005). As part of cell-mediated immune response, Th1 cytokines are 
11 
 
proinflammatory (e.g., interferon, interleukin-2 or IL-2, and tumor necrosis factor-alpha 
or TNF-α), and therefore induce tissue inflammation and activate macrophages (M1) as 
their line of defense to attack microbes (Herbein & Varin, 2010; Kurts, 2008) and get rid 
of intracellular pathogens (viruses) or tumors (Cantorna, Zhu, Froicu, & Wittke, 2004). 
Th1 also fosters the cytotoxic activities of CD8 cells or the natural killers -NK (Fevrier, 
Dorgham, & Rebollo, 2011). Simultaneously, Th1 collaborate with Th17 (another subset 
of CD4 that releases IL-17) to stimulate the release of their proinflammatory cytokines 
(Kurts, 2008).  
In HIV infection, the role of Th17 is not yet fully understood, and understandings 
remain controversial. However, it is believed that Th17 cytokines or interleukin 17 can 
lower the risk for development of opportunistic infections in HIV (Elhed & Unutmaz, 
2010), presumably because of their additional potency against fungi and parasites (Kurts, 
2008), especially in the guts where most HIV replication takes place (Fevrier et al., 
2011). Th17 cytokines seem to get more depleted during HIV infection as compared to 
Th1. Consequently, this deficiency in Th17 CD4 subset contributes to faster disease 
progression through generalized or chronic immune activation of more infected cells, 
which can lead to further depletion of infected and uninfected (naïve) CD4 cells, and to 
increased risk for opportunistic infections (Elhed & Unutmaz, 2010).  
Th2 instigates the activation of B-lymphocytes to release antibodies and therefore 
is responsible for humoral or antibody-mediated immune responses. The Th2 related 
cytokines (e.g., interleukins/ IL 4, 5, and 10) induce macrophages (M2) to promote anti-
inflammatory responses against extracellular invaders (Cantorna et al., 2004; Gunville et 
12 
 
al., 2013), and indirectly counteract the Th1 proinflammatory cellular actions (British 
Medical Journal , 2000; Cantorna, 2011; Cantorna et al., 2004; Herbein & Varin, 2010). 
Since Th1 cytokines have detrimental effects and are more implicated in accelerating 
HIV disease progression (Elhed & Unutmaz, 2010; Kurts, 2008), Th2 cytokines buffer 
their effect and inhibit Th17 differentiation to balance immune response and halt 
autoimmunity. 
The balance between Th1 and Th2 is essential for cellular homeostasis and for 
optimal immune responses to invaders; when such balance is disrupted, some diseases 
can erupt such as allergies and asthma (Th2 driven diseases) or autoimmune diseases 
such as multiple sclerosis and Type 1 diabetes (Th1 and Th17 driven; Cantorna, 2011; 
Cantorna et al., 2004). Of paramount importance, Vitamin D plays an indispensable role 
as an immunomodulator that regulates cytokines production and promotes shifting the 
immune cellular milieu from proinflammatory to anti-inflammatory (Boonstra et al., 
2001; Prietl, Treiber, Pieber, & Amrein, 2013).  
Vitamin D as an immune modulator in HIV. Vitamin D seems to have an 
influence on modulating the immune responses through targeting cytokines expression 
between Th1, Th2, Th17, and Tregs. It is postulated that Vitamin D is in its active 
hormonal form binds to Th1 and Th2, and activates CD4 cells (occasionally leading to 
excessive cellular proliferation). Since all immune cells express Vitamin D receptors 
(VDR) in their nuclei, Vitamin D can influence T helper cells functions and cytokines 
secretions through the VDR. Vitamin D first binds to these VDR and then attaches to 
Vitamin D response elements (VDRE) present on the genes in the nucleus (Bearden, 
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Beard, & Striker, 2011). This represents the vehicle through which Vitamin D activates 
immune cells and exhibits its enzymatic actions to regulate gene transcription (at the 
VDR–VDRE complex) and promote expression of T cell responses (Cantorna, 2011; 
Mathieu & Adorini, 2002). The activation of CD4 T helper cells, in its turn, induces an 
increase in the number of Vitamin D receptors VDR by five times (Kamen & Tangpricha, 
2010; Mahon, Wittke, Weaver, & Cantorna, 2003).  
Vitamin D inhibits the excessive production and action of Th1 and Th17 
cytokines in order to prevent susceptibility for autoimmune diseases; at the same time, it 
indirectly instigates the differentiation of Tregs to decelerate the immune suppression 
action (autoimmunity) and counteract the proinflammatory milieu (Cantorna, 2011; 
Gunville et al., 2013; Hewison, 2010; Prietl et al., 2013). Eventually, suppressing Th1 
cytokines can be translated in less antigen presentation of pathogens and less T-cell 
proliferation and activation. Vitamin D boosts Th2 cytokines expression and proliferation 
to counteract the effects of Th1 cytokines (Boonstra et al., 2001; Gunville et al., 2013; 
Kamen & Tangpricha, 2010; Mathieu & Adorini, 2002). Therefore, a deficiency in 
Vitamin D would allow Th1 to have a stronger control over CD4 T-cell compartment 
(Beard, Bearden, & Striker, 2011; Cantorna et al., 2004). The literature described the 
action of Vitamin D as pulling or skewing the adaptive immune system away from Th1 
and moving towards supporting Th2 responses (Bearden et al., 2011; Mathieu & Adorini, 
2002). 
In brief, Vitamin D has been known for its anti-inflammatory actions since 
discovery; whether in tuberculosis, asthma, or other respiratory and nonrespiratory 
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diseases, Vitamin D has demonstrated its efficacy as an anti-inflammatory agent 
(Gunville et al., 2013). This characteristic has been further emphasized in its potent role 
as immune modulator. Therefore, the presence of Vitamin D on immune target T cells 
that express VDR and the consequent increased number of VDR can present a protective 
effect against infections and diseases (Baeke, Takiishi, Korf, Gysemans, & Mathieu; 
2010c; Kamen & Tangpricha, 2010). Moreover, Vitamin D can provide a protective 
effect against diseases related to the immune system and secure T-cell homeostasis to 
control immune system responses (innate and adaptive) against invading pathogens. A 
deficiency in Vitamin D, and correspondingly in the number of VDR, might disrupt the 
delicate balance of T-helper cell homeostasis and lead to diseases such as autoimmune 
diseases (e.g., multiple sclerosis), diabetes, Type 1 diabetes, asthma, and inflammatory 
bowel disease–IBD (Cantorna, 2011). Since HIV presents a high state of inflammation, 
Vitamin D deficiency in HIV patients can accelerate and promote a proinflammatory 
status; thus, it can be implicated in faster immune suppression and disease progression 
(Villamor, 2006). 
Overview on the Role of Vitamin D in HIV Disease Progression  
The course of HIV infection is depicted by a progressive immune dysfunction and 
a gradual decline in CD4+ lymphocytes, the primary targets of HIV. This decline 
represents the best biomarker of disease severity and progression as it represents the 
hallmark of immune dysfunction (immune aging or weakness) and the failure to adapt 
and respond properly to pathogen invaders (CDC, 2011c; Grossman, Meier-
Schellersheim, Sousa, Victorino, & Paul, 2002; Overton & Yin, 2011). During HIV 
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infection, millions of HIV particles are generated and replaced every day with a very 
short lifespan that ranges from 0.5 to 1.5 hours. These virions, when released into the 
body, attack the CD4 cells and use them to replicate and then destroy billions of them 
daily; luckily, the CD4 daily replacement process ensures that not all CD4 cells get killed 
(Ho, 1995).  
There are different mechanisms that explain HIV disease progression and how the 
decline in CD4 count weakens the immune response and makes the patient immune-
compromised and more openly susceptible to opportunistic infections and comorbidities 
(Grossman et al., 2002; Kestens, 2005; Overton & Yin, 2011). However, these 
mechanisms about CD4 loss are still debatable. Kovacs et al. (2001) and Mohri et al. 
(2001) reinforced the argument presented by Ho (1995) and asserted that the increased 
viral replication and the exaggerated rates of CD4 simultaneous proliferation and 
replacement exhaust the immune system and lead to CD4 loss through apoptosis (cell 
death). More studies have also adopted this argument; the overstimulation of the immune 
system and the excessive activation of CD4 T cells can lead to self-destruction/depletion 
or apoptosis if left uninhibited (Langford, Ananworanich, & Cooper, 2007; Spector, 
2010). In this sense, antiretroviral treatment can be effective in reducing the loss of CD4 
cells through slowing down their excessive division and apoptosis, not through increasing 
their production (Kovacs et al., 2001; Mohri et al., 2001). As a counterargument, some 
researchers refuse this idea of exhausted immune system leading to CD4 loss, and 
suggest that two factors lead to CD4 cell depletion and disease progression: the short 
lifespan of CD4 cells due to virus-induced apoptosis and the infection of CD4 precursor 
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cells that result in production and replacement shortage (Hellerstein et al., 1999; Meyaard 
& Miedema, 1997).  
According to the CDC (2012d), significant reductions in CD4 counts below 200 
cells/μL characterize HIV disease progression. The optimal CD4 count ranges from 500 
to 1500 cells/μL (CDC, 2011c). Accordingly, a patient with a CD4 count below 200 
cells/μL is thought of as immunosuppressed and merits an AIDS diagnosis, regardless of 
clinical symptoms or events development (CDC, 2011c). CD4 count is not only clinically 
considered the best indicator of HIV disease progression and severity, but is also used as 
a marker for when treatment should be initiated (Langford et al.,, 2007). 
Despite the fact that the relationship between Vitamin D and CD4 is not clear-cut 
and has been inconsistent in the literature, findings of the significant effects of Vitamin D 
deficiency on HIV disease progression in some major studies (Mehta et al., 2010; Sudfeld 
et al., 2012; Viard et al., 2011; Villamor, 2006) constituted an impetus to further explore 
and study this relationship. In the same context and as discussed previously, Vitamin D 
modulates the immune system’s main target cell CD4 through the following known 
actions: It influences antigen presentation; regulates immune responses (protective 
effect); intercepts CD4 T lymphocytes excessive proliferation; and counteracts the 
overzealous immune response to infections by promoting Th2 and blocking the induction 
of proinflammatory cytokines (Th1 and Th17). These latter cytokines usually promote 
HIV infection while Vitamin D seeks to diminish the inflammation environment and halt 
tissue destruction (Overton & Yin, 2011).  
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Consequently, in case of sufficiency, Vitamin D is capable of enhancing normal 
immune functioning through producing peptides to combat pathogens and to control 
autophagy (cellular disintegration and degradation) in infected CD4 cells and other 
immune cells such as macrophages. Hence, Vitamin D ultimately affects or delays 
progression through reducing CD4 activation and differentiation, and influencing 
cytokines expression (Spector, 2009). On the contrary, Vitamin D deficiency or 
insufficiency is hypothesized to disrupt the immune function and response and to hasten 
CD4 destruction and disease progression. In fact, there is abundance of research that 
correlated low CD4 counts with Vitamin D deficiency in HIV patients (Haug, Müller, 
Aukrust, & Frøland, 1994; Ross et al., 2011; Stein et al., 2011; Welz et al., 2010). 
Moreover, knowing that CD4 reserves and production are already low due to immune 
dysfunction in HIV, a deficiency in Vitamin D is linked to further reduction in immune 
function, with lower CD4 counts and reduced responsiveness against intracellular 
pathogens (Langford et al., 2007).  
Although I did not discuss the association between Vitamin D deficiency and HIV 
disease progression in this study, I highlighted the relationship between Vitamin D and 
CD4 count and percent in the context of Vitamin D supplementation. Chapter 2 delves 
into the literature that explored low CD4 counts’ association with high prevalence of 
Vitamin D deficiency among HIV patients (irrespective of the causes). Correspondingly, 
I speculated whether there would be any significant improvement in the immunological 
status (measured by CD4 count and CD4 percent) of HIV patients who received Vitamin 
D supplementation. There are limited studies that investigated the importance of Vitamin 
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D supplementation or looked into the impact of supplementation on CD4 as the main or 
proxy parameter for HIV disease severity and progression. 
Statement of the Problem 
Vitamin D deficiency is a global health problem that is often and easily 
overlooked in people’s lives. NHANES statistics between 1988 and 2004 showed that 
25–35% of the U.S. population has Vitamin D deficiency with 25(OH)D level below 20 
ng/μL and up to 25% have sufficient Vitamin D level (> 30 ng/μL); the same surveys also 
showed that 10% of African Americans are sufficient, and up to 77% are Vitamin D 
deficient (Ginde et al., 2009). Interestingly, 100% of the HIV cases surveyed in the 
NHANES for the same period had Vitamin D deficiency (Lake & Adams, 2011). Vitamin 
D deficiency has been associated with many detrimental effects on chronic skeletal and 
nonskeletal diseases, including cancers, cardiovascular diseases, diabetes, and others. On 
the other hand, it is well documented that Vitamin D deficiency is common in patients 
with HIV and that it disproportionately affects more African American HIV patients as 
compared to other racial groups (Adeyemi et al., 2011). Major research on HIV-infected 
individuals (Adeyemi et al., 2011; Crutchley et al., 2012; Dao et al., 2011; Egan et al., 
2008; Mehta et al., 2010; 2011; Murphy et al., 2012; Overton & Yin, 2011; Rodriguez, 
Daniels, Gunawardene, & Robbins, 2009; Tseng et al., 2009; Van Den Bout-Van Den 
Beukel et al., 2008; Viard et al., 2011) have indicated that Vitamin D deficiency is highly 
prevalent among this population; most of this research has also demonstrated that 
Vitamin D deficiency highly correlates with black race.  
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The significant effects of Vitamin D deficiency on HIV disease progression 
constitute the impetus to understand the association between Vitamin D deficiency and 
CD4 count (and percent)—the main clinical parameter that reflects the degree of HIV 
disease progression. In fact, most above-mentioned studies dealt with predictors of 
Vitamin D deficiency and showed high consistency and similar results, although the 
association between Vitamin D deficiency and CD4 count fell short of being consistent or 
too weak to allow conclusions (Giusti et al., 2011; Griffin & Arnold, 2012; Lake & 
Adams, 2011) despite evident links between Vitamin D deficiency and HIV disease 
progression (Bang et al., 2010; Dao et al., 2011; Egger et al., 2002; Fawzi et al., 2005; 
Haug et al., 1998; Hogg et al., 2001; Lake & Adams, 2011; Langford et al., 2007; Mehta 
et al., 2010; 2011; Mueller et al., 2010; Philips & Lundgren, 2006; Rodriguez et al., 2009; 
Van Den Bout-Van Den Beukle et al., 2008; Viard et al., 2011; Villamor, 2006; Welz et 
al., 2010).  
Although Vitamin D is an immunomodulator that targets mainly CD4 T cells, the 
relationship between Vitamin D levels and CD4 count is not clearly established and has 
been less consistent across the many cross-sectional and observational studies. Although 
some researchers reported a significant association between Vitamin D and CD4 count 
(De Luis et al., 2002; Haug et al., 1998; 1994; Stein et al., 2010; Theodorou, Serste, Van 
Gossum, & Dewit, 2014; Teichmann et al., 2003; Villamor, 2006), other researchers 
failed to demonstrate such association (Arpadi et al., 2009; Bang et al., 2010; Crutchley 
et al., 2012; Dao et al., 2011; Mehta et al., 2010, 2011; Van Den Bout-Van Den Beukle et 
al., 2008). Very few researchers have looked at or evaluated the association between 
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Vitamin D deficiency and CD4 as a biomarker of disease severity with special 
consideration to before and after Vitamin D supplementation (De Luis et al., 2002; 
Kakalia et al., 2011; Poowuttikul, Thomas, Hart, & Secord, 2013; Williams et al., 2009). 
In tandem with the recognition that Vitamin D might have an influence on the course and 
outcome of HIV, most of these studies acknowledged the importance of implementing 
cost-effective Vitamin D supplementation routines in treating Vitamin D 
deficient/insufficient HIV patients (as an adjunct to ART) until randomized studies 
provide enough evidence on its protective effect (Mehta et al., 2010, 2011) and until 
appropriate research on optimal dosing becomes available (Kakalia et al., 2011). Despite 
the complex mechanisms that Vitamin D exert on the immune cells, specifically on CD4, 
this study provided additional knowledge about the relationship between Vitamin D and 
CD4 with special focus on the impact of Vitamin D supplementation on CD4 
count/percent in the Vitamin D deficient HIV subpopulation. 
Two main inspiring studies evaluated Vitamin D supplementation in deficient and 
insufficient HIV patients (children with preserved immunologic function or high CD4 
counts to start with) and assessed the impact of supplementation on CD4 count. Despite 
using different dosing in supplementation, both studies concluded that Vitamin D 
supplementation was too low and did not correlate with CD4 count changes (Kakalia et 
al., 2011; Poowuttikul et al., 2013). Therefore, it was interesting to study Vitamin D 
supplementation and its impact on CD4 count/percent among HIV African-American 
adult patients with Vitamin D deficiency and insufficiency and with somehow less 
optimal immune function compared to the studies by Kakalia et al. (2011) and 
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Poowuttikul et al. (2013). Assessing whether Vitamin D supplementation in African 
Americans Vitamin D deficient HIV patients affected their disease process and markers 
(as depicted by changes in CD4 count/percent and viral load) was important, especially 
for clinics or resource-limited settings and in high-risk population, and was worth 
investigating to extend knowledge in the field and to present the groundwork for further 
studies. 
Purpose of the Study 
The immune impact of Vitamin D deficiency and thereafter of Vitamin D 
supplementation in a cohort of HIV patients on CD4 count/percent as a proxy outcome 
reflecting disease progression is understudied and merits investigation. Moreover, the 
relationship between Vitamin D deficiency (independent variable) and CD4 
count/percent (dependent variables) reflecting immune function constitutes another 
reason for undertaking this study. The purpose of this quantitative, observational 
retrospective study was to establish whether or not Vitamin D deficiency was associated 
with CD4 count/percent, and to evaluate whether improvement in Vitamin D levels after 
supplementation with 50,000 IU per week (time frame from baseline to 6 and 12 months) 
corresponded with significant changes in CD4 count/percent (absolute changes pre–post 
for CD4 count/percent and viral load) in a group of African American HIV men on 
HAART who were attending an HIV clinic in southeast Michigan. 
Nature of the Study 
The study design relied on a quantitative approach using retrospective observation 
(chart review). Despite an abundance of possible limitations such as missing or 
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incomplete data, retrospective chart reviews provide cost-effective access to a wealth of 
medical data capable of generating new hypotheses. Data abstractions from medical 
records have been widely used in epidemiological and clinical research, in quality 
assessment and improvement studies, and in inpatient care studies (Gearing, Mian, 
Barber, & Ickowicz, 2006). The study population consisted of all HIV-infected African 
American men (aged 21 years and up) who attended a specialty HIV clinic in an 
underserved community in Southeast Michigan between 2010 and 2014. The same HIV 
physician followed up with all of the study participants.  
All personal identifiers of patients were excluded from the data collection process 
in order to avoid breaching privacy regulations. The HIV specialist who ran the clinic 
helped ensure easier access to all African American patients under his care; he also 
offered some help in the abstraction process, especially verifying all collected data. An 
earlier ballpark estimate indicated that the clinic offered services to more than 200 
African American males with HIV infection. Based on similar studies, one study had a 
sample size of 160 patients (children; Poowuttikul et al., 2013), with only 8 (5%) patients 
with normal Vitamin D level as compared to 71.9% and 23.1% with deficiency and 
insufficiency, respectively. Another study by Kakalia et al. (2011) evaluated only 54 
children with HIV and randomized them into three groups: no supplementation, Vitamin 
D supplementation, and placebo. Kakalia et al. (2011) calculated the sample size needed 
for their study based on mean percent change of CD4 percent (or count) between the 
nonsupplemented group and the supplemented group (with 80% power and α = 0.025) 
and obtained a sample of 54 participants.  
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This study used a standardized electronic database to retrospectively abstract all 
data from medical records. I used SPSS 21 software package database for data storage 
and analysis. A medical record abstraction method retrospectively collected data on the 
following: health history, lifestyle and sociodemographic characteristics, Vitamin D 
status 25-hydroxyVitamin D [25(OH)D] before and after supplementation, BMI, viral 
load, CD4 count/percent, CD8 percent, CD4/CD8 ratio, ART treatment, HIV duration 
since diagnosis, and other clinical HIV related complications or progression to AIDS.  
Vitamin D level was assessed at baseline, and the first measurement recorded in 
the chart marked the initial date of entry into the study. Based on their baseline Vitamin 
D levels, the cohort was divided into two groups: a group of HIV infected African 
American men with Vitamin D levels of less than 30 ng/μL (Vitamin D deficiency cutoff 
point is set at < 30 ng/μL and included insufficiency cutoff point at 21–29 ng/μL) and a 
group of HIV infected African American men with adequate or sufficient levels of 
Vitamin D (≥ 30 ng/μL). Both deficient and nondeficient/sufficient groups underwent 
evaluation of their CD4 count/percent and viral load at baseline in accordance with the 
first Vitamin D level at study initiation. 
The analysis assessed the changes in CD4 count/percent and viral load as major 
HIV immune parameters and biomarkers of disease course, and evaluated the effect of 
supplementation on Vitamin D levels. The outcome measures consisted of calculating the 
absolute change in CD4 count/percent and viral load before and after Vitamin D 
supplementation. The follow-up period consisted of a minimum of 3 months and went up 
to 14 months. Correlation analyses were run between Vitamin D levels and CD4 count 
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and CD4 percent at baseline and at follow-up visits. Comparative analyses from baseline 
to follow-up were conducted using t test, Mann-Whitney U test, paired t test, and 
Wilcoxon signed-rank test, in addition to chi square or Fisher’s exact test. Linear 
regression was used to discern all factors associated with Vitamin D deficiency, and 
Spearman’s rho to check for correlation between Vitamin D and CD4 count/percent. All 
data were analyzed using SPSS.  
Research Questions 
RQ1: Do Vitamin D levels significantly correlate with CD4 count/percent in this 
group of HIV-infected African American adult men? Time frame: 0, 6 months, and 12 
months. 
Null Hypothesis H0: There is no statistically significant correlation between 
Vitamin D levels and CD4 count/percent.   
RQ2 (Quantitative): Does Vitamin D supplementation have a statistically 
significant effect on CD4 count/percent in HIV-infected African American adult men in 
this study? Time frame: 6 and 12 months.  
Null Hypothesis H0: There is no statistically significant difference or change in 
CD4 count/percent after Vitamin D supplementation in HIV-infected African American 
men in this study. 
Conceptual Background/Foundation 
The interaction between Vitamin D deficiency and HIV is complex and 
ambiguous to a certain degree. The HIV literature showed that HIV patients were more 
likely to be Vitamin D deficient as compared to the general population; it also 
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demonstrated how Vitamin D deficiency was more prominent among patients with 
advanced HIV infection or AIDS (Beard et al., 2011; Conesa-Botella et al., 2010; Mehta 
et al., 2010; Mueller et al., 2010; Ross & McComsey, 2012). Over the last 2 decades, 
Vitamin D has been more and more recognized for its involvement in modulating the 
immune system, specifically CD4 T cells as main targets. However, the lack of clear-cut 
consensus on the association between Vitamin D and CD4 count/percent, in addition to 
the lack of consistency in defining cut-off levels for Vitamin D deficiency and the 
associated clinical endpoints, complicated matters even further (Lake & Adams, 2011).  
Since CD4 count/percent are proxy measures of immune functioning, disease 
severity, and disease progression, this study utilized a conceptual framework that was 
based on existing knowledge of the interplay between CD4 and Vitamin D. Due to the 
complexity of Vitamin D cell-mediated mechanisms that entail several immunological, 
genomic, and physiological activities, the conceptual framework for this study offered a 
simpler overview about the overall role of Vitamin D as an immunomodulator of CD4 
cells in HIV that eventually fit the context of the postulated hypotheses and the research 









Figure 1. Theoretical framework about the effects of Vitamin D deficiency on overall 
HIV disease course and the postulated effects of Vitamin D supplementation on CD4. 
 
While 25(OH)D reflects the total amount of Vitamin D available to the body, 
generated from both sun exposure and dietary/supplementary ingestion, 1,25(OH)2D, the 
metabolite of Vitamin D that results from hydroxylation in the liver and kidneys is 
considered the biologically active compound (hormonal form) known for its immune 
modulator effects on both the innate and the adaptive immune system (Kamen & 
Tangpricha, 2010). I will discuss the influence of Vitamin D on the innate and adaptive 
immune systems in detail in Chapter 2. After renal hydroxylation, Vitamin D in its active 
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hormonal form 1,25(OH)2D binds to VDR (nuclear receptor) that are present on most 
body tissues and cells such as, monocytes, stimulated macrophages, dendritic cells, and, 
more importantly, on T and B lymphocytes (Mahon et al., 2003; Norman, 2006; White, 
2008). The bioactive Vitamin D or 1,25(OH)2D directly and indirectly activates CD4 T 
cells and insinuates a five-fold increase in VDR gene expression (Mahon et al., 2003). 
The amplified number of VDR allows Vitamin D to increase its modulating effect on 
CD4 T cells in a way that dictates regulation and expression of a number of genes 
(Mahon et al., 2003). Furthermore, Vitamin D influences the antigen presentation on the 
VDR of T cells and regulates immune response to pathogens by increasing the production 
of cathelicidin antimicrobial peptide (CAMP), the potent antimicrobial that fights 
invaders (Wang et al., 2004). Once Vitamin D attaches to the VDR, it enters the nucleus 
of cells, binds to VDRE on DNA, and starts regulating transcription of genes. It should be 
noted that Vitamin D could control more than 2000 genes (Holick, 2007).  
Although the immune-modulatory effects of Vitamin D are spread across the 
different immune cells types, this study, first and foremost, focused on the known 
influences of Vitamin D on the immune response of activated CD4 T cells in HIV 
infection. The literature noted that low supply and production of Vitamin D could further 
promote and amplify proinflammatory cytokine (e.g., Th1 and Th17) generation and 
action (Lake & Adams, 2011). Since HIV infection depicts a constant inflammatory state 
characterized by a Th1-like response, Vitamin D deficiency is postulated to increase T 
lymphocytes turnover, increase cytokines activities, increase viral replication, distort 
inflammatory milieu, and eventually reduce CD4 counts (Lake & Adams, 2011). 
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Therefore, this study was concerned with the modulating influence of Vitamin D on the 
CD4 cell milieu and immune response. Upon VDR activation of CD4 T cells, Vitamin D 
induces a series of effects such as: responding to antigen (pathogen) presentation on the 
VDR of T cells by increasing the production of CAMP (Wang et al., 2004); intercepting 
T-lymphocytes proliferation and suppressing activation; altering cytokine secretion 
phenotype through inhibiting proinflammatory Th1 and Th17 cytokine production; 
inducing the production of anti-inflammatory cytokines Th2 to reduce inflammatory 
milieu (Kamen & Tangpricha, 2010; Lake & Adams, 2011); and promoting the 
generation of Tregs (Youssef et al., 2011). These Tregs are usually responsible for 
preventing development of autoimmune disorders and graft rejection posttransplantation 
(Baeke et al., 2007), but in HIV, they help circumvent CD4 T cell proliferation (Smolders 
et al., 2009).  
This conceptual framework describes expected repletion of Vitamin D to alter the 
immune and metabolic milieu and improve the main immune parameters in HIV patients, 
specifically CD4 count/percent, in a way that would enhance immune functioning and 
slow progression towards AIDS. Restoration of serum 25(OH)D levels to normal could 
minimize ongoing inflammation and the complications of HIV (and that of ART) and 
could minimize severity of infections and malignancies associated with HIV disease 
course (Lake & Adams, 2011). The framework supported the hypothesis that Vitamin D 
active metabolite is capable of skewing T cells compartment towards anti-inflammatory 
Th2 pathways (Boonstra et al., 2001; Cantorna, 2011), therefore improving CD4 
count/percent restoration and delaying progression towards AIDS. 
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Definitions of Terms 
The following technical terms were defined with the use of the Glossary of 
HIV/AIDS-Related Terms (AIDSinfo, 2011), available online. 
AIDS: Acquired Immunodeficiency Syndrome, a disease of the immune system 
due to HIV; this most advanced stage of HIV infection is characterized by the destruction 
of immune cells called CD4 T lymphocytes, leaving the patient vulnerable to 
opportunistic infections and cancers.  
Antigen: A foreign body such as a pathogen (e.g., bacteria, viruses, and allergens) 
that triggers an immune response. 
Antiretroviral (ARV): A drug that prevents the HIV retrovirus from replication. 
Antiretroviral therapy (ART): also known as highly active retroviral therapy, 
HAART refers to the combination of two or more ARV drugs that stop HIV viral 
replication. 
B lymphocytes: Also called B-cells, are immune cells that produce antibodies (e.g. 
immunoglobulin) to fight infection.  
Cathelicidin: An antimicrobial peptide also known as CAMP produced by 
macrophages and monocytes. It is responsible for killing pathogens and reducing cellular 
inflammation. It also has antiviral properties and can play a role in HIV infection. 
CD4 T lymphocytes: Also called CD4+ T cells, T Helper cells or just T 
lymphocytes. These CD4 cells regulate immune response to fight infection by stimulating 
other immune cells such as macrophages, B cells, and CD8 T lymphocytes. HIV weakens 
the immune system by depleting CD4 cells.   
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CD4 count: Also known as CD4 T lymphocytes count, the biomarker of immune 
function and the strongest predictor of HIV disease progression. Clinicians consider it as 
a decisive factor for starting ART and as a marker of ART effectiveness. 
CD4 percentage: Percentage of white blood cells that are CD4 cells. 
CD8 T lymphocyte: Also called CD8 cell, cytotoxic T lymphocytes, killer T cells. 
These cells identify cells with antigens (e.g., bacteria and viruses) and destroy them.  
Cytokine: Proteins produced by immune cells that act as chemical messengers 
between cells in immune responses (e.g., cytokines are interferon-IFN and interleukin-
IL).  
HIV: Human immunodeficiency virus that causes AIDS.  
HIV disease progression: Advance of HIV disease that can be measured by 
change in CD4 count below 200, and by occurrence of one or more AIDS defining 
illnesses. 
Immune response: The actions of the immune system triggered against foreign 
pathogens. 
Immune system cells: White blood cells (T and B lymphocytes), dendritic cells, 
monocytes, and macrophages. 
Immunomodulator: A natural or synthetic substance (e.g., Vitamin D in this case) 
that influences the immune response by activating, enhancing, or suppressing actions.  
Innate immunity: The immunity that is born with the individual; natural killer 
(NK) cells and toll-like receptors (TLRs) are part of innate immunity.  
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Macrophage: A white blood cell type that ingests foreign bodies, acts as antigen-
presenting cells, and stimulates other immune cells to fight infection. 
Opportunistic infections: Recurrent, severe infections that take advantage to 
attack patients when their immune systems are weak and compromised.  
Viral load: The amount of HIV RNA copies in the blood. ART medications work 
on suppressing viral load to an undetectable level.  
Viral replication: The process of viral multiplication.  
Viremia: The state of viruses in the blood. 
Assumptions 
The literature supported the assumption that the participants have a high 
prevalence of Vitamin D deficiency, especially African American patients. Despite being 
observational and retrospective in nature, this study also assumed that the sample was 
highly representative of HIV male populations in the geographic area, based on close 
interaction and feedback from the HIV specialized physician in the clinic. It was 
important to note here that the majority of patients who presented to the clinic were under 
the Ryan White program umbrella. Based on a quick inquiry at the clinic and on the 
clinician feedback, the study assumed that testing for Vitamin D levels and treating 
deficiency with supplementation was formally initiated at the clinic in 2010. Testing and 
treating for Vitamin D deficiency was mainly based on the clinicians’ astuteness with 
regard to recognizing a high prevalence of Vitamin D deficiency in HIV and in non-HIV 
patients. This study also assumed that the data documentation on Vitamin D levels and 
supplementation was available to a great extent for all HIV patients with Vitamin D 
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deficiency. Eventually, I assumed that correcting for Vitamin D deficiency was essential 
for HIV patients besides being considered a safe and a cost-effective practice capable of 
promoting good health.  
Limitations and Delimitations 
This study was observational and retrospective in nature, a fact that posed some 
inherent methodological limitations related to external and internal validity. The ultimate 
design for this study would have been a randomized controlled trial (RCT), which was 
beyond the scope of this dissertation study due to lack of time and resources to carry out 
a prospective intervention. Furthermore, due to time and cost limits for collecting data of 
qualitative nature, a mixed method approach was not considered feasible for this study. 
Moreover, the study was limited to African American adult men aged 21 and up 
presenting to one clinic in southeast Michigan serving an underserved community. The 
results of this study might not be generalized to other African American men at the 
broader geographical level beyond the clinic or at the state level. Study results should be 
interpreted cautiously and not be generalized to other busy urban settings even though the 
study site’s clinic was considerably busy and caters mostly to African American HIV 
patients because of its location in metropolitan Detroit, Michigan. Being retrospective in 
nature, the accuracy of data with regard to compliance with Vitamin D supplementation 
treatment might not be available. Furthermore, some ART drugs could be considered as 
confounding variables because they might affect Vitamin D deficiency (Giusti et al., 
2011; Mehta et al., 2010; Van Den Bout-Van Den Beukle et al., 2008) and might have 
affected CD4 counts/percent and Vitamin D levels. However, the study could not account 
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for the types of ART due to the longitudinal nature of the study and the complexity of 
collecting such data over time. 
Significance of the Study 
There is a scarcity of research that deals with HIV-positive African Americans, 
despite the fact that they are considered a high-risk group with innate biologic tendency 
for Vitamin D deficiency. Based on the aforementioned literature, there are racial 
disparities that are translated as higher prevalence of Vitamin D deficiency and 
consequent negative HIV outcomes among African Americans as compared to other 
racial groups (Egan et al., 2008; Kim et al., 2012; Murphy et al., 2009; Tseng et al., 
2009). This fact justifies the need to correct Vitamin D status in order to reduce the gap 
and improve health outcomes in this subpopulation. The growing body of evidence in the 
literature about the health benefits of Vitamin D for the population at large suggests that 
adequate Vitamin D supplementation may be even more important for HIV patients as it 
can influence the course of disease with respect to rate of progression and CD4 counts 
(Lake & Adams, 2011; Mueller et al., 2010; Ross & McComsey, 2012; Rustein et al., 
2011). Furthermore, some researchers found that Vitamin D supplementation may protect 
against a myriad of negative health outcomes related to Vitamin D deficiency (e.g., CVD, 
cancers, and autoimmune diseases), including potential protection against opportunistic 
infections (Hossein-Nezhad & Holick, 2012; Lake & Adams, 2011). Some researchers 
reported that correcting Vitamin D deficiency could lead to reduction in viral replication 
(Campbell & Spector, 2012; Conesa-Botella et al., 2010; Mehta et al., 2009, 2010). 
Practically, this study highlighted the prevalence of Vitamin D deficiency in a cohort of 
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African American, HIV-infected patients, but more importantly, it explored whether this 
deficiency correlated with the immune function biomarkers and whether replenishing 
Vitamin D level through supplementation could impact the course of HIV infection 
through affecting changes in the CD4 count/percent and viral load. 
This observational study on Vitamin D supplementation should be looked at as a 
prelude to a RCT. Only RCTs could provide evidence-based results on the potential 
benefits of replenishing Vitamin D levels on HIV outcomes (Lake & Adams, 2011). 
Barbosa et al. (2014) carried out a systematic review about the immunological impact of 
Vitamin D in HIV (besides summarizing its role in osteoporosis). In this review, the 
authors compiled findings from different pertinent studies (RCTs, experimental, and 
observational) in the field of HIV; Barbosa et al. concluded that in view of the health 
benefits of sufficient Vitamin D on the course of HIV disease and on delaying the 
occurrence of chronic diseases, there was a need to expand the research efforts to 
emphasize the potential health gains from supplementation (preferably in large RCTs), 
rather than focusing on the negative implications of Vitamin D deficiency. The 
researchers concluded that Vitamin D supplementation can be viewed as a cost-effective 
and safe method for the general population and for HIV patients in specific who are 
prone for even more pronounced Vitamin D deficiency (Barbosa et al., 2014). Hence, my 
research also investigated whether Vitamin D testing and supplementation for highly-
impacted HIV patients could be considered an important routine clinical practice in the 
course of managing this immunological disease and improving its outcomes, especially as 
far as the immune function of patients is concerned.  
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Based on the controversial results in the literature about the correlation between 
Vitamin D and CD4 (discussed thoroughly in Chapter 2), this research, unlike many 
cross-sectional studies in this topic, looked retrospectively at testing this correlation 
through analyzing longitudinal data on CD4 count/percent and Vitamin D levels 
measured concomitantly at each clinical visit up to 14 months follow-up. Moreover, this 
research performed correlation analysis on CD4 percent (in addition to CD4 count) 
because it has been reported to be a more stable measure than CD4 count (AIDS InfoNet, 
2014). An advantage in this study was that the HIV physician at the study site used a 
uniform Vitamin D supplementation protocol (50,000 IU once per week) on all patients. 
This avoided discrepancy in analyzing Vitamin D results and allowed the observation of 
a possible dose dependent effect. Note that the literature on Vitamin D supplementation 
yielded inconsistent findings with regard to achieving optimal levels, possibly due to the 
use of different supplementation protocols.  
In short, while this study cannot offer evidence-based findings about the impact of 
Vitamin D on CD4, the longitudinal, simultaneous data on both measures (Vitamin D and 
CD4) allowed observation of their relationship and assessment of whether modifying 
Vitamin D levels can have any significant influence on the main immune function 
parameters and in alleviating the course of HIV disease.  
Implications for Social Change 
Vitamin D deficiency is a worldwide epidemic that is linked to many adverse 
health outcomes, including all-cause mortality. The high prevalence of Vitamin D 
deficiency among HIV patients is a red flag that should alarm clinicians about the need to 
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screen for it and correct it. Based on the collected evidence to date, Vitamin D 
supplementation is viewed as a cost-effective, safe, and favorable intervention for the 
general population and for HIV patients in specific who are prone for even more 
pronounced deficiency (Holick, 2007; Pinzone et al., 2013; Prietl et al., 2013; Villamor, 
2006). Replenishing Vitamin D can be viewed as an inexpensive and cost-effective 
therapeutic option that can help delay HIV progression and reduce risks for other 
comorbidities or chronic diseases in patients with HIV (Giusti et al., 2011; Haug et al., 
1998; Mehta et al., 2010). Since HIV incidence and progression rates are still on the rise 
among young adults African Americans as compared to other HIV subpopulations, it is 
imperative to address their needs, not only through prevention efforts to reduce 
transmission and prevent infection, but also through embracing proper medical 
management after HIV diagnosis to slow down progression to AIDS. As a national 
response, the President’s National HIV/AIDS Strategy-NHAS (The White House, 2010) 
has set an action plan to eliminate racial and ethnic health disparities in HIV morbidity 
and mortality. The strategy seeks to eliminate barriers to early HIV diagnosis and to 
increase access to HIV treatment in order to improve survival and HIV-related health 
outcomes among all HIV patients with special focus on high-risk and minority groups 
(e.g., African Americans).  
The health literature offers a plethora of research that shows the protective and 
positive health effects of Vitamin D on a wide array of chronic diseases and its effects on 
the immune system (Holick, 2003, 2004; Holick et al., 2011; Hossein-Nezhad & Holick, 
2013; Ross & McComsey, 2012; Rustein et al., 2011). Still, the mechanism through 
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which Vitamin D influences the immune system is very complex and needs further 
investigation as the field of immunology and HIV are both ever expanding. The risk 
reduction and preventive properties of Vitamin D (or Vitamin D supplementation) against 
major chronic diseases, including HIV, have earned Vitamin D a worldwide reputation 
beyond bone health; however, reputation remains founded largely on speculation if 
researchers do not conduct further studies.  
Addressing Vitamin D deficiency should be observed from the public health 
perspective of improving the overall health of HIV patients (Giusti et al., 2011; Hossein-
Nezhad & Holick, 2013) and offering an opportunity to close the racial disparity gap in 
HIV-related morbidity and mortality. Furthermore, in this study, I sought to promote 
public health efforts that highlight the health hazards of Vitamin D deficiency, a very 
common yet overlooked global health problem, through addressing and informing the 
general public, the patients, the health workers, the policy makers, and the clinicians 
about the importance of screening for Vitamin D deficiency and the potential benefits of 
correcting it. Yet, Vitamin D supplementation and impact on immune health in HIV 
remains understudied; there is a need to undertake large clinical and epidemiological 
studies to elucidate the overall immunological effects of Vitamin D. One of this study’s 
contribution to the published research in the field of HIV is to emphasize the importance 
of modifying Vitamin D deficiency, a simple parameter which has the ability to influence 
the immune function in HIV patients and is hypothesized to have a potential positive 
impact in alleviating the course of HIV if properly managed and corrected.  
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Finally, in this current research, I did not seek to resolve the controversy of 
Vitamin D supplementation impact on CD4 count/percent; rather it explored the possible 
benefits of supplementation for the immune system with respect to HIV (Mehta et al., 
2009; Ross & McComsey, 2012; Rustein et al., 2011). It also aimed to elucidate and 
challenge a less corroborated hypothesis about a possible correlation between Vitamin D 
and immune health in a disease that was primarily immunological in nature. This study 
explored whether Vitamin D deficiency is an influential or detrimental risk factor in HIV 
and sets the field for further research to verify the correlation between Vitamin D and 
CD4 count/percent. This study could bring about positive social change by providing 
public health professionals and HIV patients with the necessary knowledge to understand 
Vitamin D deficiency and its related health hazards in HIV, and by empowering them to 
use this knowledge to diminish the burden of HIV disease. The positive social change 
would not be complete without extending the knowledge to clinicians and policymakers 
to engage them in evaluating their medical decisions and their health legislations in the 
favor of their communities.    
Summary 
This chapter provided some background knowledge about the prevalence of 
Vitamin D deficiency in HIV-infected patients and its overall health consequences. It also 
discussed the immunomodulating effects of Vitamin D on the main target immune cells 
in HIV, the CD4 cells, and proposed a conceptual framework about the physiological 
mechanisms of Vitamin D exerted mainly on CD4 cells. The chapter highlighted the 
postulated beneficial role of Vitamin D in delaying HIV disease progression and reducing 
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mortality in HIV (Mehta et al., 2010; Viard et al., 2011). The discrepancies in the 
literature about the correlation between Vitamin D as an immune modulator and CD4 
count/percent instigated the need to further investigate this issue and partly justified the 
need to conduct this study. Moreover, the shortage of studies on Vitamin D 
supplementation and its assumed benefits on the immune system in HIV further elicited 
the interest to explore the impact of supplementation on CD4 count/percent in HIV 
patients. Chapter 2 discusses the published literature in detail, and Chapter 3 goes over 
the methodology chosen for this research study.  
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Chapter 2: Literature Review 
Introduction 
In view of the gray area in research with regard to the nature of the association 
between CD4 count/percent, the main immune function parameter, and Vitamin D, there 
is a need to cover the topic extensively. This chapter examines the factors that lead to 
Vitamin D deficiency, followed by a review of Vitamin D deficiency and its health 
implications on the immune system and overall disease course in patients with HIV. 
There is special emphasis on covering the relationship between Vitamin D and CD4 and 
the extrapolated impact of deficiency on CD4 count/percent as a proxy measure of 
immune function. Finally, the literature review examines the role and impact of Vitamin 
D supplementation on CD4 count/percent through reviewing the most pertinent results of 
different studies in the field. A review of the effects of Vitamin D deficiency on HIV 
disease course was already discussed in Chapter 1, but I will revisited it in this chapter. 
Moreover, I explore some of the factors that influence both Vitamin D deficiency and 
CD4. Due to the scientific nature of the topic, the review of the literature exposed many 
conflicting results available to date, but it also highlighted the importance of undertaking 
more studies to add to the existing knowledge in the field. 
Search Strategy 
The literature search has identified related studies that are published in the last 10 
years but with more emphasis on new research publications in the last 5 years between 
2009 and 2015. I included some studies that dated back more than 10 years because they 
contained knowledge that is still pertinent to the field today. The search strategy 
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consisted of checking several online databases from Walden University library and other 
academic online libraries in addition to using Google Scholar. I also browsed peer-
reviewed articles from specialized journals of relevance in the field of HIV/AIDS or 
infectious diseases. I also searched the ProQuest Dissertations and Theses database and 
databases with systematic reviews or meta-analyses such as Cochrane to identify similar, 
related, or relevant studies without any limits to patients’ age, gender, ethnicity/race, 
language, or setting.  
Eventually, I obtained the selected articles for this review from the following 
databases: Medline/Pubmed, Academic Search Premier, CINAHL, Cochrane, Psychinfo, 
and others. The main search terms or keywords used in the searches query were: HIV 
and/or AIDS, human immunodeficiency virus, disease progession, CD4, CD4+ T cells, T 
lymphocytes, CD4 count, CD4 percent, Vitamin D, 25(OH)D, Vitamin D deficiency, 
Vitamin D supplementation, and immune system.  
I searched some specific journals that publish articles in the field of HIV/AIDS 
using the same queries to ensure no relevant articles were missed by the search strategy. 
Websites related to HIV/AIDS, the CDC, and the World Health Organization (WHO) 
were also searched for relevant information and statistics. Moreover, I undertook careful 
examination of reference lists from review articles and from all of the primary articles to 
further identify relevant articles. I screened abstracts and articles for relevance and 
irrelevance, and articles that did not account for Vitamin D and CD4 or were not related 
to HIV population were excluded. For a more inclusive literature review, I selected the 
most frequently cited articles and some of the classical articles still considered of 
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particular relevance to the topic even if they were published more than 10 years ago. The 
literature review included studies that assessed and reported levels of Vitamin D as 
25(OH)D. All quantitative study designs were eligible for this review, experimental and 
nonexperimental. The majority of the studies on this topic were observational in nature 
such as retrospective chart review, cross-sectional, prospective cohort studies, and case-
control studies; there were few RCTs.  
Vitamin D: Definition and Function 
Vitamin D or the “sunshine vitamin” (Wacker & Holick, 2013) a steroid hormone 
that has far reaching effects on general health. Historically, Vitamin D gained recognition 
at the dawn of the British Industrial Revolution in the 1700s, specifically upon the 
manifestation of excessive incidences of rickets, a debilitating bone and skeletal 
deformities in children accompanied often with mental growth retardation; that condition 
exposed the presence of an epidemic of Vitamin D deficiency (Holick, 2003; National 
Academy of Sciences, 2000). It was not until the 19th century that scientists discovered 
that moderate exposure to UVB rays through sunlight or irradiation using a special 
mercury arc lamp and fortifying milk with Vitamin D actually prevented rickets rather 
than eradicated it (Holick, 2003; Holick & Chen, 2008; National Academy of Sciences, 
2000). Later, in 1903, the discovery that increased Vitamin D production from exposure 
to UV light could cure a cutaneous form of tuberculosis (called lupus vulgaris) earned 
Niels Finsen the third Nobel Prize in Medicine (Moller, Kongshoj, Philipsen, Thomsen, 
& Wulf, 2005; Wacker & Holick, 2013).  
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Vitamin D has been linked to bone health and has been known to be responsible 
for enhancing calcium absorption through the intestines and bones (i.e., regulates calcium 
metabolism in accordance with parathyroid gland hormone; Holick, 2007; Holick & 
Chen, 2008; Kamen & Tangpricha, 2010). However, from the 1980s on, Vitamin D has 
been gaining more recognition for its nonclassical, rather noncalcemic roles, especially in 
the immune system, due to a major scientific finding in 1975. That specific year unveiled 
the discovery of VDR that bind Vitamin D to the nucleus of various body cells (Deluca & 
Cantorna, 2001; Kamen & Tangpricha, 2010). Far from immunology in infectious 
diseases, rather in a cancer research context, a Japanese researcher found that adding the 
hormonal active form of Vitamin D to immature leukemia cells with VDR stopped their 
growth by inducing cellular differentiation, maturation, and ultimately cellular death 
(National Academy of Science, 2000); this discovery was a crucial moment in cancer 
prevention research that led to further research on the genomic nature of Vitamin D 
actions since the nuclear VDR is involved in gene transcription and in the ability to 
modulate immune responses in most body cells/tissues (Deluca & Cantorna, 2001). 
Moreover, VDR are present on more than 800 genes (Williams et al., 2009); others claim 
that Vitamin D receptors regulate more than 2000 genes (Wacker & Holick, 2011).  
Eventually, VDRs were found in almost all body tissues and cells, such as, 
immune cells T and B lymphocytes, macrophages, brain, adipose tissues, bone marrow, 
and cancer cells (Holick, 2007; Holick & Chen, 2008). This in fact put Vitamin D under 
the spotlight and instigated more research to explore the physiologic and metabolic 
implications of Vitamin D in many acute and chronic diseases, including skeletal and 
44 
 
nonskeletal diseases, autoimmune diseases, some types of cancer, cardiovascular 
diseases, infectious diseases, and HIV (Holick, 2007; Norman, 2012; Villamor, 2006; 
Wacker & Holick, 2013). Figure 2 shows the different roles and contributions of Vitamin 
D to human health as adapted from Norman (2012).  
Vitamin D Metabolism  
Most of Vitamin D production or synthesis occurs in the skin upon exposure to 
sunlight (UVB rays); in fact, exposure to sunlight is responsible for about 90% of 
Vitamin D synthesis (Holick, 2003) and the rest comes from nutritional intake. There are 
several factors that can influence the amount of Vitamin D production such as: the 
quantity and quality of UVB radiation, the season of the year, the geographical latitude, 
the concentration of melanin in the skin, older age, BMI, and the use of sunscreen 
(Holick & Chen, 2008). The topical application of a sunscreen with a 30 sun protection 
factor is capable of blocking most UVB radiation and of reducing the skin synthesis of 
Vitamin D by more than 95%, according to a study by Matsuoka et al. (1987). Melanin, 
the skin color pigment, acts as a UVB light filter that blocks Vitamin D3 synthesis, and 
therefore places dark skinned people such as African Americans at higher risk for 
Vitamin D deficiency as compared to fair skinned people (Hannan et al., 2008; Holick & 






Figure 2. From “The history of the discovery of Vitamin D and its daughter steroid 
hormone,” by A. W. Norman, 2012, Annals of Nutrition and Metabolism, 61, p. 204 
 
Furthermore, sun exposure for most of the winter is not adequate for Vitamin D 
synthesis (Holick et al., 2011), especially in northern cold climates because the sun is too 
low in the sky (Mathieu & Van Der Schueren, 2011). On the other hand, exposing the 
whole body or parts of it to sunlight (for a short period of time 2–3 times weekly) and the 
occurrence of mild pinkish skin coloration (minimal erythemal dose [MED]) 24 hours 
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later is equivalent to Vitamin D2 supplement intake of 10,000 to 25,000 IU (Holick, 
2007; Holick et al., 2011; Holick & Chen, 2008; Wacker & Holick, 2011). However, 
although it is a tempting idea to produce Vitamin D from sun exposure (at least face and 
hand) for half an hour every day (Mathieu & Van Der Schueren, 2011), this also comes at 
a price because the UVB wavelength needed for Vitamin D production is the same as the 
one causing nonmelanoma skin cancer and skin aging (Reichrath, 2009). Based on 
thorough review of many cancer studies and UV radiation in relation to Vitamin D 
deficiency, Reichrath (2009) recommended sun protection and Vitamin D 
supplementation as a safe method to prevent Vitamin D deficiency and yet to protect 
against different types of cancers that may result from mutagenic solar UV-exposure. 
Holick (2007) reported that tanning beds discharge up to 6% of UVB radiation and can 
be used as a source of Vitamin D3 to prevent deficiency, provided it is used in 
moderation; tanning is especially recommended for people with fat or Vitamin D 
malabsorption.    
Vitamin D, whether ingested or photosynthesized in the skin, is stored in fat cells 
and gets released and transported to the blood circulation via Vitamin D- binding protein 
(DBP; Holick, 2007). When UVB rays mediate the photochemical conversion of 7-
dehydroxycholesterol in the skin, it converts it into pre-Vitamin D3 or 1,25-
hydroxyVitamin D3 (1,25(OH)2D3) and later into Vitamin D3 (Holick, 2007; Kulie, 
Groff, Redmer, Hounshell, & Schrager, 2009). The lymphatic system transports the 
resultant Vitamin D3 into the circulation where it gets metabolized in the liver 
(hydroxylation) to produce 25-hydroxyVitamin D [25(OH)D], the main circulating form 
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of Vitamin D that is used clinically to measure Vitamin D status (Holick, 2007; Villamor, 
2006). This 25(OH)D form of Vitamin D is considered biologically inactive until further 
hydroxylation and metabolizing in the kidneys (Deluca & Cantorna, 2001; Holick, 2007). 
However, the cumulative amount of 25(OH)D in the blood is very important because it 
will decide the amount of active form of Vitamin D available for multiple physiological 
functions (Kamen & Tangpricha, 2010).  
The inactive 25(OH)D liver metabolite undergoes the second hydroxylation in the 
kidneys; it attaches to DBP and is carried to the kidneys where it is further metabolized 
through the enzyme 1-alpha-hydroxylase (1α-Oase) to produce 1,25(OH)2D, the active 
hormonal form of Vitamin D. This renal metabolite of Vitamin D (1,25(OH)2D) enters 
target cells and binds to corresponding VDR in the small intestines, kidneys, and bone 
tissues to stimulate calcium absorption, and to exert other physiological effects (Holick, 
2007). Any deactivation of this enzymatic conversion through the kidneys will lead to 
Vitamin D deficiency (Norman, 2012; Villamor, 2006). On the other hand, 1,25(OH)2D 
is also responsible for many cellular actions such as regulating hormone secretion and 
immune function, and affecting cellular growth, proliferation and differentiation in 
musculoskeletal and extraskeletal tissues (Giusti et al., 2011; Holick, 2007; Norman, 
1998, 2012).  
More importantly, the discovery of the presence of the enzyme 1-alpha-
hydroxylase (CYP27B1) in many cells (e.g., immune cells) outside the kidney was 
considered another major scientific breakthrough in the field because it indicated that 
these cells possessed their own enzymatic machinery to produce their own hormonal 
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form of Vitamin D (1,25(OH)2D) or calcitriol (Holick, 2007). In other words, this implies 
that Vitamin D acts not only through endocrine (kidney-related) pathways but also 
through autocrine (intracellular and nonrenal) pathways to exert biological reactions; the 
latter enhance its ability to fight infectious diseases (Holick, 2006, 2007; Kamen & 
Tangpricha, 2010; Lappe, 2011). The ability of the immune cells to produce their own 
hormonal Vitamin D and then its binding to the VDRs would serve as an important 
pathway for a series of immune modulating actions, including gene transcription and 
cellular proliferation (Williams et al., 2009). In this context, serum Vitamin D deficiency 
would translate into reduced availability for cells and tissues to run enzymatic process 
(hydroxylation) and produce their own hormonal Vitamin D; ultimately, this would 
reduce the body ability to fight infection and to increased autoimmunity (Aranow, 2011). 
Vitamin D Deficiency and Its General Health Implications 
The evaluation of Vitamin D status has been based on the serum level of 
25(OH)D, the main circulating metabolite of Vitamin D (Adeyemi et al., 2011; Holick; 
2007; White, 2008). Vitamin D in its inactive form, 25(OH)D, has little metabolic 
activity but has high affinity for Vitamin D binding protein (DBP); that explains its 
relatively long half-life of 2 weeks in the bloodstream as compared to a very short half-
life for active 1,25(OH)2D that is present in very little amount in the blood and therefore 
cannot be used as a biomarker of Vitamin D adequacy (Jones, 2008). The production of 
1,25(OH)2D is greatly influenced by serum levels of other hormones or ions such as PTH 
(parathyroid hormone), calcium, and phosphorus (Monk & Bushinsky, 2011). It is known 
that 1,25(OH)2D inhibits PTH secretion; therefore, elevated levels of PTH indicate 
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Vitamin D insufficiency or deficiency. As a result, Vitamin D supplementation will 
indirectly lead to reduction in PTH levels (Monk & Bushinsky, 2011).  
As mentioned before and for the purpose of this study, severe Vitamin D 
deficiency, deficiency, and insufficiency status were considered in combination and 
referred to 25(OH)D levels below 30 ng/μL. A normal or sufficient Vitamin D level is 
any 25(OH)D value equal or more than 30 ng/μL (Holick, 2006, 2007). Vitamin D 
deficiency has been implicated in a series of morbidities such as bone diseases (Childs et 
al., 2012; Holick, 2003, 2007; Yin, 2012), cardiovascular diseases (Baz-Hecht & 
Goldfine, 2010; Holick, 2004; Lavie, Lee, & Milani, 2011), autoimmune diseases 
(Antico, Tampoia, Tozzoli, & Bizzaro, 2012), some types of cancers such as breast, 
prostate, and colon (Holick, 2004, 2007; Spina et al., 2006), diabetes (Baz-Hecht & 
Goldfine, 2010), tuberculosis (Campbell & Spector, 2012; Kibirige, Mutebi, Ssekitoleko, 
Worodria, & Mayanja-Kizza, 2013), hypertension (Judd, Nanes, Ziegler, Wilson, & 
Tangpricha, 2008), end-stage renal disease (Lavie, Lee, & Milani, 2011; Williams et al., 
2009), depression (Ganji, Milone, Cody, McCarthy, & Wang, 2010), impaired lipid 
metabolism (Maki et al., 2009), and impaired immune and neurocognitive functions 
(Buell & Dawson-Hughes, 2008; Nimitphong & Holick, 2011). Even in utero, maternal 
Vitamin D deficiency can lead to fetal growth retardation and bone deformities with 
higher risk of fractures in the future (Holick, 2007; Wacker & Holick, 2013). In HIV, 
Vitamin D deficiency has not only been implicated in disease progression, it also affects 
the risk for HIV acquisition, as De La Torre et al. (2008) found in a recent study in HIV-
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infected and noninfected drug users. The following sections discuss in detail the natural 
history of HIV and the role of Vitamin D as an immunomodulator in HIV. 
Natural History of HIV  
HIV refers to the retrovirus that attacks the immune cells (T and B lymphocytes) 
and damages them; AIDS refers to the advanced or progressed stage of HIV infection 
characterized by a severely weakened or compromised immune system (WHO, 2006). 
HIV is a retrovirus that belongs to the family of lentiviruses (slow viruses) that are 
characterized by a long latency period from time of infection to appearance of symptoms 
(National Institute of Health/National Institute of Allergy and Infectious Diseases- 
NIH/NIAID, 2012). Each HIV spherical viral particle (called virion) has an outer 
envelope layer or membrane made up of lipids with 72 spikes representing embedded 
proteins (glycoproteins or gp120 and gp41). The particle has a core (capsid) that mainly 
contains two strands of the HIV genetic material ribonucleic acid (RNA), along with 
three types of enzymes necessary for viral replication: reverse transcriptase, integrase, 
and protease (NIH/NIAID, 2012), hence exits different types of antiretroviral medications 
that work at the different levels of viral replication. 
The natural course of HIV is depicted by a continuous and gradual damage to the 
immune system from time of infection (acute infection), to clinical latency 
(asymptomatic or chronic HIV infection), and until the manifestation of AIDS symptoms 
(marking progression). After transmission, the life cycle of HIV begins when the virus 
enters the human body and attaches itself through its viral envelope spikes of gp120 to 
the cell membrane of immune cells, specifically to a type of white blood cells called T-
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helper cells – also known as T lymphocytes or CD4 (Barlett, 2010). Within weeks and up 
to six months post viral transmission, acute HIV infection or seroconversion takes place; 
most patients are not symptomatic at this stage but the virus has already started invading 
the lymphoid tissue (the main reservoir), disrupting the physical structure of the lymph 
nodes and entering into the blood stream to attack CD4 T lymphocytes (Barlett, 2010). 
The CD4 cells are responsible for fighting and destroying infected cells and germs 
throughout the body, and for initiating antiviral responses against viruses that are 
acquired through infection (or through vaccination) (Sant & McMichael, 2012).  
Once attached to CD4, the HIV virus releases its content (the viral RNA and the 
enzymes) inside the CD4 cell and starts the damaging process to the immune system 
through viral replication and enzymatic processes (NIH/NIAID, 2012). For instance, the 
reverse transcriptase enzyme induces reverse transcription of viral RNA into viral DNA 
to make copies of the viral RNA (viral load buildup) but often makes random errors with 
copying, the fact that results in new strains of HIV that replicate at different rates and 
confuse the immune system. The integrase enzyme incorporates this viral DNA into the 
infected CD4 DNA (NIH/NIAID, 2012), thus, marking the seroconversion stage and 
clinical latency. 
Upon seroconversion, the patients move to the second phase, called the clinical 
latency, whereby they do not witness symptoms but have chronic HIV infection with 
viral reproduction. This stage portrays a massive systemic immune response 
characterized by high T-cell activation and turnover (viral replication and viral antigens 
expression on the CD4) that cause a simultaneous excessive stimulation of B 
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lymphocytes (another type of immune cells) to release antibodies (NIH/NIAID, 2012). 
The excessive secretion and circulation of antibodies (immunoglobulins) by highly 
activated B-lymphocytes make the patient even more susceptible for opportunistic 
infections (Barlett, 2010). The immune system tries to maintain cellular balance as the 
CD8 T-killer cells lower the HIV viral load, the B-lymphocytes produce more antibodies, 
and the CD4 counts experience some rebound replacement and remain stable 
(NIH/NIAID, 2012). Antiviral treatment with HAART at this stage becomes an urgent 
necessity to partly restore immunity and reduce risk for opportunistic infections (Barlett, 
2010). 
A high viral load (high HIV RNA level) detected in the blood usually correlates 
with higher CD4 destruction (low CD4 counts) accompanied with a higher chance for 
disease progression- if patients lack appropriate immune responses to control the 
infection or do not get treatment on time (Barlett, 2010). Giorgi et al. (2002) found that 
viral load early in the course of infection can be predictive of progression to AIDS and 
that CD4 count has more prognostic value later in the course.  
At this stage, CD4 lymphocytes continue to multiply to combat the infection; they 
are at the same time making more copies of HIV (viral replication). HIV protease enzyme 
plays an important role in helping the newly formed HIV viruses inside the CD4 nucleus 
to cleave or bud out from the cell surface using the CD4 cell machinery. The budding 
process can kill or destroy the infected CD4 cells and the released viruses proceed to 
infect more CD4 cells. The released copies of HIV spread throughout the body, they may 
hide and lie dormant away from the immune system, usually within the genome or DNA 
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of the infected cells (constituting latent reservoir for the HIV viruses) (NIH/NIAID, 
2012). 
Most of the time, when the CD4 cell machinery gets too beaten with HIV 
replication, CD4 can undergo apoptosis or programmed cell death. At some point, HIV 
may kill bystander-uninfected cells at a rapid pace (Spector, 2011) because the killer T 
cells –called CD8 (or memory cytotoxic T-cells) get activated and destroy these 
bystander lymphocytes due to the resemblance of some molecules on the CD4 cells (viral 
antigens expression) to the envelope proteins of HIV (NIH/NIAID, 2012). On the other 
hand, Spector (2011) emphasized the role played by the HIV virus in down-regulating 
autophagy in infected macrophages and CD4 cells in tandem with the process of 
apoptosis. His work showed that the virus does not only destroy the macrophages and the 
CD4 cells, but reduces both cells’ cellular autophagy function in a way that would allow 
for more viral replication and longer survival of these infected cells as compared to 
uninfected bystander cells. Therefore, some drugs are used to induce autophagy and 
reduce viral replication. In that sense, Spector (2011), Campbell and Spector (2012), and 
Pirotte et al. (2013) suggested that active Vitamin D stimulate autophagy in macrophages, 
and therefore can enhance destruction of intracellular pathogens (i.e. autolysis of 
pathogens including HIV viruses) and reduce HIV viral replication (and ultimately, 
leading to HIV infection inhibition). 
The HIV clinical latency stage is the longest; it can range from one year and up to 
more than 15 years. The probability of progression from HIV infection to AIDS diagnosis 
is estimated to be within 3 years after treatment; otherwise, if left untreated, HIV patients 
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can witness early progression to AIDS within one year of infection (May et al., 2010). 
Despite active replication to build-up viremia, still, patients can remain asymptomatic as 
long as the CD4 cellular destruction is in tandem with CD4 cellular replacement (Barlett, 
2010). Consequently, an infected HIV patient may remain symptom-free for years during 
clinical latency until the immune system defenses start waning (immunosuppression) and 
the CD4 count goes down (NIH/NIAID, 2012) making way for disease progression 
towards AIDS, the last stage of HIV. 
Overview on Vitamin D Deficiency and HIV Disease Progression 
The HIV literature is inundating with studies that linked Vitamin D deficiency to 
HIV severity and disease progression. For instance, a large scale prospective European 
cohort study by Viard et al. (2011) reported a high prevalence of Vitamin D deficiency 
among 83% of HIV patients on ART (N = 2000); similarly, in another major prospective 
study, Mehta et al. (2011) provided a clearer picture on the potential correlation between 
Vitamin D deficiency and HIV disease progression; however, they only studied 
Tanzanian pregnant women with HIV (N = 884) and assessed their Vitamin D levels at 
baseline. All women were put on multivitamin supplementation that excluded Vitamin D 
and were then followed up for a median of 70 months, during which all clinical HIV and 
non-HIV outcomes were recorded. The authors used proportional hazards models to 
calculate risk of HIV disease progression (incidence rate ratios of AIDS related 
outcomes) based on baseline Vitamin D status. Their findings indicated that Vitamin D 
deficiency in these women significantly correlated with HIV disease progression, thus, 
Vitamin D deficiency could be considered a major risk factor in the incidence of HIV-
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related complications and correcting deficiency status would offer a protection against 
these complications and against all-cause mortality. The authors acknowledged the 
importance of implementing cost-effective Vitamin D supplementation routine in treating 
Vitamin D deficient HIV patients once randomized studies provide enough evidence on 
its protective effect (Mehta et al., 2010, 2011).   
Adeyemi et al. (2011) in their large scale study that compared Vitamin D 
deficiency among racially diverse HIV women and HIV uninfected women (total sample 
N = 1778; n (HIV+) = 1268); the authors found a higher prevalence of Vitamin D 
deficiency among HIV infected women (60%) as compared to non-infected HIV women 
and concluded that black race was the most significant and the most robust predictor of 
this deficiency. Adeyemi at al. (2011) also contributed another significant finding that 
high BMI level (more prevalent among AA women) highly correlated with Vitamin D 
deficiency; Egan et al. found a similar result earlier in 2008 whereby they compared non-
HIV infected African American adults to their white counterparts, and BMI was a major 
predictor of Vitamin D deficiency. Similarly to other results in the literature (e.g., Kim et 
al., 2012; Egan et al., 2008; Van Den Bout-Van Den Beukel et al., 2008), they also found 
a high correlation between Vitamin D deficiency and high viral load, low CD4 count, and 
the use of special class of ART medications (non-nucleoside reverse transcriptase 
inhibitor-NNRTI). Only one study by Ormesher et al. (2011) had indicated that as 
compared to a matched cohort of HIV-uninfected African American men from the 
National Health and Nutrition Examination survey, a cohort of HIV-infected African 
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American men significantly exhibited a lower prevalence of Vitamin D deficiency (18 
ng/μL versus 14 ng/μL, p < 0.0001).  
Giusti et al. (2011) carried out a systematic review on Vitamin D deficiency in 
HIV-infected patients, whereby they compared and contrasted heterogeneous results on 
Vitamin D deficiency in HIV patients obtained mainly from 28 cross-sectional 
observational studies done in the United States and in Europe. Nine of these studies 
compared HIV patients to healthy subjects, and three of which used matched controls. 
Only nineteen studies gathered information on Vitamin D supplementation use (9 studies 
reported use that ranged from 2% to 49% among their participants). Due to the 
heterogeneity of the different studies’ participants and to methodological discrepancies, 
the analysis showed inconsistent results and failed to provide a decisive answer on how 
Vitamin D deficiency affects HIV disease course; instead, the systematic review 
indicated various correlations between Vitamin D deficiency and CD4 T cell count (i.e., 
low Vitamin D correlates with low CD4 count), as well as with ART, viral load, and 
duration of HIV infection (Giusti et al., 2011).  
Similarly, a review paper by Childs et al. (2012) identified some major HIV 
parameters that were found in the literature to be associated with Vitamin D deficiency; 
these included: intravenous drug use; length of HIV diagnosis; low CD4 cell count 
(below 200 cells/μL); current use of ART; and HIV RNA level (viral load). Childs et al. 
concluded that despite limited data on supplementation, still, Vitamin D repletion could 




In the era of the revolutionary HIV/AIDS treatment using highly active retroviral 
therapy (HAART or ART), HIV infection stopped being the equivalence of a death 
sentence, especially in the developed countries where treatment is more accessible and 
available to the patients. ART modified the natural course of HIV infection epidemic by 
slowing the process of immunological suppression and deterioration depicted by major 
decline in CD4 counts, hence, halted viral replication and provided faster CD4 recovery 
in treated patients (restoring immune function) (Williams, Lima, & Gouws, 2011). As a 
result, HIV mortality rates diminished in the last decade due to HAART, but remained 
higher when compared to non-HIV population (Harrison, Song, & Zhang, 2010). 
Moreover, survival analysis from different studies showed that HIV patients witnessed a 
remarkable increase in their life expectancies (by more than 20 years) provided they 
started their treatment before HIV infection progressed to AIDS (i.e. CD4 count of less 
than 200 cells/μL) (BMJ, 2011; Harrison et al., 2010; Johnson et al., 2013).  
Furthermore, in tandem with an increase in HIV patients’ life expectancy and a 
decreased mortality secondary to advances in antiretroviral therapy, several studies have 
showed that HIV patients are at a higher risk for prematurely exhibiting serious aging co-
morbidities such as osteoporosis, cardiovascular diseases, obesity, diabetes, 
neurocognitive impairment, autoimmune dysfunctions, inflammatory diseases, renal 
abnormalities, and cancer (Bhavan, Kampalath, & Overton, 2008; Overton & Yin, 2011). 
The risk for the aforementioned morbidities gets amplified when HIV patients suffer 
from Vitamin D deficiency.  
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At the International AIDS Society meeting in July 2013, Hogg et al. (2013) 
declared major strides in the life expectancy of a large cohort of American and Canadian 
HIV patients (N = 22,937; 62% white) diagnosed and treated with antiretroviral between 
2000 and 2007. The researchers highlighted the importance of early treatment with ART 
before any drop of CD4 count below 350 cells/μL. Such approach would ensue a 
considerable increase in the life expectancy of treated HIV patients in a way that 
approximate that of the general population. According to their findings, a typical 20-year-
old HIV patient who started ART with a CD4 count above 350 cells/μL is expected to 
live 68.6 more years as compared to 46.9 more years with ART started at a CD4 count 
below 350 cells/μL. While nonwhites and injection drug users also experienced a rise in 
their life expectancy (ranged between 29.7 to 48.4 years, as per baseline CD4 count at 
start), they were disproportionately more affected and their prognosis lagged behind. In a 
previous study, Hogg et al. (2001), accentuated the importance of CD4 as the most 
significant independent marker of severity and predictor of mortality in HIV; and they 
reported that in a cohort of 1219 patients on ART followed up over a median of 28 
months, starting ART at a CD4 threshold of 200 cells/μL and up reflected lower 
cumulative mortality and better HIV prognosis. 
Such longevity of HIV patients in the era of HAART and the expansive role of 
Vitamin D in regulating hormone secretion, cellular differentiation and proliferation, and 
other immune modulatory functions (besides its role in skeletal health) revealed that the 
consequences of Vitamin D deficiency should not be underestimated and should be 
treated. At the same token, while Vitamin D downplays the immune system (discussed 
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later in details), some HAART medications (e.g., nonnucleoside-reverse transcriptase 
inhibitor –NNRTI) may further reduce Vitamin D level and may exacerbate the effects of 
Vitamin D deficiency on the course of HIV disease (Conesa-Botella et al., 2010; Dao et 
al., 2011; Griffin & Arnold, 2012; Mueller et al., 2010; Rodriguez et al., 2009; Van Den 
Bout-Van Den Beukel et al., 2008; Viard et al., 2011). Examining the effects of some 
HAART medications on Vitamin D was beyond the scope of this study but would only be 
considered under the predictors of Vitamin D deficiency. 
HIV disease progression into AIDS can vary from one patient to another 
depending on the immune responses of the host to HIV replication and on the timing of 
treatment since diagnosis (Langford et al., 2007). Progression can range from rapid (few 
years after infection), to intermediate (70-80% of patients belong to this category and 
present with symptoms within 6-10 years after infection), and late (about 5 percent of 
patients fall in this category and can remain symptom free for over 10 years) (Langford et 
al., 2007). Some HIV patients’ immune system is capable of adjusting (mounting) the 
immune response to HIV antigens in a way that delays disease progression for over a 
decade or two without being on HAART and without manifesting any symptom; these 
patients are identified as long-term nonprogressors (Barlett, 2010; Langford et al., 2007). 
On the other hand, patients with advanced AIDS who present with a very low CD4 count 
below 50 cells/μL have poor prognosis with short survival even if they are receiving 
treatment (Barlett, 2010). In a nutshell, progression mainly depends on the rate of 
depletion of CD4 cell counts (as a cut off marker) and on the emergence of AIDS-related 
events or symptoms.   
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The CDC requires CD4 counts and occurrence of AIDS-related events to classify 
stages of disease progression from HIV to AIDS (CDC, 2012d). The CDC uses three HIV 
infection stages: Stage 1 refers to a CD4+T- lymphocytes count of > 500 cells/μL and the 
lack of AIDS-defining condition; stage 2 is characterized by CD4 count of 200-499 
cells/μL and lack of AIDS events; and stage 3 is the AIDS stage whereby the CD4 count 
is ≤ 200 cells/μL and one or more AIDS defining condition is/are present. The CDC also 
uses a “stage unknown” term when there is lack of information on CD4 counts or AIDS –
related events (CDC, 2012d).  
Since CD4 cells constitute the main target for both HIV and Vitamin D, a 
deficiency in the latter may contribute to a modified immune response that is conducive 
to disease progression. It is important to look into the role of Vitamin D as modulator of 
the immune system and the potential benefits of adjunctive treatments such as Vitamin D 
supplementation that could go hand in hand with HAART to boost the immune 
functioning. Therefore, it is imperative to explain the role of Vitamin D in modulating the 
immune system in the course of HIV infection, with emphasis on its relation to CD4.   
Vitamin D Modulating Effects on Immune Function and in HIV 
It is known that the hormonal Vitamin D (1,25(OH)2D3 or calcitriol) has gained 
great reputation for its role in enhancing innate immunity in diseases such as tuberculosis 
(Aranow, 2012; Campbell & Spector, 2012; Heany, 2008; Wolff, Jones, & Hansen, 2008; 
Yuk et al., 2009). The favorable therapeutic role of Vitamin D in tuberculosis (TB) was 
an eye-opener due to its antiviral and antimicrobial responses (anti-inflammatory) at the 
intracellular level that influenced the course of tuberculosis, as well as some other 
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respiratory infectious diseases (Liu, Stenger, Tang, & Modlin, 2007). Of particular 
interest has been the role of antimicrobial peptide cathelicidin in fighting TB and a broad 
range of bacteria, viruses, and fungi (Kamen & Tangpricha, 2011). Likewise, the effects 
of low Vitamin D on the immune system in HIV started to emerge in the literature in the 
1980s after the major discovery of VDRs in most body tissues and cells, particularly in 
immune cells (Deluca & Cantorna, 2001). Also, the presence of the extra-renal enzyme 1-
alpha hydroxylase (called CYP27B1 enzyme) in immune cells and the subsequent 
synthesis of their own active Vitamin D locally contributed further to the body of 
knowledge (Beard et al., 2011; Holick, 2007). Eventually, VDRs and CYP27B1 in 
immune cells exert their immunomodulatory effects and give Vitamin D its reputation as 
a potent immune-modulator.  
The presence of VDR (Vitamin D receptors) in immune cells is one of the most 
plausible physiological mechanisms of how Vitamin D influences pathogens’ antigen 
presentation and regulates immune system responses (Beard et al., 2011; Deluca & 
Cantorna, 2001; Holick, 2007; Overton & Yin, 2011). The VDR is thought of as a natural 
ligand-activated transcription factor that binds to the Vitamin D related genetic material 
of immune cells and interferes with regulating their signaling pathways and their 
respective responses towards pathogens (Baeke et al., 2010b). Heany (2008) described 
the hormonal Vitamin D (1,25(OH)2D3) or calcitriol as being “the right key to open up 
the locked stores of DNA information, allowing the cell to transcribe the plans and 
produce the proteins needed for tissue-specific responses” (p.1536). Hormonal Vitamin D 
can modulate the various genes in the cells with VDR by either turning on or off their 
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expression, just like Villamor (2006) described it as having paradoxical 
immunomodulating actions. Vitamin D is involved in regulating more than 2000 genes 
(Wacker & Holick, 2013); these genes control cellular growth and differentiation and 
overall innate response to pathogens (Holick, 2007; Wacker & Holick, 2007).  
Bioactive Vitamin D (1,25(OH)2D3) acts through its VDR on target cells and 
binds to DNA sequence elements VDRE located on the genes of these cells and encodes 
their DNA blueprints in order to initiate a series of molecular interactions that modulate 
and transcribe the gene expression in many tissues throughout the body (Lin & White, 
2004). Vitamin D attaches to VDRs on the following immune cells: T lymphocytes (CD4 
& CD8 T-cells), B-lymphocytes, neutrophils, monocytes, and antigen-presenting cells 
[APCs] such as macrophages and dendritic cells (Baeke, Takiishi, Korf, Gysemans, & 
Mathieu, 2010c). Furthermore, immune cells contain 1α-hydroxylase and when 
stimulated, they locally synthesize 1,25(OH)2D through autocrine or paracrine pathways 
(Baeke et al., 2010c). As a potent immune modulator, Vitamin D intermediates the 
transcription of genes and the production of antimicrobial peptides in response to 
infectious agents, in particular the cathelicidin antimicrobial peptide or CAMP (Wang et 
al., 2004). 
Without sufficient amount of hormonal Vitamin D produced locally in the cells, 
there will be limited antimicrobial gene transcription/expression and reduced ability to 
fight microbes (Lappe, 2011). Therefore, Vitamin D deficiency weakens and impairs the 
immune response. The amount of Vitamin D 25(OH)D available in the serum dictates or 
fuels the autocrine production of sufficient amount of active Vitamin D (1,25(OH)2D3) 
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(Williams et al., 2009) and the successive synthesis of antimicrobial peptides 
(cathelicidin or CAMP) to kill pathogens through lysis i.e., degrading the microbe cell 
contents (Heany, 2008; Kamen & Tangpricha, 2010; Liu et al., 2006). The following 
section discusses the influence of Vitamin D on immune cells and separates the responses 
into innate and adaptive immune responses.  
Vitamin D and the Innate Immune Response 
Most of our understanding on the role of Vitamin D in innate immunity stemmed 
from research on Mycobacterium Tuberculosis, with special emphasis on monocytes and 
macrophages as key players and their corresponding pathogen recognition receptors (Liu 
et al., 2006; Liu et al., 2007). The innate immune system is genetically pre-programmed 
and is at the alert and ready to start a response even before pathogen attack; it acts as the 
first line of defense and as the main detector of invading pathogens through using pattern 
recognition receptors known as toll-like receptors (TLRs) (Miller & Gallo, 2010). These 
TLRs are capable of recognizing the pathogen-associated molecular patterns of foreign 
invaders in order to initiate an appropriate innate immune response and destroy them 
(Medzhitov, 2007; Trinchieri & Sher, 2007). An innate response is directly followed by 
an antigen-specific adaptive immune response as well (Medzhitov, 2007) that can be 
supportive (complementary), parallel (synergistic), or opposing (antagonistic) (Trinchieri 
& Sher, 2007). Therefore, it is essential to understand that TLRs modulate both innate 
and adaptive immune responses.  
Vitamin D is an immune response enhancer, and in an innate response, it activates 
the toll-like receptors (TLRs) mainly on macrophages, monocytes, and dendritic cells 
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(Baeke et al., 2010b). These TLRs detect the molecular patterns of invading microbes and 
send signals to the immune system. When the microbe attaches to the TLRs, the complex 
formed induces local release or expression of 1-alpha hydroxylase (CYP27B1); this 
enzyme converts serum 25(OH)D into the biologically active hormonal form 
1,25(OH)2D3 (Lappe, 2011). Once TLRs are triggered, 1,25(OH)2D3 binds to VDR and 
VDRE and initiates a series of antimicrobial activities, most important of which is 
encoding antimicrobial gene program that express antimicrobial peptides 
(cathelicidin/CAMP or defensin β) (See Figure 3) (Aranow, 2012; Campbell, Fantacone 
& Gombart, 2012; Gombart, O’Kelly, Saito, & Koeffler, 2007; Heany, 2008; Kamen & 
Tangpricha, 2010; Liu et al., 2007; Schwalfenberg, 2010; Wang et al., 2004; White, 
2012; Wolff et al., 2008).  
Cathelicidin is the only anti-microbial peptide present in human beings and it is 
sometimes referred to as hCAP18 (Kosciuczuk et al., 2012) or as LL-37 in its cleaved off 
peptide form (Beard et al., 2011; Bergman, Walter-Jallow, Broliden, Agerberth, & 
Soderlund, 2007). CAMP is considered the forerunner of innate immune response against 
bacterial invasion (Baeke, Van Etten, Overbergh, & Mathieu, 2007; Wang et al., 2004); it 
is often alluded to as an antibiotic protein (Wang et al., 2004). However, cathelicidin has 
antiviral properties too (Beard et al., 2011); for instance, it exerts its antiviral effects 
against HIV and impedes HIV viral replication (Bergman et al., 2007; Wang et al., 2004). 
CAMP and other peptides are highly present (and stored) in neutrophils and 
macrophages, and to a lesser extent in monocytes and lymphocytes (Gombart et al., 2007; 
Kosciuczuk et al., 2012; Schwalfenberg, 2010); they are also present in epithelial or skin 
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cells, respiratory cells, bone marrow cells, and gastrointestinal cells (Kosciuczuk et al., 
2012).  
 
Figure 3. From Abuzeid, Akbar, & Zacharek (2012), available at 
http://www.medscape.com/viewarticle/757649_4, originally reprinted from “Vitamin D 
and musculoskeletal health” by Wolff, A.E., Jones, A.N., & Hansen, K.E. 2008, Nature 
Clinical Practice Rheumatology, 4(11), p.585.  
 
 CAMP production and expression is highly reliant on the availability of sufficient 
serum Vitamin D, sufficient VDR, and CYP27B1 as prerequisites for conversion to 
bioactive Vitamin D that is necessary for optimal immune cellular functions (Beard et al., 
2011; Liu et al., 2006; Wang et al., 2004)- most important of which is killing the 
microbes. A study by Jeng et al. (2009) demonstrated that critically ill patients with 
sepsis had high prevalence of Vitamin D deficiency/insufficiency that was associated 
with low levels of cathelicidin (LL-37); they concluded that such association between 
low LL-37 levels and low Vitamin D levels -(measured also by number of DBP- Vitamin 
66 
 
D binding protein, the carriers of 25(OH)D in the circulation), could reflect the 
importance of treating Vitamin D insufficiency/deficiency to prevent systemic 
inflammation in critically ill patients and to enhance their antimicrobial defenses. 
Likewise, in response to invaders, macrophages make use of Vitamin D to 
synthesize cathelicidin – the only antimicrobial peptide synthesized in humans with wide 
spectrum against bacteria, fungus and viruses (Abuzeid, Akbar, & Zacharek, 2012). 
Neutrophils and some epithelial cells use Vitamin D to produce proteins (cytokines) 
needed for specific responses based on DNA transcription unlocked by Vitamin D 
response elements (VDREs) (Abuzeid et al., 2012). Moreover, the innate immune 
responses mediated by 1,25(OH)2D include enhanced macrophage activity and 
phagocytosis (Wang et al., 2004; White, 2012). Vitamin D deficiency would disrupt the 
macrophages antimicrobial functions (reduced phagocytosis and tumor cell-cytotoxicity) 
and would suppress the innate immune response (Baeke et al., 2010b). Similarly to 
macrophages, dendritic cells (DCs) also have 1α-hydroxylase enzymes that locally 
produce 1,25(OH)2D, which in turn is capable of reducing the inflammation milieu and of 
regulating immune responses (Baeke et al., 2010b; Liu et al., 2006). Vitamin D-mediated 
cathelicidin production is responsible for modulating antigen presentation by 
macrophages, monocytes and dendritic cells, the so-called antigen presenting cells or 
APCs (which highly express VDR); eventually, sufficient Vitamin D or Vitamin D 
supplementation would lead to inhibition of DC maturation, suppression of antigen 
presentation, and promotion of T-cell responses (in adaptive responses) (Hewison, 2012). 
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Additionally, Liu et al. (2006) found that TLRs of activated monocytes increased 
the number of VDRs and CYP27B1 and expressed more CAMP- provided there was 
sufficient amount of circulating Vitamin D. The authors referred to a very important 
finding that, in African Americans, the activated monocytes and their TLRs produce less 
CAMP as compared to Caucasian counterparts. Such finding would reflect the indigenous 
low levels of Vitamin D or deficiency secondary to low skin synthesis of Vitamin D 
(melanin being a UV filter) and/or to poor dietary intake of Vitamin D rich foods. In 
brief, Vitamin D deficiency would result in lower CAMP production (Baeke et al., 2007) 
and would down-regulate immune response. Ultimately, supplementation can be 
considered an appealing and a promising method that can raise serum Vitamin D and 
improve antimicrobial action through instigating more CAMP production. Kamen and 
Tangpricha (2010) summarized the mechanism of Vitamin D on the innate immune 






Figure 4. Adapted from “Vitamin D and molecular actions on the immune system: 
Modulation of innate and autoimmunity” by Kamen, D.L., & Tangpricha, V. (2010). 
Journal of Molecular Medicine, 88(5), p. 442. Retrieved from 
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2861286/?report=classic 
 
Vitamin D and the Adaptive Immune Response: 
In adaptive immunity, antigen presenting cells APCs, such as DCs and 
monocytes, are again considered targets for VDR compounds through which Vitamin D 
regulates T cell-mediated responses (with T cells subsets: Th1, Th2, Th17, & T 
regulatory cells; Gunville et al., 2013). T cells or lymphocytes refer to CD4 and CD8 
cells. The T lymphocytes (CD4 & CD8), B-lymphocytes, and macrophages also express 
VDR (Kamen & Tangpricha, 2010). Deluca and Cantorna (2001) reported that CD4 T 
cells and macrophages possess small yet worthwhile quantity of VDR (at resting without 
stimulation), and mature CD8 have the highest VDR concentrations (B lymphocytes have 
minimal non-detectable concentration of VDR). Once activated, T and B cells increase 
their VDR expression that impacts their proliferation or differentiation (Mahon, Wittke, 
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Weaver, & Cantorna, 2003; Prietl et al., 2013). When Vitamin D is sufficient, the number 
of VDRs increases by five times to respond to excessive T cell differentiation (Kamen & 
Tangpricha, 2010).  
The innate response regulates the adaptive response upon detecting danger. Once 
TLRs in the innate immune cells APCs detect invading antigens, these APCs (especially 
DCs) capture and present the antigens to T & B cells to start an adaptive response. As a 
result, the B-lymphocytes secrete immunoglubulins to kill the microbe antigens presented 
to them by APCs i.e., macrophages and dendritic cells (Lappe, 2011). On the other hand, 
the T lymphocytes get stimulated and differentiate into T helper cells, mainly Th1, Th2, 
and Th17 cells, and start releasing cytokines (Adams & Hewison, 2010; Baeke et al., 
2010c; Beard et al., 2011). These cytokines have antigen receptors that sense the presence 
of pathogens and send signal to the immune system to start an antigen-specific immune 
reaction and protect the inside cellular environment (T-cellular compartment) against 
invaders (Beard et al., 2011; Cantorna et al., 2004).  
Th1 cytokine is pro-inflammatory and releases interleukin IL-2, Interferon IFN γ, 
and tumor necrosis factor TNF-α; Th1 usually ensues cell-mediated responses related to 
intracellular invasion of viruses and tumors (Cantorna et al., 2004). On the contrary, Th2 
cytokine is more anti-inflammatory (and anti-allergic) and it secretes interleukins IL-3, 
IL-4, IL-5, IL-10 (Adams & Hewison, 2008; Gunville et al., 2013) and it usually initiates 
antibody-mediated responses to extracellular pathogens such as bacteria and parasites, or 
antigens from the environment such as allergic antigens (Cantorna et al., 2004). Usually, 
Th1 and Th2 cell responses regulate each other in a way that secures a normal adaptive 
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response. However, upon provocative invasion to the immune system, any disequilibrium 
in Th-cell responses would result in either a Th2-driven good outcome (fighting 
infection) or a Th1 & Th17-driven negative outcome (e.g., higher susceptibility to 
developing autoimmunity, diabetes type-1, multiple sclerosis, & asthma) (Cantorna et al., 
2004).  
As an immunomodulator, 1,25(OH)2D is thought of as a safeguard of immune 
homeostasis (Baeke et al., 2010a). However, in adaptive immune response, 1,25(OH)2D 
is implicated in more suppressive or inhibitory functions as compared to its stimulating 
functions in innate responses (Hart et al., 2011). Since antigen stimulation to T-cells leads 
to increased differentiation into different Th cells phenotypes, 1,25(OH)2D responds to 
inflammation by the following: suppressing excessive T lymphocytes proliferation; 
blocking or inhibiting the induction of inflammatory cytokines Th1 and Th17 while 
favoring the expression of cytokine phenotype Th2 and the development of T regulatory 
cells in DCs; inhibiting inflammation-mediated by monocytes, especially by tumor 
necrosis factor (TNF-α) and Th1 (Baeke et al., 2010b; Beard et al., 2011; Penna et al., 
2005); and finally, intercepting B lymphocytes proliferation and differentiation into 
memory cells, blocking their immunoglobulin antibody production, and promoting their 
apoptosis (Baeke et al., 2010a; Chen et al., 2007; Youssef et al., 2011)- such actions are 
well appreciated in terms of preventing autoimmune diseases (Prietl et al., 2013).    
At the same time, DCs play an important role in adaptive responses and remain 
direct targets for 1,25(OH)2D. Therefore, 1,25(OH)2D modulates DCs and inhibits their 
maturation and differentiation, and changes the DC-derived cytokine phenotype 
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expression through inhibiting Th1 & Th17 and elevating anti-inflammatory Th1 & IL-10 
cytokines (Baeke et al., 2010a). These Vitamin D-modulated and IL-10- induced DCs 
develop T regulatory cells, which main function is to suppress and resolve infections 
(Baeke et al., 2010a) through halting cellular damage and diminishing the excessive 
immune responses and the pro-inflammatory milieu effects (Kamen & Tangpricha, 2010; 
Overton & Yin, 2011; Prietl et al., 2013). This is considered a triumphant role of Vitamin 
D in suppressing the overzealous adaptive immune responses and reflects its suppressive 
and protective mechanism against pathogens, especially in autoimmune diseases (Lappe, 
2010; Prietl et al., 2013) and HIV (Spector, 2009; 2010). Figure 5 summarizes the main 
modulatory effects of Vitamin D on the adaptive immune system. 
Vitamin D- or VDR-deficient hosts have elevated Th1 cell-associated responses 
and decreased Th2 cell-associated responses. Vitamin D sufficiency and the consequent 
presence of sufficient VDRs enable Vitamin D to skew the T cellular compartment’s 
inflammatory status and to suppress T helper cells proliferation (e.g., Th1 and Th17) 




Figure 5. Main Immune-modulating Effects of Bioactive Vitamin D (1,25(OH)2D3) on 
Immune Cells. 
 
Prevalence of Vitamin D Deficiency in HIV 
Most published studies have focused on Vitamin D deficiency in HIV and its 
significant role in skeletal health. The negative implications of Vitamin D deficiency on 
bone diseases (e.g., osteoporosis, osteomalacia, and osteopenia) and the consequent 
reduced bone mineral density were highlighted in the literature as distinctive marks of 
HIV infection metabolic complications (Villamor, 2006). There are several factors that 
can alter Vitamin D metabolism and can contribute, consequently, to Vitamin D 
deficiency or insufficiency in HIV patients; these might include: limited sun exposure; 
low Vitamin D intake from food; altered Vitamin D absorption, activation, or metabolism 
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treatment HAART side effects (Cozzolino et al., 2003), especially non-nucleoside reverse 
transcriptase inhibitors (NNRTIs) (Griffin & Arnold, 2012). 
 
 
Figure 6. Adapted from “Vitamin D and the immune system: New perspectives on an old 
theme” by Hewison, M. (2010). Endocrinol Metab Clin North Am, 39(2), p. 379. Online 
at http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2879394/pdf/nihms180153.pdf 
Abbreviations: TLR, toll like receptor; DC, dendritic cell, Mφ, macrophage; T-cell, T-lymphocyte; cyto T-
cell, cytotoxic T-cell; B-cell, B-lymphocyte; Treg, regulatory T-cell. 
 
In-depth systematic reviews of several studies have demonstrated that Vitamin D 
deficiency status seems to be more pronounced among HIV patients (Giusti et al., 2011; 
Overton & Yin, 2011; Tafazoli & Khalili, 2013; Villamor, 2006). There is still ongoing 
research to understand why HIV patients have more Vitamin D deficiency compared to 
others- ranging from 70.3 to 89 percent (Dao et al., 2011; Viard et al., 2011). Besides the 
effects of non-HIV related factors (e.g., gender, older age, winter season, low Vitamin D 
dietary intake, dark skin, and reduced sun exposure), some studies pinpointed to a 
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possible defect in kidney hydroxylation of Vitamin D as a possible contributing factor to 
deficiency in HIV; the inadequate levels of renal 1-alpha hydroxylase enzyme 
(CYP27B1), essential to produce active Vitamin D metabolite, could derive from the 
influence of pro-inflammatory cytokines and/or from effects of ART intake (Haug et al., 
1998; Mueller et al., 2010; Villamor, 2006; Welz et al., 2010).  
Advanced HIV infection or progression to AIDS by itself may lead to an 
“inflammation-related impairment of 1-α hydroxylation” (Mueller et al., 2010, p. 1132) 
that can be associated with immunological hyperactivity as shown by Haug et al. (1994, 
1998). Cervero et al. (2012) found a high prevalence of Vitamin D deficiency in a cohort 
of Spanish HIV-infected patients that exceeded by 16.4 percent that of non-HIV adults. A 
French study by Allavena et al. (2012) also found that 86.7% of their cohort (n = 2994) 
had Vitamin D deficiency (31.1%) or insufficiency (55.6%). In an Iranian study on adult 
HIV patients, Vitamin D deficiency reached 86.7 percent (Etminani-Esfahani et al., 
2012). Bang et al. (2010) reported a 95 percent Vitamin D deficiency in a cohort of 
Danish male patients. Likewise, the EuroSIDA study, the largest on HIV in Europe, 
reported an 89 percent rate of Vitamin D deficiency (23.7% of which had severe 
deficiency < 10 ng/μL and 65.3% between 10 ng/μL & 30 ng/μL) in a cohort of 1985 
individuals and associated such high prevalence with greater risk for AIDS and mortality 
(Viard et al., 2011).   
In contrast, some studies found that this high prevalence was not any different 
than in the general population or in comparison groups. For instance, results from the 
SUN study (Study to Understand the Natural History of HIV and AIDS in the Era of 
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Effective Therapy) by Dao et al. (2011) showed a high prevalence of Vitamin D 
deficiency (70.3 percent, 95% CI, 68.1%-74.9%) among a cohort of HIV adults (N = 672) 
in the U.S. that is comparable to that of the U.S. general adult population based on 
NHANES data 2003-2006 (79.1 percent, 95% CI [76.7-81.3]). A study by Ormesher et 
al. (2011) reported that Vitamin D deficiency was less prevalent among HIV patients as 
compared to the general population, similar to the findings in a study by Yin et al. (2010) 
on postmenopausal women with HIV as compared to the general population. Likewise, 
the Women’s Interagency HIV study (WIHS)- one of the largest prospective US study on 
women with HIV- found a Vitamin D deficiency prevalence of 60 percent among women 
(mostly African American) with HIV as compared to 72 percent among HIV negative 
women, p < 0.001 (Adeyemi et al., 2011). Interestingly, Adeyemi and colleagues’ study 
(2011) found a positive association between Vitamin D deficiency and low CD4 count  < 
200 cells/μL. However, despite these contradicting results in diverse studies, meta-
analyses and many reviews discussed throughout this study have confirmed one thing: 
Higher prevalence of Vitamin D deficiency in HIV populations as compared to non-HIV 
people.  
Vitamin D deficiency and ART: 
It is indisputable that ART has revolutionized the perception of HIV and changed 
the fatal scenario that used to be associated with HIV diagnosis; it has led to a significant 
decline in mortality, and resulted in prolonged longevity that made HIV another chronic 
disease readily modulated or influenced by Vitamin D (Mueller et al., 2010). Some ART 
impair Vitamin D metabolism and results in Vitamin D deficiency (Cozzolino et al., 
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2003). For instance, protease inhibitors or PIs inhibit the two major enzymes activities in 
Vitamin D metabolism, 25-hydroxylase and 1-alpha-hydroxylase, in a reversible and 
dose-dependent manner resulting in reduced active Vitamin D production (1,25(OH)2D3) 
(Poowuttikul et al., 2013).  
ART is presented here in this study as a potential contributing risk factor to 
Vitamin D deficiency. As far as treatment is concerned, Bang et al. (2010) and Van Den 
Bout-Van Den Beukel et al. (2008) found no difference in the Vitamin D deficiency 
status between HIV patients on ART and those naïve not-treated patients, in contrast to 
some cross-sectional studies that associated Vitamin D deficiency with some types of 
ART such as Efavirenz (Conesa-Botella et al., 2010; Dao et al., 2011; Fox et al., 2011; 
Pasquet et al., 2011; Welz et al., 2010; Wiboonchutikul et al., 2012). Paul et al. (2010) 
reported a higher prevalence of Vitamin D deficiency among Indian patients using 
HAART (74 percent) as compared to untreated patients (37 percent) or non-HIV controls 
(37 percent).  
Efavirenz, a NNRTI, stimulates an increase in 24-hydroxylase enzyme or 
CYP450 (also called CYP24A1) that counteracts the effects of CYP27B1 or α-
hydroxylase; this leads to increased catabolism of 25(OH)D and of active 1, 25(OH)2D3 
and to their conversion into the inactive form 24,25(OH)2D that gets excreted in the urine 
(Overton & Yin, 2011; Van Den Bout-Van Den Beukel et al., 2008; Vescini et al., 2011; 
Welz et al., 2010)- thus leading to further Vitamin D deficiency. A type of ART called 
Tenofovir or TDF increases serum parathyroid hormone levels (PTH); it is known that 
Vitamin D deficiency coupled with high PTH are implicated in reducing bone density in 
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HIV patients on ART and increase their risk for fractures (Tafazoli & Khalili, 2013)- that 
makes a good reason why Vitamin D supplementation is essential for HIV patients on 
ART even beyond bone health.  
 In this context, the MONET trial found that patients exhibited higher levels of 
Vitamin D after stopping NNRTIs and shifting to PIs (Fox et al., 2011). Similarly, a large 
scale Spanish study by Cervero et al. (2013) reported that using boosted PI monotherapy 
was associated with lower risk for Vitamin D deficiency/insufficiency as compared to 
using NNRTIs or no treatment (OR = 0.08, 95% CI [0.01-0.6], p = 0.018). Interestingly, 
Mueller et al. (2010) admitted the high prevalence of Vitamin D deficiency among 
patients receiving combined ART (cART) but could not find conclusive results on the net 
clinical effects of using NNRTIs or PIs (Tenofovir-TDF) on Vitamin D levels and 
recommended further studying.  
On the other hand, in a large Italian cohort (N = 810 patients that contributed 1408 
Vitamin D measures), Vescini et al. (2011) reported higher Vitamin D deficiency 
prevalence among NNRTIs users as compared to PI users, and an overall higher 
deficiency among HIV patients as compared to the general population. The authors 
highlighted the hypothesis that the HIV virus and/or cART impair Vitamin D 
metabolism, in addition to the interference of confounding variables that differ between 
HIV positive and HIV negative subpopulations. It was noteworthy that Vescini et al. 
(2011) found that Vitamin D deficiency was predictive of HIV disease progression 
(AIDS), in addition to its association with the occurrence of negative health events (such 
as diabetes, cardiovascular or kidney diseases-related events). They also concurred with 
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Mueller et al. (2010) findings about the inflammation-related impairment of 1 α-
hydroxylation phenomenon associated with the virus and/or with cART effects.   
In view of the discrepancies in ART effects on Vitamin D deficiency, some 
studies could not find significant association between Vitamin D deficiency and ART 
regimen or HAART due to the heterogeneity of treatments, as shown in Rustein et al. 
(2011); however, others investigated the controversies about the deleterious effects of 
ART (Theodorou et al., 2013). In a retrospective cohort of 2044 HIV patients in Belgium, 
the researchers associated Vitamin D deficiency (89.2%, of which 32.4% < 10ng/mL) 
with longer duration of ART treatment, and with the use of sequential complex treatment 
modalities that include combinations of NNRTIs and PIs (Theodorou et al., 2013). 
Theodorou et al. (2013) reached the same conclusion as Mueller and colleagues’ (2010) 
and all other studies in the literature that pinpointed (or incriminated) NNRTIs use as 
compared to PIs. Patients treated with a combination of two or three NNRTIs had 
significantly lower Vitamin D levels as those treated with a combination of NNRTIs plus 
PI; but untreated patients exhibited statistically significant higher Vitamin D levels as 
compared to treated patients (15.1 ng/μL vs. 12.8 ng/μL, respectively, p = 0.0003) 
(Theodorou et al., 2013). Similarly, Brown and McComsey (2010) found that within a 
year of ART initiation, there was a statistically significant reduction in serum Vitamin D 
levels among patients using Efavirenz (prevalence ratio of 1.8; p = 0.007) as compared to 
non-EFV users (mostly PI users). 
In the famous large prospective SUN study, Dao et al. (2011) reported that the use 
of cART in general increased the odds of Vitamin D deficiency and insufficiency 
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especially among those using Efavirenz (OR =1.98, 95% CI [1.18-3.34]) as compared to 
patients not receiving ART. Pinzone et al. (2013) emphasized the need for large 
prospective studies that mainly aim to test the existence of a causal relationship between 
ART and Vitamin D deficiency instead of relying on controversial results from studies 
that used cross-sectional design. Additionally, there is a need to study the impact of 
Vitamin D supplementation on reversing the detrimental side effects of some ART drugs 
on Vitamin D levels.   
CD4 Cells in HIV Infection: Preamble to Vitamin D and CD4 Relationship 
The previous sections so far and some sections in Chapter 1 discussed the 
implications of Vitamin D deficiency in general and in HIV, and highlighted its 
modulating actions on the immune system and on the HIV course of infection. To recap, 
the HIV virus- despite treatment and continuous immune defenses- shows high resistance 
and persistence in lingering on immune cells (T and B lymphocytes), mainly on antigen-
presenting cells or APCs such as dendritic cells, monocytes, and macrophages (Campbell 
& Spector, 2011; Deluca & Cantorna, 2001).  In order to secure its survival, the virus 
itself sabotages the host cell machinery in a way to enhance its own replication and 
differentiation, and at the same time, it suppresses toll-like receptor (TLR) signaling and 
activation against its replication (Campbell & Spector, 2011). This ultimately results in 
increased viral replication and in gradual decline in the number of CD4 cells. 
To recap, as discussed previously, Vitamin D induces the following main actions 
in HIV: producing cathelicidin to combat pathogens that can lead to inhibiting and 
delaying HIV infection events (Spector, 2009); suppressing viral replication; allowing 
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HIV infected CD4 to survive longer than bystander or uninfected CD4 cells (i.e., 
deferring their programmed cell death)- thus delaying HIV disease progression 
(Campbell & Spector, 2012; Spector, 2011); inhibiting dendritic cell maturation and 
differentiation; controlling autophagy (cellular disintegration or degradation) in infected 
CD4 T-cells; enhancing phagocytic activity of macrophages (such as increasing 
production and maturation of cytokines); and increasing natural killer cells (NK) to boost 
host’s defense antiviral response and reduce HIV viral replication (Campbell & Spector, 
2012; Walker & Modlin, 2009).  
Of particular interest is the role of VDR in the course of HIV. Vitamin D as 
25(OH)D has little or no interaction with VDRs, while 1,25(OH) 2D, the active 
metabolite, elicits the modulatory actions of Vitamin D and induces VDR-activated 
responses (Prentice, Goldberg, & Schoenmakers, 2008). Campbell and Spector (2011) 
were the first to demonstrate a novel role for Vitamin D and VDR-driven responses; their 
study demonstrated that the active Vitamin D metabolite could be an autophagy inducer 
in macrophages, which in turn, can inhibit viral replication in these macrophages. The 
authors called for studies to understand more this autophagy-dependent molecular 
mechanism through which Vitamin D mediated inhibition of viral replication in HIV. At 
the same time, structural mutations and polymorphism in VDR gene influences 
susceptibility to HIV infection (and to other infectious diseases such as TB or leprosy) by 
reducing VDR functions, inducing immune hyper-stimulation and Vitamin D signaling, 
and promoting disease progression (De la Torre et al., 2008; Nevado, Tenbaum, Castillo, 
Sanchez-Pacheco, & Aranda, 2007; Van Den Bout-Van Den Beukel et al., 2008). 
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Subsequently, Vitamin D deficient patients have diminished number of VDR, and that in 
fact cripples the VDR-driven responses in stimulated cells (Walker & Modlin, 2009). 
These HIV patients would be more likely to witness an increase in their susceptibility to 
opportunistic infections, earlier occurrence of chronic diseases, as well as higher 
incidence of multiple organ systems complications as compared to non-deficient patients 
(Giusti et al., 2011; Villamor, 2006). 
In the course of HIV infection, the whole immunological mechanism on how 
Vitamin D deficiency affects HIV outcomes remains less clear and ambiguous, despite 
the numerous studies carried out in this field. A major study by Haug et al. in 1994 was 
the first to pinpoint to a correlation between low serum concentration of 1,25(OH)2D and 
low CD4 counts and a corresponding shorter survival rate in HIV patients with advanced 
disease as compared to controls. Later, more in-vivo and in-vitro studies in 1980s and 
1990s have highlighted the modulating effects of Vitamin D in HIV, and demonstrated 
how Vitamin D deficiency impaired cellular immunity and compromised patients’ 
immune defenses (Haug et al., 1998). Such findings encouraged more research 
undertakings to explore to what extent 1,25(OH)2D affect immune cells in diseases such 
as HIV and influence the course of disease. 
As previously discussed, HIV virus mainly attacks macrophages, dendritic cells, 
and CD4 T-cells. Upon acquiring infection and transmission, the HIV viral glycoprotein 
(GP-120) binds to CD4 (cluster of differentiation 4) molecules on the surface membrane 
of dendritic cells, macrophages, and CD4 T cells. In fact, the CD4 molecules act as the 
primary target surface receptors and fuse with infected cells; this fusion creates a port of 
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entry that allows entrance of the virus into the cell membrane of immune cells. Once 
virus releases its viral core into the cell membrane, HIV starts replicating (building viral 
load) and spreading to lymph nodes and to blood circulation, followed by a spread to 
different body organs (Barlett, 2010; Simon, Ho, & Abdool Karim, 2006). After a series 
of immune T-cells activation and division, the virus destroys and depletes these CD4 
receptors in T-cells expressing CD4- making way for disease to progress to AIDS (Giusti 
et al., 2011; Grossman et al., 2002). At the same time, besides destroying activated T 
cells, chronic immune activation in HIV also destroys, to a great extent, naïve (resting) 
CD4 and memory CD4 cells as a consequence of the high activation and turnover rate 
(Douek, Picker, & Koup, 2003; Hazenberg et al., 2003; Miedema et al., 2013; Simon et 
al., 2006) or burst-like activation of T cells (Grossman et al., 2002). As the CD4 cells 
react to their HIV infection by multiplying, they are making more copies of the virus 
itself, and paradoxically, they get gradually destroyed and depleted. Some of these cells 
die progressively from programmed activation-induced cell death or apoptosis (discussed 
earlier) (Grossman et al., 2002; Spector, 2010).  
Accordingly, CD4 count (or CD4 percent) is considered the most plausible 
biological marker of the immune health in HIV (Hogg et al., 2001; Lodi et al., 2013; 
Miedema et al., 2013), reflecting the degree of CD4 cells destruction by HIV 
(immunodeficiency), and at the same time, the low degree of proliferation of CD4 T cells 
(Miedema et al., 2013). CD4 count is commonly used for HIV disease classification, 
along with emergence of AIDS-related clinical events (CDC, 2011c). The optimal CD4 
count ranges from 500–1500 cells/μL. A CD4 count below this normal range reflects the 
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degree of damage to the immune system and extent of immunosuppression. According to 
the CDC guidelines (2011c), clinical HIV staging based on CD4 counts in the absence of 
AIDS-related events is the following: CD4 count ≥ 500 cells/μL (CD4 percent ≥ 29%) 
indicates a stage 1 HIV disease; a CD4 count of 200-499 cells/μL (CD4 percent 14-28%) 
represents stage 2 HIV disease or moderate immune suppression; while CD4 count < 200 
cells/μL or a CD4 percent < 14% indicates stage 3 or disease progression and AIDS 
diagnosis (CDC, 2011c).  
In 2013, a panel from the Department of Health and Human Services (DHHS) 
reviewed the guidelines with regard to ARV (same as ART) initiation and CD4 count. 
The panel recommended ART for all HIV patients with the goal of reducing risk for 
disease progression and preventing HIV transmission. It is urgently and highly 
recommended for patients with CD4 count < 350 cells/μL to start treatment; and CD4 
count can be restored to normal values in treated patients (CDC, 2011c; DHHS, 2013). 
Besides CD4 count, there are other immune parameters that are taken into 
consideration when evaluating HIV course of infection. Viral load or HIV RNA level 
denotes the number of viruses in the host’s circulation. Giusti et al. (2011) presented a car 
analogy in order to simplify how CD4 and viral load operate together; the authors 
symbolized CD4 as the distance from immunosuppression or how far from AIDS, while 
viral load designated the speed of movement towards disease progression or AIDS. The 
higher the viral load, the faster the CD4 depletion; therefore, HAART is used to lower 
viral load and to slow down the infection process in a way to allow some CD4 recovery 
or repletion (Giusti et al., 2011).  
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Eventually, viral load can be used as a measure that predicts risk of viral 
transmission, knowing that viral load registers very high levels (106 to 107 copies per mL) 
in two instances: acute infection and advanced/progressed infection (Simon et al., 2006). 
Viral load is used as an adjunctive measure to CD4 to evaluate the degree of HIV 
suppression; both markers gauge disease severity and progression, and predict mortality 
and survival (Hogg et al., 2001). In addition, both CD4 count and HIV RNA levels are 
considered upon treatment initiation and are closely monitored to determine the 
effectiveness of HIV medical management using ART (Giusti et al., 2011; Hogg et al., 
2001). Clinically, it is used to test the effectiveness of ART therapy in reducing the viral 
load to a non-detectable level (DHHS, 2013). The optimal undetectable viral load level 
should be less than 400 copies/mL (Giusti et al., 2011).  
CD4 Count and Vitamin D: A Controversial Relationship 
No one can doubt the immune modulatory effects of Vitamin D on the innate and 
adaptive immune system. However, a large body of HIV literature has presented 
contradicting results on the relationship between CD4 count -as the main biomarker of 
immune function- and Vitamin D. While some studies described an association or 
correlation, others failed to demonstrate any significant relationship. Most of the studies 
involving Vitamin D and CD4 counts aimed to assess HIV disease progression, such as 
the work done by Haug (1994), Hogg et al. (2001), Sudfeld et al. (2012), Viard et al. 
(2011), and Mehta et al. (2010). Most of these studies examined the association between 
Vitamin D deficiency and CD4 count in multivariate analyses not as an endpoint by 
itself, but as a mean to explain factors predisposing or contributing to HIV disease 
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progression. Consecutive studies focused more on testing the association between 
Vitamin D and CD4 count under the realm of Vitamin D supplementation. On the whole 
and regardless of their main objectives, most of the studies that examined Vitamin D 
deficiency and its association with CD4 count provided conflicting results, but were 
predominantly observational and subject to confounding of some sort.  
Vitamin D & CD4 Count: Correlation? No Correlation? 
A cross-sectional study by Stein et al. (2010) showed a weak but significant 
correlation between higher serum Vitamin D levels and higher CD4 counts in a 
convenience sample of  HIV positive minority (AA) postmenopausal women on ART (N 
= 68; r = 0.32, p < 0.01). The authors emphasized that such correlation could underline a 
better immune competence and function (denoted by CD4 repletion) and better general 
health secondary to higher Vitamin D levels. The same study reported comparable results 
with regard to serum 25(OH)D and 1,25(OH)2D levels among women on ART, women 
on different ART regimens, and women not on ART (control group). However, serum 
25(OH)D level should be considered because it is a better indicator of Vitamin D 
available for later immune functions as compared to the short-lived hormone in the blood 
1,25(OH)2D (Holick et al., 2011). Knowing that higher 25(OH)D level does not 
necessarily reflect higher 1,25(OH)2D level or vice versa (Rodriguez et al., 2009; 
Stephensen et al., 2006). In other words, Vitamin D deficiency has no effect on 
1,25(OH)2D levels (Childs et al., 2012).  
In their quest to reveal the role of micronutrients in HIV disease progression, De 
Luis et al. (2002) did a study in Spain on 119 HIV patients (mean age 37.9 ± 9.9 years) 
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that aimed to compare the correlation between dietary micronutrient intake including 
Vitamin D and the immune status as denoted by CD4 count in Vitamin D deficient versus 
Vitamin D insufficient. The researchers found a significant positive association between 
high Vitamin D intake and high CD4 counts; the consecutive multivariate analysis (after 
adjusting for age, sex, energy and protein intake, and ART) showed that each one 
microgram of Vitamin D intake correlated with a 34 points increase in CD4 count (95% 
CI [5.81-167.3], p < 0.001). Such result clearly portrayed Vitamin D as an independent 
predictor of CD4 count. However, this study used a combination of vitamin A and D. 
Therefore, the small scale of the study and its cross-sectional design along with the 
accompanying threats to validity, warrant the need for further research investigation to 
delineate the distinctive effect of Vitamin D on CD4 count.  
Another study by Ross et al. (2011) sought to explore the association between 
Vitamin D levels and CD4 count in a group of HIV patients on ART with Vitamin D 
insufficiency (n = 149). The researchers hypothesized that such association existed 
knowing the immune modulator effects of Vitamin D on the overall immune system and 
on CD4 cells. Their results indicated a positive association between an increase in 
Vitamin D level that corresponded with a significant change in CD4 counts (current CD4 
count minus lowest or nadir CD4 count) (p < 0.01). From a clinical perspective, the 
authors emphasized the potential adjunctive role of Vitamin D supplementation in 
restoring the immune function (increasing CD4 count) of patients starting ART (Ross et 
al., 2011). There is a great need for further research to find an indisputable answer to the 
issue of association between Vitamin D status and CD4 count before or parallel to 
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embarking on studying the clinical benefits of Vitamin D supplementation in deficient 
HIV patients.  
Upon examining the factors associated with Vitamin D deficiency in a large 
sample of HIV patients (n = 2044) in Belgium, Theodorou et al. (2013) compared median 
Vitamin D concentrations according to CD4 count, viral load, and ART type. It was quite 
interesting to find a significant correlation between Vitamin D deficiency and low CD4 
counts (similar to Stein et al’s study in 2010). Based on data from all Vitamin D deficient 
patients taking different treatment modalities, the analysis showed that a median 
25(OH)D level of 11.5 ng/μL significantly correlated with a median CD4 count < 200 
cells/μL as compared to median 25(OH)D of 14.1 ng/μL that correlated with median CD4 
count > 200 cells/μL (p = 0.0003). The authors pinpointed to their major finding on 
severe Vitamin D deficiency (< 10 ng/mL) and its association with low CD4 counts (< 
200 cells/μL) and called upon the need to consider Vitamin D supplementation to 
overcome and to prevent the detrimental effects of deficiency in HIV patients.   
In a large-scale French study by Legeai et al. (2013), the researchers examined the 
immunological markers (in addition to metabolic and inflammatory markers) associated 
with Vitamin D deficiency in a cohort of 355 recently diagnosed young adults HIV 
patients (70 percent males; 43 percent Black) not yet on ART (ART naïve). In this cross-
sectional COPANA study, the researchers reported a 93 percent prevalence rate of 
Vitamin D insufficiency (< 30 ng/μL), 67% of which referred to Vitamin D deficiency (< 
20 ng/μL), and 24% referred to severe Vitamin D deficiency (< 10 ng/μL). The cohort 
median CD4 count at enrollment was 300 cells/μL (IQR: 173-463); however, median 
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CD4 counts were significantly lower among Black patients (245 cells/μL) as compared to 
Whites (344 cells/μL) (p < 0.001). Severe Vitamin D deficiency was associated with 
significant immune suppression in 18 percent of patients with a CD4 count < 100 
cells/μL as compared to 10.7 percent of those with Vitamin D levels >10 ng/μL (p < 
0.04). This study proved a significant association between severe Vitamin D deficiency 
and low CD4 count (< 100 cells/μL) without any metabolic influence from ART. 
However, although it provided further evidence that linked Vitamin D deficiency to HIV 
disease progression, still, this non-causative association diminished to a certain extent 
due to an intervening role of some inflammation markers in the analysis (e.g., high TNF-
α & IL-6).   
In a novel cross-sectional study by Aziz et al. (2013), the researchers investigated 
the influence of HAART initiation on CD4 recovery (immune reconstitution) in 204 
women (60 percent Black) with advanced HIV participating in the Women’s Interagency 
HIV Study (WIHS). About 89 percent of the women had Vitamin D insufficiency or 
deficiency < 3o ng/μL; these women were older than 38 years (p = 0.04), most likely 
Black (p = 0.0001), and had higher BMI (p = 0.002) as compared to women with Vitamin 
D sufficiency, but had comparable CD4 counts (nadir count or lowest registered) and 
viral load before HAART initiation (p > 0.05). After HAART initiation, the researchers 
investigated CD4 count recovery at six, twelve, and twenty-four months; they ran logistic 
regression that took into consideration Vitamin D status (< 30 & > 30 ng/μL), ethnicity, 
BMI, prior ART use (ART naïve or no), viral load pre-HAART, and undetectable viral 
load at 24 months. The difference in mean CD4 count gain or recovery from pre-HAART 
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to post-HAART according to Vitamin D status (insufficient/deficient versus sufficient) 
was not significant (p > 0.05), unlike the results of the study done by Ross et al. (2011), 
which could imply methodological discrepancies in measuring CD4 counts. It should be 
noted that the CD4 count results were compared against baseline pre-HAART Vitamin D 
levels, and the researchers justified that other studies of longitudinal nature also based 
their analyses on baseline Vitamin D levels. The authors concluded that the impaired 
CD4 count reconstitution after HAART associated with Vitamin D 
insufficiency/deficiency could be due to the impaired modulatory effects of Vitamin D 
that led to suppression of T-cell activation and production- especially of naïve CD4 cells 
(Aziz et al., 2013).  
In their retrospective study aiming to examine the predictors of Vitamin D 
deficiency in a convenience sample of children and young adults with perinatal 
acquisition of HIV (n = 81; mean age 13.8 ± 4.1 years) seen at one clinic, Rustein et al. 
(2011) compared their Vitamin D status and associations with predictors against another 
sample of healthy subjects (n = 372). In the HIV sample, 83 percent were Black, 54 
percent had advanced clinical stage (immunosuppression) denoted by nadir CD4 count < 
200 cells/μL, a great majority were receiving HAART, and a little more than half had 
almost undetectable viral load (HIV RNA< 400 copies/mL). Like other studies, the 
prevalence of severe Vitamin D deficiency (marked at <11 ng/μL) was significantly more 
pronounced in the HIV group (36% vs. 15% in controls, p < 0.0001); about 56% of HIV 
patients had Vitamin D deficiency < 15 ng/μL as compared to 27% of the healthy 
participants. After adjusting for covariates, the researchers found a significant correlation 
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between low CD4 counts or poor immune status (not viral load) and black race in the 
HIV group; overall, low CD4 counts, black race, high BMI score, advanced clinical stage 
as per CDC classification, and Vitamin D obtained in Winter/Spring, were among the 
significant predisposing factors to Vitamin D deficiency (Rustein et al., 2011).  
Similar to Viard et al. (2011), Mehta et al. (2009; 2010) whose imperative work 
underscored the association between Vitamin D insufficiency/deficiency and the 
increased risk for HIV disease progression and mortality, both studies could not find a 
significant association between Vitamin D levels and CD4 counts. The authors acclaimed 
the need for more studies to elucidate this controversy and to further inspect the potential 
beneficial role of Vitamin D supplementation in HIV patients with deficiency.  
Furthermore, Van Den Bout-Van Den Beukel et al. (2008) asserted the lack of 
association between Vitamin D insufficiency (25(OH)D levels (10-14 ng/μL) in middle-
aged HIV patients (n = 252) and no subsequent association between Vitamin D status and 
CD4 recovery rate after initiating ART.  
In a retrospective (chart review) cross-sectional study, Turett et al. (2013) 
reported a 90 percent prevalence of Vitamin D deficiency among HIV patients (n = 133) 
who attended a hospital-based clinic in New York City compared to 55.8 percent 
prevalence among HIV negative patients (n = 104) attending a private clinic within the 
same urban geographic location. The study ran multivariate analysis to compare the 
factors that correlate with Vitamin D deficiency in both groups. Their results showed lack 
of association between Vitamin D deficiency and CD4 count or viral load. In a 
descriptive cross-sectional Danish study, Bang et al. (2010) found that Vitamin D 
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insufficiency and deficiency was about 60 percent in 115 mostly Caucasian HIV males 
(median age 44 years), and about 62% the patients were on HAART. The study failed to 
find a significant correlation between Vitamin D level and CD4 count, even after 
comparing those on HAART versus those untreated (Rho = 0.232, p = 0.599). Low 
Vitamin D levels also did not correlate with viral load or with CDC class C advanced 
clinical stage in 32 patients (the rest of patients were class A and class B, 56 and 27, 
respectively). These results congregate with those from Wasserman and Rubin’s study 
(2010), which also could not attain a correlation between CD4 count and Vitamin D 
insufficiency and deficiency (76.8 percent) in 62 men with some degree of immune 
competence (85 percent had viral load of < 200 copies/mL; median CD4 count 541 
cells/μL).  
In a cross-sectional study on a sample of 112 HIV patients (mean age 44.2 years) 
who volunteered to participate, Bearden et al. (2013) sought to elucidate the potential 
immune-modulating effects of Vitamin D through examining the associations of 
25(OH)D and 1,25(OH)2D with viral load and CD4 count. Their results showed that 
Vitamin D insufficiency/deficiency (< 30 ng/μL) was prevalent in 53% of the sample, 
and 22% had severe Vitamin D deficiency < 10 ng/μL); however, the study could not 
establish a significant association between Vitamin D and CD4 count. On the other hand, 
the authors found an interesting U-shaped relationship between low 1,25(OH)2D and 
higher viral loads, but recommended further investigation of this finding. Lack of 
association between CD4 count and Vitamin D deficiency/insufficiency was also featured 
in a cross-sectional study from the UK (Gedala, Edwards, Benn, & Grant, 2013). The 
92 
 
authors argued that despite the high prevalence of Vitamin D deficiency (58.5 percent 
had 25(OH)D < 50 nmol/L) in their largely White male HIV patients, this did not even 
associate with viral load or clinical stage -knowing that patients were ART- naïve (not on 
treatment).  
Vitamin D Supplementation 
Based on the aforementioned thorough review about Vitamin D deficiency and its 
consequences on the immune system and on HIV course of disease, it is essential to 
present some of the major studies that actually assessed Vitamin D supplementation in 
HIV populations. Most of the studies examined Vitamin D deficiency and 
supplementation in relation to bone health; some limited studies have addressed Vitamin 
D supplementation in HIV patients with tuberculosis co-infection (Wejse et al., 2009), 
especially that the role of Vitamin D is known to halt replication of HIV and 
mycobacterium avium in infected macrophage cells (Campbell & Spector, 2012).  
Vitamin D insufficiency results in reduced monocytes and macrophage innate immunity 
to infectious agents such as mycobacterium TB, the leading cause of death in many parts 
of the world. However, in their double blind RCT, Wejse et al. (2009) could not establish 
any significant impact of Vitamin D supplementation on enhancing the TB clinical 
outcomes of HIV study population or on reducing its related-mortality; the researchers 
alluded to low supplementation dose as a possible explanation for the lack of effect.  
Nevertheless, Vitamin D supplementation has some questionable metabolic 
outcomes. The Canadian and United States governments commissioned the Agency for 
Healthcare Research and Quality (AHRQ) to perform evidence-based systematic reviews 
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about what is the adequate or optimal level of Vitamin D; they reviewed bone health or 
skeletal health, and failed to obtain impressive results and to demonstrate causal benefit 
of Vitamin D supplementation on health outcomes (Bischoff-Ferrari et al., 2006). In 
general, 100 IU of Vitamin D is thought to raise serum levels of 25(OH)D by 1 ng/μL, 
although the increase may only be in fact 0.7 ng/μL (Heaney, Davies, Chen, Holick, & 
Barger-Lux, 2003). However, absorption of Vitamin D is not in a linear dose-dependent 
manner; the IOM (2011) concluded that in most children and adults, a total Vitamin D 
intake of 600 IU/day (for those older than 70, 800 IU/day) were adequate to raise the 
level to at least 20 ng/μL (50 nmol/L).  
Vitamin D supplementation comes in two forms: Vitamin D2 or ergocalciferol 
and D3 as cholecalciferol. Both are used by the body same way. Each person gets a 
combination of both through ambient UV exposure (provides D3) and habitual dietary 
intake of D3 rich or fortified foods, and vitamin supplements (D2 or D3). D2 and D3 
function as pro-hormones so they have no biological effect before liver and renal 
hydroxylation and conversion into active compounds (Tripkovic et al., 2012). Tripkovic 
et al. (2012) aimed to determine whether there was a difference in the efficacy of D2 
versus D3 in raising serum Vitamin D, and for that reason, they led a systematic review 
(Medline, and Cochrane database, and clinicaltrials.gov) and a meta-analysis of all RCTs. 
Their review challenged to overthrow the old perception or presumption that D2 and D3 
were equally efficacious in raising serum 25(OH)D, as Holick et al. (2008) and 
Biancuzzo et al. (2013) believed.  
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Despite having the same hydroxylation process and the same outcome 
1,25(OH)2D (calcitriol), most data have shown that there was a difference in the efficacy 
of 1,25(OH)2D2 and 1,25(OH)2D3 in raising serum Vitamin D levels due to their 
dissimilar affinity to VDR (Houghton & Vieth, 2006). In their extensive study, Houghton 
and Vieth (2006) provided evidence on the different metabolic fates of D2 and D3 that 
indirectly affected the rate of D2 and D3 conversion to serum 25(OH)D and their affinity 
to VDR. While D3 retained a greater capacity to bind to VDR after kidney hydroxylation, 
D3 got deactivated biologically later than D2, and remained biologically active and 
maintained Vitamin D status for longer (greater bio-efficacy). This finding is similar to 
that in Mistretta et al. (2008) about the very short circulating plasma half-life of D2 and 
its lower affinity to bind to the Vitamin D biding protein and to VDR. D3 metabolite after 
hydroxylation had around 40% more affinity capability to bind to VDR that would allow 
it to generate significant biological activities with longer systemic influence (Houghton & 
Vieth, 2006). In conclusion, Houghton and Vieth (2006) called for disregarding D2 as 
supplementation or fortification to correct Vitamin D deficiency. Similarly, Armas et al. 
(2004) showed that D3 was three times more potent in correcting Vitamin D deficiency 
as compared to D2. Another study showed that on the long run and irrespective of 
dosage, whether daily or bolus (weekly or monthly), frequent or infrequent, still D3 was 
found better in evidence (Logan, Gray, Peddie, Harper, & Houghton, 2013).  
In the same context, Tripkovic et al. (2012) found in their meta-analysis based on 
seven studies that the great absolute change in serum 25(OH)D from baseline favored 
cholecalciferol D3 intervention with a weighted mean difference of 15.23 nmol/L (95% 
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CI: 6.12-24.34; p = 0.001). Overall, total serum 25(OH)D concentrations were 21 nmol/L 
(95 % CI [14, 30]) lower in participants receiving Vitamin D2 compared to those 
receiving D3 (p < 0.001), among whom total serum 25(OH)D concentrations remained 
unchanged. Accordingly, a study by Mastaglia et al. (2006) reported that two and a half 
fold of D2 dosage is needed to achieve the same serum level achieved by D3. Tripkovic 
et al. (2012) asserted that despite the high heterogeneity among studies, separate analysis 
still showed that studies that used bolus single or multiple doses of D3 or D2, weekly or 
monthly like 50,000-300,000 IU with anywhere between 4 weeks to 1 year of follow-up, 
bolus doses with D3 had better results and increased serum 25(OH)D with a weighted 
mean difference of 34.1 ng/μL (95%CI [16.38-51.83]; p = 0.0002). On the other hand, 
there was no clear-cut differentiation between the two forms D2 or D3 in studies that 
used daily supplementation; a clear preference was shown for D3 with a weight mean 
difference of 4.83 ng/μL, but did not reach statistical significance.  
In fact, the major prescription preparations of Vitamin D in the United States are 
in the form of D2 not D3. Most commonly used is the prescribed Vitamin D2 one pill of 
50,000 IU. Armas et al. (2004) showed that it is true that D2 corrects deficiency with 
50,000 IU, however, such dosage is equivalent to less than 15,000 IU of D3 and closer to 
5000 IU D3. Serum D2 concentrations fell rapidly back to baseline after only 14 days, 
whereas 25(OH)D3 concentrations peaked and returned to baseline at the end of 28-day 
intervention. Recently, more companies in the US and Europe have been reformulating 
their products to contain Vitamin D in the form of D3. This should not lessen the 
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importance of D2 addition to milk and food and its role in eradicating rickets in 1930s 
(Houghton & Vieth, 2006).  
Data are still lacking with regard to efficacy of Vitamin D supplementation and 
the outcomes in HIV patients. There are contrasting results from methodologically 
diverse studies and population samples; therefore, any kind of outcome, positive or 
negative, cannot be considered sufficiently evidence-based. Calling for well-designed 
randomized controlled studies to evaluate supplementation effects on HIV seem to be the 
most common recommendation in all studies. In HIV research, Vitamin D 
supplementation is speculated to have potential therapeutic effects. To consider 
supplementation, it sufficed to say that Vitamin D enhanced the immune system ability to 
fight microbial and viral infections, and that deficiency correlated with many unfavorable 
health outcomes (Kamen & Tangpricha, 2010). Moreover, Spector (2011) concluded that 
Vitamin D supplementation in HIV can reduce viral replication, increase CD4 counts, 
slow the rate of disease progression, improve control of opportunistic infections, reduce 
risk of HIV related neurocognitive impairment, and improve overall survival.  
The most favorable effect of Vitamin D supplementation in patients with HIV is 
recognized under bone health. Few studies on Vitamin D supplementation in HIV 
populations that examined its effect on CD4 count and, therefore, provided some basis 
for this study (Arpadi et al., 2009; 2012; Bang et al., 2012; Giacomet et al., 2013; Havens 
et al., 2012; Kakalia et al., 2011; Poowuttikul et al., 2013; Van den Bout-Van den Beukel 
et al., 2008). Only the most pertinent for this current study are discussed in this chapter. 
While Vitamin D supplementation at different doses is considered safe and may result in 
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significant increases in serum Vitamin D concentrations in HIV patients (Arpadi et al., 
2009; Van den Bout-Van den Beukel et al., 2008), Vitamin D supplementation does not 
directly increase the CD4 cell count in HIV patients as per two major studies by Kakalia 
et al. (2011) and Bang et al. (2012)- these two studies evaluated effect of Vitamin D on 
activation of CD4 lymphocytes. Potential beneficial effect of supplementation on CD4 
count was suggested by cross-sectional studies on adults with HIV (see Haug et al., 1994; 
Teichmann et al., 2003). These potential benefits did not translate in the prospective 
cohort studies done by Van Den Bout-Van Den Beukel et al. (2008) in adults and Arpadi 
et al. (2009) in children.  
Kakalia et al. (2011) study was very relevant to the current research because it 
evaluated in a randomized, non-blinded, controlled fashion the impact of Vitamin D 
supplementation on CD4 count and percent and other measures of Vitamin D 
homeostasis (25(OH)D and 1,25(OH)2D) in children with stable HIV (n = 53). The 
children (age range 3-18 years; mean age 10.3 ± 3.9 years) consisted of 55 percent 
females and 64 percent African-Canadians. They were divided into three groups and were 
followed up for 6 months: no supplementation (Group 1), 5600 IU/week supplementation 
(Group 2), and 11,200 IU/week (Group 3). Once weekly dosing was used for more 
convenience and compliance. The study used liquid Vitamin D drops (D3) 
cholecalciferol. Adherence was assessed through measuring remaining Vitamin D liquid 
in the bottle. Patients in the placebo group were treated later. The study used a dietary 
questionnaire administered by a nurse or a physician before the initiation of 
supplementation to assess dietary intake of calcium and Vitamin D; though not formally 
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validated, this questionnaire was frequently used in the calcium bone clinic. Same 
questionnaire was reused at the end of the study to assess dietary changes. Vitamin D 
deficiency and insufficiency were defined as such: < 10 ng/μL and 10-30 ng/μL, 
respectively. Vitamin D levels and CD4 counts were measured at baseline, three and six 
months. The baseline results showed that the mean 25(OH)D was 53.1 ± 24.8 nmol/L; 
only 15% were Vitamin D sufficient at enrollment.  
The three groups were comparable with no significant differences with respect to 
age, sex, BMI, ethnicity, CDC clinical or immunological category, receipt and duration 
of ART, CD4 percent, CD4 count, or viral load. Most importantly, there was no 
difference in 25(OH)D levels or 25(OH)2D at baseline (p = 0.1 for both). Also, there was 
no significant difference in dietary Vitamin D intake (p = 0.32). Vitamin D insufficiency 
and deficiency exceeded 80 percent in all groups. Results showed significant increases in 
Vitamin D level in both supplemented groups; normalizing and achieving Vitamin D 
sufficiency level was significant in both groups: for Group 2 with 800 IU/day, there was 
an increase from 17% to 39% (p = 0.0002), and from 6% to 67% (p < 0.0001) for Group 
3 with 1600 IU/day. This reflected some kind of dose-dependent increase in achieved 
level that corresponded with higher supplementation dose. There was no significant 
increase in Vitamin D level in the placebo group. The increase in 25(OH)D differed 
significantly between groups (p = 0.0002); in Group 2, 25(OH)D improved from baseline 
49.9 nmol/L (SD = 22.5) to 76.5 nmol/L (SD = 30.3), and from 42.7 nmol/L (SD = 18.1) 
to 96.5 nmol/L (SD = 41.9) in Group 3.  
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There was no significant difference in the levels of 1,25(OH)2D, CD4% (p = 0.80) 
or CD4 count (p = 0.10), and viral load log10 (p = 0.99). The lack of significant impact of 
Vitamin D supplementation on CD4 percent, CD4 count, or viral load (even after 
adjusting for potential confounding variables) incited the authors to run a separate 
analysis to examine the change in serum Vitamin D level and the association with CD4 
count and percent irrespective of randomization group; they found a negative but 
significant association between change in serum Vitamin D level and change in CD4 
count (p = 0.02). The variables that were associated with change in CD4 percent on 
univariate analysis included age (p = 0.03), duration of ART (p = 0.03), and BMI (p = 
0.06). In summary, Vitamin D supplementation at both doses did not lead to an increase 
in CD4 count or percent in HIV positive children with somehow preserved immunologic 
function (mean 927 cells/μL ± 468), despite the fact that about 85 percent were Vitamin 
D deficient and insufficient and had significant increases during the course of study. 
However, the researchers raised the issue of investigating the need for higher 
supplementation dosage tailored for HIV patients, since about two-third of the children in 
the study failed to achieve the optimal serum level of 75 nmol/L. The researchers 
indirectly questioned the adequacy of 600 IU/day recommended dose by the Institute of 
Medicine in HIV patients; they recommended, instead, having a more appropriate dose 
such as 1000 to 2000 IU/day with monitoring.  
The results of Kakalia’s study (2011) resonate with those from Arpadi et al. 
(2009, 2012) study, especially that the latter’s study population resembled Kakalia’s, 
which also recruited healthy HIV-infected children and adolescents with a median 
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baseline CD4 percent of 30.6 ± 10.5, and CD4 count of 769 cells/μL ± 343. However, 
Arpadi et al. (2009) carried out their first study in 2009 before Kakalia and were quite 
content with their unique assessment of Vitamin D supplementation over a one-year 
period. The aim of Kakalia et al. (2011) study was to evaluate the effect of bimonthly 
(every two months) administration of oral cholecalciferol D3 100,000 IU plus 1 g/day of 
calcium (2 chews daily) on serum Vitamin D levels, serum and urine calcium, and on 
HIV disease progression during a 12-month period in HIV infected children and 
adolescents. The researchers assigned study personnel to dispense and administer 
Vitamin D or the placebo every two months during study visits (both personnel and 
participants were blinded to treatment allocation) to ensure adherence and remove bias. 
Kakalia et al. (2011) recruited 59 children and adolescents with deficiency and 
insufficiency aged six to sixteen years from hospital-based pediatric HIV treatment 
programs in New York City between 2004-2005, but only 56 completed the 12-months 
study. For this randomized controlled study, subjects were randomly assigned through 
computer generated random numbers in SAS to receive Vitamin D supplementation D3 
and calcium (VD+) or were double placebo (VD-). Stratified by gender, age, and study 
site, the final sample consisted of 29 in VD+ and 27 in VD-. At baseline, both groups 
VD+ and VD- were comparable. After 12 months, the mean monthly serum 25(OH)D 
level was significantly higher for VD+ (32.4 ng/μL ± 9.0) as compared to VD- (21.9 
ng/μL ± 9.4), p < 0.001. By the end of the twelve months, only two subjects (6.7%) from 
the VD+ group remained deficient < 20 ng/μL, as compared to 14 (50%) of participants 
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from the VD- group. Optimal Vitamin D level ≥ 30 ng/μL was noted in 44.4% (n = 12) in 
the VD+ as compared to 11.1% (n = 3) from the VD-, (p < 0.02).  
Regarding the immune effect of supplementation in Kakalia et al. (2011) study, 
there was no significant difference in markers of HIV disease progression between the 
two groups as measured by changes in CD4 count, CD4 percent, and vital load. For 
instance, in VD+, CD4 count at baseline was 771 ± 328 cells/μL and by the end of the 12 
months, it registered 776 ± 359 cells/μL, while CD4 count decreased from a baseline of 
719 ± 382 cells/μL to 661 ± 363 cells/μL at one year (p = 0.18). Despite the safe and 
well-tolerated supplementation regimen used in this study, the significant increase in 
Vitamin D level in the supplemented group was still below expectation and not up to par 
with bone health or with immune health. The researchers recommended caution with 
interpretation of results mainly due to the small sample size and suggested need for 
additional studies.  
Kakalia’s et al. (2011) and Arpadi’s et al. (2009) results suggested that in case of 
relatively preserved immunological function in children as measured by CD4 count at 
baseline, Vitamin D supplementation in 800mg or 1600mg daily doses did not lead to 
significant increase in CD4 count; but this might not be generalized to children with more 
advanced HIV disease and with low baseline CD4 counts. In a randomized controlled 
study in Italy, Giacomet et al. (2013) studied 52 HIV+ youths (aged 8-26 years) with 
Vitamin D deficiency < 30 ng/μL; the study aimed to test whether 100,000 IU D3 
administered every three months and over a one-year period (4 doses total) to a 
supplementation group (n = 26) - and withheld from or placebo group (n = 26) - would 
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lead to improvement in Vitamin D levels and T-cell phenotype (mainly CD4 count, plus 
T-lymphocyte VDR expression, Th1, Th2, Th17, and Treg lymphocytes). Both 
supplementation and placebo groups were comparable at baseline, more than 80% of 
patients in each group were receiving ART and had undetectable viral load; and both 
groups were similar in their immunological and Vitamin D profiles at baseline.  
At the end of the study, Vitamin D levels increased considerably in the 
supplemented group with a mean difference of 27 ng/μL (95% CI [10 - 44], p < 0.001) as 
compared to placebo, while insufficiency persisted in only 20% as compared to 60% in 
the placebo group (p = 0.007). It was interesting to find that Vitamin D increase became 
more prominent after six months of supplementation; in this case, it coincided with the 
summer months and more sun exposure- indicating a possible effect on Vitamin D 
synthesis. Both 25(OH)D and 1,25(OH)2D increased but at different paces, the latter 
taking more time probably due to an acceptable degree of immune functioning. On the 
other hand, the study failed to show significant changes in CD4 counts in both groups. 
Knowing that the baseline CD4 counts were 663 cells/μL (95% CI [507 - 796]) in the 
supplemented group and 673 cells/μL (95% CI [601 – 773]), p > 0.05. Such result again 
concurred with Kakalia’s et al. (2011) study and recommended studying subjects with 
less immune preservation in order to elucidate the link between Vitamin D 
supplementation and CD4 counts.  
Perhaps, Poowuttikul et al. (2013) study is considered a real inspiration for the 
current study, especially with regard to the similarities in the location of the study, the 
type of participants who are predominantly dark skinned in a low sunlight area (Detroit, 
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Michigan), and the used methodology (retrospective chart review study). Similar to the 
aforementioned studies, Poowuttikul et al. (2013) aimed to examine the prevalence of 
Vitamin D deficiency in children and young adults with HIV (2 – 26 years old) and to 
assess whether Vitamin D supplementation would improve their immune disease 
markers, mainly viral load, CD4 counts, and CD4 percent. The researchers recruited 160 
patients during routine clinic visits between 2010 and 2011. The sample was 
predominantly African American (152 out of 160 or 95 percent), and it consisted mainly 
of males (76.3 percent). Moreover, the proportion of young patients aged 21-26 years was 
about 47 percent, while those aged ≥ 10 years summed up to 8 percent. The majority of 
participants were on ARV, and only 28 percent were not. The investigators used ≤ 20 
ng/μL and ≤ 35 ng/μL as thresholds for Vitamin D deficiency and insufficiency, 
respectively. At baseline, only eight children were Vitamin D sufficient, and therefore, 
were used in normal Vitamin D comparison group against insufficient and deficient 
groups. Out of the 152 with low Vitamin D, almost 72 percent (n = 115) had Vitamin D 
deficiency (≥ 20 ng/μL), 23 percent (n = 37) had insufficiency (21-35 ng/μL). It was kind 
of expected since the majority of patients were African Americans and lived in a cold 
climate area with low sun exposure. All patients whose Vitamin D level was ≤ 35 ng/μL 
received Vitamin D3 supplementation as part of routine care (cholecalciferol D3 1000 
units/day), and Vitamin D testing was repeated every three months.  
HIV plasma RNA (viral load), absolute CD4 counts, CD4 percent were compared 
between low Vitamin D subjects (n = 152) and the group with normal Vitamin D (n = 8) 
pre- and post-Vitamin D supplementation. At baseline, the results were comparable and 
104 
 
showed that HIV children aged ≤ 10 years had higher Vitamin D level (mean 24.8 ng/μL) 
as compared to adolescents aged 11-20 years (16.9 ng/μL) and young adults aged 21-26 
years (mean = 17.6 ng/μL). Patients with severe deficiency (≤ 10 ng/μL) had lower mean 
absolute CD4 count of 574.41 (± 306.17) cells/μL compared to 701.15 (± 444.19) 
cells/μL among subjects with higher Vitamin D level (p = 0.09). After supplementation, 
only 39.5 percent (n = 60) of the 152 increased their Vitamin D level from a mean level 
of 13.7 (± 7) ng/μL pre-supplementation to 25.0 (± 13.3) ng/μL post-supplementation 
(only 10 patients reached normalization of 25(OH)D). About 45 percent (n = 27) had 
insufficiency (21-35 ng/μL), and 38.3 percent (n = 23) remained deficient (≤ 20 ng/μL). 
Similar to the aforementioned studies, and despite relative improvement in Vitamin D 
levels, mean CD4 counts post-supplementation 702.3 (± 446.7) cells/μL did not 
significantly differ from pre-supplementation mean count 734 (± 496.9) cells/μL, p = 
0.26. It was quite interesting to find that mean viral load remained high and did not 
decrease significantly from pre-supplementation 22,310.77 (± 98,793.34) copies/mL to 
10,209.65 (± 25,015.93) copies/mL post-supplementation, p = 0.31. The researchers 
stated that the low CD4 counts were most likely due to high viral load, and they referred 
to poor adherence to ARV that might have led to insignificant decrease in HIV viral load, 
rather than in response to the effect of Vitamin D. In the same sense, they suggested the 
need for more aggressive Vitamin D supplementation to change CD4 count and viral 
load. The fact that the majority of subjects remained deficient after supplementation 
might have reflected issues of poor adherence to Vitamin D, inadequate dose, poor diet, 




Overall, the literature review emphasized that Vitamin D deficiency is associated 
with negative outcomes in HIV patients. It also gathered sufficient evidence regarding the 
risk factors of Vitamin D deficiency. There is evidence about the benefits of 
supplementation on bone health, but there is lack of sufficient data on its equal benefits 
on the immune system function in HIV, especially in view of the high volume of 
observational studies and a mediocre number of randomized clinical trials in HIV 
patients. Prevention of Vitamin D deficiency through attenuating the risk factors is highly 
needed. Vitamin D supplementation and impact on immune health remains substantially 
under-studied. There is a clear need for randomized controlled well-designed studies in 
order to establish a causative association between Vitamin D deficiency and CD4 count 
and to examine the real impact of supplementation on immune function. Armed with the 
postulation that Vitamin D supplementation might hold some promising results as far as 
boosting the immune system is concerned in HIV population, this current research did not 
seek to resolve the controversy of Vitamin D supplementation impact on CD4, rather it 
attempted to add further knowledge to the current public health literature in this complex 









Chapter 3: Research Method 
Introduction 
This study explored the impact of Vitamin D supplementation on the immune 
function of a sample of African American, male HIV patients with Vitamin D deficiency. 
Vitamin D status categorization (normal, deficiency, or insufficiency) depended on 
Vitamin D [25(OH)D] level in the blood. The study also investigated the relationship 
between Vitamin D level and CD4 count and CD4 percentage. The study utilized 
secondary data obtained from reviewing patients’ medical charts. This methodology 
chapter presented and discussed the following major sections: The study design; the 
setting and sample size; the ethical precautions; the types of data and variables; the data 
collection process and tools; and the analysis plan. Moreover, the chapter concluded with 
an overall description on the potential threats to validity (internal and external).  
Research Design and Approach 
The research design relied on a quantitative approach using retrospective 
observation (chart review), which is widely utilized in both public health and 
epidemiology, in addition to clinical research (Gearing et al., 2006). Retrospective chart 
review is generally underestimated and underutilized in the clinical and health care field 
and can be beneficial if researchers understand how to implement it correctly and how to 
minimize its limitations (Gearing et al., 2006). Retrospective chart review may not be the 
ideal research methodology that provides evidence of sound methodological standards 
due to the potential limitations in data completeness; still, it provides a cost-effective 
accessibility to readily available secondary data capable of answering most research 
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questions and of generating new hypotheses for future studies (Gearing et al., 2006). This 
study is observational/non-experimental and consists of following a cohort of HIV 
patients retrospectively from exposure to outcome. Moreover, the study is also 
considered analytical in nature (rather than descriptive) because it uses a comparison 
group and it seeks to test hypothesized association between exposure and outcome.  
In this study, a standardized chart review data abstraction electronic form was 
used to collect data on specific demographic, socioeconomic, and clinical variables. An 
important methodological drawback in a retrospective chart review study, which is also 
known as medical record review (MRR), is when the abstractor lacks proper 
medical/clinical knowledge or training for understanding and dealing with the study 
variables (such as proper coding and using standardized abstraction forms) (Allisson et 
al., 2000). Failure to control for this drawback in the abstraction process jeopardizes the 
validity and reliability of data (Vassar & Holzmann, 2013; Worster, Bledsoe, Cleve, 
Fernandes, Upadhye, & Eva, 2005; Worster & Haines, 2004). Another methodological 
standard that should be guarded in the same context is the abstractor’s blinding to the 
study research questions or hypothesis in order to remain objective and unbiased 
(Allisson et al., 2000; Gearing et al., 2006; Vatt & Holzmann, 2013). In view of the lack 
of financial and logistic resources to hire abstractors (Findley & Daum, 1989), this 
researcher, as a health professional with training in the medical and clinical field, 
abstracted data from charts into an electronic database and followed strict definition and 
coding manual for each variable to circumvent the lack of blinding to the study purpose 
(Allisson et al., 2000). Furthermore, inter-observer or inter-rater reliability testing can be 
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done to ensure reliability of collected data between abstractors but is totally beyond the 
scope of this study (Worster et al., 2005). On the other hand, Allisson et al. (2000) and 
Gearing et al. (2006) recommended an intra-rater reliability for the same abstractor, that 
is, reviewing same charts on two different occasions and measure a kappa intra-class 
correlation coefficient (ICC) to examine degree of resemblance and achieve more than 
80% reliability score.  
This retrospective design provided an opportunity to study a unique population at 
a single site and to capture all the necessary data. The study population consisted of all 
HIV-infected African American men (aged 21 years and up) who attended a specialty 
HIV clinic in an underserved community in Southeast Michigan between 2010 and 2014. 
Selecting a comparison group from the same clinic and HIV population was done to 
reduce sampling bias because both exposed and non-exposed groups (Vitamin D 
deficient and non-deficient/sufficient, respectively) assumingly share similar risk factors 
and characteristics, especially that they come from same geographic area and live in 
similar latitude. Retrospective studies are automatically free from information biases that 
result from recall bias, provided that the medical records have complete and accurate data 
(Gearing et al., 2006). In this case, chart review allows more reliance on specific 
objective biomarkers in the charts that significantly relate to the variables under study 
and the research hypotheses. 
In this study, I adopted the Institute of Medicine (IOM) and the Endocrine 
Society’s guidelines’ definitions of the different Vitamin D statuses, whereby Vitamin D 
levels ≤ 20 ng/μL (equivalent to ≤ 50 nmol/L) represented deficiency status; 21-29 ng/μL 
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(equivalent to 51-74 nmol/L) represented insufficiency status; and levels ≥ 30 ng/μL 
sufficient (equivalent to 75 nmol/L) pertained to normal or sufficiency status (Holick et 
al., 2011; Holick & Chen, 2008; IOM, 2011). Vitamin D level at baseline was assessed 
and the first measurement recorded in the chart marked the initial date of entry into the 
study. Based on baseline Vitamin D levels, the cohort was divided into two groups: 
Group 1, deficient group, consisting of HIV infected African American men with 
Vitamin D levels of < 30 ng/μL (Vitamin D deficiency cutoff point is set at ≤ 20 ng/μL 
and insufficiency cutoff point at 21-29 ng/μL); Group 2, nondeficient or sufficient group, 
consisted of HIV infected African American men with adequate levels of Vitamin D (≥ 
30 ng/μL). Both deficient and nondeficient groups underwent evaluation of their CD4 
count/percent at baseline before supplementation in accordance with the first Vitamin D 
level at study initiation.  
The study assessed CD4 count as the major biomarker reflecting the immune 
function. CD4 count test reflects the actual number of CD4 cells per microliter of blood 
sample (number of cells/μL is equivalent to number of cells in mm3 of blood); the normal 
laboratory range for CD4 count is set between 500 and 1600 cells/μL (AIDS InfoNet, 
2014). Moreover, the study assessed CD4 percentage (CD4%) as an additional immune 
function endpoint. The CD4% estimates the percentage of white blood cells or 
lymphocytes that are CD4 T-cells per microliter of blood. In fact, the HIV literature have 
shown the advantage of using both CD4 count and CD4 percent as equally important 
clinical markers of HIV disease progression and better assessors of overall immune 
function (Guiguet et al., 2009; Hulgan et al., 2007; Moore et al., 2006; Pirzada, Khuder, 
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& Donabedian, 2006). However, since CD4 count fluctuates in response to some factors 
such as stress level, diet, exercise, time of day the blood was drawn, presence of infection 
or illness, some HIV clinical literature have pinpointed to the importance of relying on 
CD4 percent in adjunct to CD4 count as another surrogate marker of immune function 
that is more stable and clinically accurate- provided patients are AIDS-free (i.e., with 
CD4 count > 200 cells/μL) (AIDS InfoNet, 2014; Guiguet et al., 2009; Hoffman, Van 
Griensven, Colebunders, & McKellar, 2010; Hulgan et al., 2007; Moore et al., 2006; 
Pirzada, Khuder, & Donabedian, 2006). On the other hand, when a patient experiences a 
transient and sudden drop in CD4 count that does not go hand in hand with a drop in CD4 
percent, this could mean that this drop in CD4 count is most likely related to other factors 
(as mentioned above), and therefore, it is considered clinically insignificant since CD4 
percent remained stable (Pirzada, Khuder, & Donabedian, 2006).  
When CD4 count is evaluated, it is advised to take into consideration the trend or 
mean of several test results every 3-6 months for patients with CD4 count < 350 cells/μL, 
to capture the CD4 trend and the magnitude of immune cell recuperation/restoration 
(DHHS, 2012; 2014). According to the newest guidelines (DHHS, 2014), patients with 
CD4 count that ranges from 300 to 500 cells/μL and with controlled viral suppression can 
have a retesting of their CD4 count every 12 months; when patients experience a rebound 
in viremia (viral load increase) or clinical symptoms, then, frequent CD4 count testing 
should be resumed.  
CD4 count and percentage follow the CDC (2008b) immune classification and 
staging system, whereby a CD4 count < 200 cells/μL is considered a severe immune 
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suppression and merits AIDS diagnosis, and CD4 count between 200 to 499 cells/μL is 
moderate immune suppression (refer to Table 2). CD4 count (or percent) follow-up on 
patients is essentially needed to monitor HIV disease course path and response to 
treatment, the need for ART commencement to restore immune function or halt immune 
deterioration, and to assess the need for prophylaxis against opportunistic infections 
(DHHS, 2012). On the other hand, recent clinical guidelines urge clinicians to start ART 
once patients’ CD4 counts drop to 350 cells/μL and below, and recommend close 
examination of viral load to ensure viral suppression (DHHS, 2012). However, the most 
recent revised guidelines (DHHS, 2014) urge clinicians to proactively and aggressively 
start ART without waiting for the drop in CD4 count to 350 cells/μL. In addition to CD4 
count and percentage, viral load is also accounted for in the immune function. HIV RNA 
or viral load is considered another important immunological marker that depicts response 
to ART and its effectiveness in suppressing viral replication or viremia (below 200 
copies/mL) after initiating ART (DHHS, 2014). 
Based on theoretical grounds discussed in the literature review, this study was 
guided by two predominant research questions and the following null hypotheses:  
1. There is significant correlation between Vitamin D levels (independent variable 
measured as normal or deficient) and CD4 count and CD4 percent (dependent variables)- 
after adjusting for potential confounders in the sample.  
2. There is a significant effect of supplementation as depicted by a statistically 




CDC Immune Stages According to CD4 Percentage & CD4 Count Groups 
CDC Stage  CD4 Percentage (%) CD4 Counts (cells/μL) 
1 >29 >500 
2 14-28 200-499 
3 (AIDS) <14 <200 
Unknown NA NA 
Source: CDC. (2008b). Revised surveillance case definitions for HIV infection among adults, 
adolescents, and children aged <18 months and for HIV infection and AIDS among children aged 
18 months to <13 years—United States, 2008. MMWR, 57(RR10), 1-8.  
 
The outcome measures consisted of running correlation analyses between Vitamin 
D level and CD4 count/percent, and of calculating the absolute change in Vitamin D 
levels, in addition to examining the changes in CD4 count, CD4 percent, and viral load 
from before to after Vitamin D supplementation (pre and post-supplementation). A 
randomized controlled trial with pretest and posttest could have been optimal but not 
logistically possible for the scope of the study and with regard to the retrospective nature 
of the study. As for ethical considerations, the IRB team at Walden University did not see 
the necessity to seek individual consent from each patient in the study as long as patients’ 
describers were not gathered and reported, and as long as patients’ privacy was secured in 
accordance with HIPPA regulations. The IRB approval number for this study is 01-08-
15-0055963. 
Setting and Sample 
This study utilized data collected on HIV patients who presented to an 
underserved specialty clinic ACCESS in Dearborn, Michigan between 2010 and 2014. 
The convenience sample included only African American male HIV patients, aged 21 
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years and up, residing in Metropolitan Detroit area in Michigan and attending the same 
HIV clinic, under the care of the same physician. Besides treating patients who have 
health insurance, the ACCESS clinic also receives federal financial support from the 
Ryan White HIV/AIDS Program that funds treatment and medical care for uninsured or 
underinsured HIV/AIDS patients. The clinic has a high retention rate of patients that 
exceeds 95% a year with only one death that has been reported since initiation of services 
in 2008. The physician at the clinic has infectious diseases and HIV medical subspecialty 
and is the only physician who has been treating all HIV patients coming to the clinic. 
This HIV specialist at the clinic uses an aggressive approach in treating HIV, whereby 
almost all patients with CD4 counts below 350 cells/μL get treated.  
The clinic started treating HIV patients since 2008 and has treated so far about 
300 HIV patients (roughly estimated that more than 90% are males). However, regular 
checking for Vitamin D level on all patients started in 2010; therefore, only patients with 
baseline Vitamin D levels before supplementation were eligible for inclusion in the study. 
First Vitamin D measurement marks initial data of entry or time 0 (denoted as T0). This 
study recruited African American male HIV patients who were tested for Vitamin D at 
baseline as part of routine care and who only had subsequent Vitamin D levels at 
different follow-up visits. Professional phlebotomists at the on-site laboratory available at 
the clinic facility were responsible for withdrawing all blood specimens, and the Detroit 




A sampling frame was formed of all the HIV patients who presented to the clinic 
in 2010 and onward; only those who fulfilled the inclusion criteria and had baseline 
Vitamin D in records were considered. Unfortunately, the clinic has not yet established 
electronic medical records or EMR but it keeps a list of all HIV patients separate from 
other patients seen for other medical reasons at the clinic. The presence of an active 
outreach HIV screening and prevention program at the clinic constitutes a major hub for 
recruiting these HIV patients and bringing them into medical care. Therefore, all HIV 
patients who fit the eligibility criteria were selected and constituted the main sampling 
frame for the non-probability sample. As for inclusion criteria, all eligible male HIV 
patients should be African Americans and should have the following: age (21 years and 
up); baseline and consecutive (post-supplementation) tests on Vitamin D level, viral load, 
CD4 count, and CD4 percent; stability on ART regimen without medication change for at 
least three months before study initiation (i.e., first baseline Vitamin D level); no prior 
Vitamin D supplementation before study initiation; and stable clinical HIV disease. 
Exclusion criteria would contain presence of strong confounding factors such as subject 
already taking or took Vitamin D supplementation (there is two months wash out period), 
or having chronic comorbidities that would affect the validity of the data.  
As mentioned earlier, based on their 25(OH)D level at baseline (T0), patients 
were divided into two groups: normal (sufficient or nondeficient) group and deficient 
group (insufficient and deficient). Only the deficient group who received Vitamin D 
supplementation was followed up for at least twelve months in retrospect to assess effect 
of supplementation on Vitamin D and CD4 count and percent. The supplementation 
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regimen consisted of a high dose 50,000 IU taken orally only once weekly to encourage 
more compliance; after 8-16 weeks, repeated 25(OH)D levels were reassessed again and 
collected within the follow-up period up to one year. On their clinical routine visits, all 
patients with Vitamin D deficiency were verbally encouraged by the physician to take 
their Vitamin D supplementation; there was only verbal follow-up on compliance through 
directly asking the patient on the medications taken on each follow-up visit.  
In order to obtain an adequate number of participants, initially, all eligible patients 
under routine care were included (convenience sample). It was hard and impractical to 
select a random sample for this study and to avoid random sampling error that is 
characterized by a biased selection of participants (Suresh, Thomas, & Suresh, 2011). 
This would be a major drawback that may threaten external validity or generalizability of 
inferences and results to the greater population from which the sample is derived. 
However, the study will attempt to avoid the pitfalls of non-sampling errors throughout 
the processes of data collection, measurements, and analyses (e.g., through including 
potential confounders) (Suresh et al., 2011). Besides, selection bias can be reduced if 
both groups, deficient and non-deficient, displayed similar baseline characteristics. On 
the other hand, the statistical tests suggested to answer the proposed correlation and 
comparative research questions would dictate the suitable sample size. 
Generally-speaking, in order to estimate the sample size needed, it would be 
essential to run power analysis to make sure that the selected statistical tests could 
improve the precision and certainty of results, along with increasing the likelihood to find 
an association between variables or to detect a treatment effect in comparison to a control 
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group (Findley & Daum, 1989; Suresh, Thomas, & Suresh, 2011). Once the statistical test 
is chosen (e.g., correlation r or t test), there are three elements that are essential for power 
analysis:  
1. Alpha level or type I error, which is conventionally set at 5% or p = 0.05 level 
of significance; that means that there is only 5% chance that the researcher would 
incorrectly reject null hypothesis (Laureate, Education, Inc., 2010).  
2. Effect size: usually, a predetermined effect size is used from previous research.  
3. Sample size: in case there is lack of previous data in the literature, it will be 
wise to specify a Cohen’s effect d (usually small effect or medium) and determine the 
corresponding sample size (Laureate, Education, Inc., 2010).  
As far as effect size is concerned, it is important to take an idea or identify a 
clinically significant difference between treatment and comparison group from similar 
studies in the literature. Sometimes it is hard to find an effect size, the researcher can then 
deduce a clinically significant difference from using standard deviation units and 
subtracting highest and lowest mean values from the literature (Conroy, 2004). In fact, 
this is similar to the original work of Cohen (1988) on effect size d, in which d designates 
a statistical difference between two groups, and is calculated by dividing mean difference 
before and after treatment by standard deviation. Cohen (1988) specified the following 
effect sizes: small d < .50; medium d = .50 –.80; and large d > .80. In correlation studies, 




 In order to calculate any sample size, a power analysis is usually set between 80% 
and 95%, that is, the researcher has set a probability of 95% for finding a treatment effect 
size and there is no more than 5% margin of error (95% of the time expecting to get an 
effect) (Laureate, Education, Inc., 2010). While this study may fail to ensure the 
representativeness of the sample (affecting external validity) because of the use of a 
convenience sample, at least, an adequate sample size with sufficient statistical power 
might be able to detect effect, associations, and correlations with adequate precision 
(Suresh et al., 2011) and salvage internal validity to a certain extent.  
Consequently, the researcher reviewed similar studies to examine indicators used 
in calculating sample size (e.g., effect size, or power analysis). From the literature, the 
most recent DHHS guidelines (2014), reported that a 30% change in the absolute CD4 
count or a standard deviation difference between two CD4 count tests by two points – 
equivalent to a three percentage points difference in CD4 percent – was considered 
significant. Moreover, four methodologically similar studies influenced sample size 
determination for this study; all four dealt with Vitamin D deficiency in HIV population 
and assessed Vitamin D supplementation. In a retrospective chart review study by 
Poowuttikul et al. (2013), the researchers used routine visits in three clinics over one year 
from 2010 to 2011 and recruited 160 HIV-infected subjects (152 were African 
Americans), aged 2–26 years, with Vitamin D deficiency (≤ 35ng/μL). Only eight 
subjects had normal Vitamin D levels (nondeficient). The study did not mention sample 
size determination method. The researchers ran comparative analysis using a very small 
number of participants in the non-deficient group (n = 8), the fact that could have skewed 
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the results; therefore, in order to reduce this potential problem that ensued from this small 
number of non-deficient subjects, the researchers divided the deficient group into three 
subgroups: insufficient (37 subjects); deficient (74 subjects); and severely deficient (41 
subjects). Consequently, in order to reduce between subjects variability, all three groups 
and the 4th non-deficient groups were compared pre and post supplementation for 
changes in Vitamin D, CD4 counts, and CD4%, and viral load.  
The second study by Arpadi et al. (2009) studied the effect of bimonthly Vitamin 
D supplementation on Vitamin D levels and calcium levels in 56 HIV children and 
adolescents (aged 6–16 years) recruited from four hospital-based pediatric HIV treatment 
programs in New York. They specified that they randomly assigned subjects to 
supplementation group (VD+ = 29) or placebo (VD- = 27). The methodology did not 
specify how the statistician calculated the sample size, but rather discussed the 
randomization process to treatment and placebo. On the other hand, Kakalia et al. study 
(2011), the most resembling –methodologically– to the proposed study, provided all 
necessary details about sample size calculation. The purpose of Kakalia et al. study 
(2011) was to assess the impact of Vitamin D supplementation on CD4 count, percent, 
and Vitamin D levels in children with HIV. The researchers based their sample size 
calculation on previous data analysis done at their clinic that showed a CD4 percent mean 
of 20 ± 3 (SD); then they assumed a 3% CD4 percent change between Vitamin D levels 
in supplemented versus nonsupplemented with an alpha level of 0.025 and a power of 
80%. Their final sample consisted of 54 subjects and was randomized into three groups 
for analyses. Lastly, Bang et al. (2012) in their placebo-controlled randomized study 
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sought to examine the impact of Vitamin D supplementation on CD4+ T cells and Tregs 
in HIV males; they determined a sample size equivalent to 50 patients, based on a power 
of 90% and an assumed increase in 25(OH)D level of 20 nmol/L following Vitamin D 
supplementation compared to no increase in the placebo group.  
Based on the preceding sample size discussion, the study adopted Kakalia et al. 
(2011) published sample size calculation (n = 54). As previously mentioned, this study 
aimed to test the correlation between Vitamin D level and CD4 count or percent, and to 
examine the impact of Vitamin D supplementation on CD4 count and percent through 
comparing before and after levels and comparing between groups levels (deficient versus 
nondeficient). To answer the research question about comparing pre supplementation and 
post supplementation parameters, the researcher assumed a Cohen’s effect size of d = 0.5 
between the supplemented and nonsupplemented group at 80% power level for two-tailed 
alpha = 0.05; therefore, the researcher needed 95 participants for between groups 
comparison, and only 42 for within groups comparisons (Cohen, 1988). When comparing 
pre and post values or within subjects change values from baseline to follow-up, the 
variability in values as well as the standard deviation value is expected to be lower; this is 
expected to result in higher precision and power of the results as compared to between 
patients variability in the two groups comparison, and thus, would demand a smaller 
sample size (Shintani, 2008). On the other hand, if the sample size calculation was based 
on the other research question related to investigating the correlation between Vitamin D 
and CD4 count/percent, then, at 80% power level and a two-tailed alpha = 0.05, only 41 
participants were needed in order to detect r = 0.5 (Cohen, 1988). Based on ballpark 
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estimate and the physician’s opinion on the HIV population he treated at the clinic, about 
100 patients would fit the inclusion criteria; therefore, this study originally sought to 
achieve a total sample size of 100 patients, but ended up recruiting only 70.  
Data Collection and Analysis 
I collected data and entered it manually into the electronic database of SPSS 
version 21.0 (SPSS Inc., Chicago) to perform statistical analysis. The total follow-up time 
to all patients ranged from six months to at least one year (maximum 14 months). The 
continuous data were presented as means and standard deviation, or median with 
interquartile range (IQR). All categorical or nominal variables were presented as 
frequency and percentages. The main dependent variables in this study were CD4 count, 
CD4 percent, and viral load. The independent variable is Vitamin D deficiency, 25(OH)D 
< 30 ng/μL. In order to test the main study hypotheses, the following variables (Table 3) 
were examined because of their potential direct bearing on the study: age; BMI; smoking; 
injection drug use; hepatitis C; time since HIV diagnosis or HIV duration; season of 
measurement; serum 25(OH)D; serum 25(OH)D category; ART; CD4 count; CD4 
percent; CD8%, CD4/CD8 ratio; and HIV plasma RNA (viral load).  
Table 3 provided a list of all the variables with their type of measurement and the 
corresponding type of results, parametric or non-parametric – depending on the 
distribution of data. Date of the first 25(OH)D level was used as time of entry into the 
study. Dates for all relevant laboratory results of all successive visits were entered to 
verify timeline between baseline and repeated measures, and to verify season of blood 
draw for Vitamin D. Only successive laboratory results within a one–year study time 
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frame were considered. A baseline and post-supplementation analyses were performed to 
check changes in parameters at baseline, after six months, and up to one year of 
supplementation. Participants were measured at T0 (baseline), T1 (six months), and T2 
(12 months).  
Table 3 
List of Variables Included in The Study and Their Descriptive Statistics  
Variables Statistic 
Age, years Mean (SD) 
Median (range) 
BMI Kg/m2 Mean (SD) 
Median (IQR) 
Smoking (yes, no) Number (%) 
Injection drug use (yes, no) Number (%) 
Chronic hepatitis C (yes, no) Number (%) 
Season of measurement: 
• Winter months (November- February) 
• Sunlight months (March-October) 
Number (%) 
HIV duration (years) Mean (SD) 
Median (IQR) 
ART Number (%) 
Serum 25(OH)D (ng/μL) Mean (SD) 
Median (IQR) 
Serum 25(OH)D category 
• Deficient  
• Sufficient/Non-deficient 
Number (%) 
CD4 cell count (cells/μL) Mean (SD) 
Median (range) 
CD4% (cells/μL) Mean (SD) 
Median (range) 
CD8% (cells/μL) Mean (SD) 
Median (range) 
CD4/CD8 ratio (cells/μL) Mean (SD) 
Median (range) 




The main focus of this study addressed the two aforementioned types of research 
questions: comparative and associational/correlational (Morgan & Harmon, 2000). 
Although the study was not descriptive in nature, it was still essential to run a preliminary 
descriptive analysis to learn about the characteristics of the sample at baseline through 
summarizing demographic and clinical data, and to examine whether both groups are 
similar at baseline. To check for normality of distribution of continuous data, Shapiro-
Wilk test was used. In order to assess significant differences between groups and 
delineate effect of Vitamin D supplementation on Vitamin D levels and on CD4 
count/percent, this study sought to answer one correlational research question (Vitamin D 
and CD4) and one major comparative pre–post question.  
The first correlation question addressed whether there was a correlation between 
Vitamin D deficiency and CD4 count or CD4 percent. Pearson’s correlation (“r” ranging 
from 0 to 1) or Spearman rho (rs) were used when both variables were continuous; they 
also assessed linear association between both variables. A Pearson’s or Spearman’s 
correlation coefficient that is equal to 1 means perfect correlation, 0 means no 
correlation, and -1 means inverse correlation. When the data were skewed, the 
nonparametric Spearman rho correlation was used instead of Pearson’s. Most of the time, 
both parametric and nonparametric correlation analyses were run even when the 
assumption of normality was not met. P value set at < 0.05 depicted statistical 
significance for all analyses.  
1. RQ1: Do Vitamin D levels significantly correlate with CD4 count (percent)?  
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• Null H0: There is no statistically significant correlation between Vitamin D levels 
and CD4 count (percent) in supplemented group versus nonsupplemented.  
• Alternative H1: There is statistically significant correlation between Vitamin D   
levels and CD4 count (percent) in supplemented group as compared to 
nonsupplemented.  
2. RQ2: Does Vitamin D supplementation have a statistically significant effect on CD4 
count/percent in HIV-infected African American adult men in this study [time frame: 
baseline, six, and twelve months]?  
• Null H0: There is no statistically significant effect of Vitamin D supplementation 
on CD4 count/percent in HIV-infected African American men in this study. 
• Alternative H1: There is a statistically significant effect of Vitamin D 
supplementation on CD4 count/percent in HIV-infected African American men in 
this study. 
In order to answer the second research question that dealt with assessing effect of 
Vitamin D supplementation on CD4 count/percent in the supplemented group, the 
researcher performed statistical tests to examine changes in Vitamin D levels, and in 
absolute CD4 count and CD4 percent between pre and postsupplementation. The 
statistical tests that were used: paired t test, repeated measures ANOVA, or the non-
parametric Wilcoxon signed rank test (for skewed or not normally distributed data) to 
compare data before and after. The best way to calculate the change in score was to 
subtract post-test CD4 count/percent from pre-test CD4 count/percent; when the change 
score got multiplied by 100, this displayed percent increase (or decrease) in CD4 count. 
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Same thing applied to CD4 percent and viral load. At the same time, RQ2 addressed the 
difference in CD4 count/percent change scores from baseline between supplemented 
group and non-supplemented group. For that reason, t test was used to compare means of 
the two groups when variables were continuous and their data were normally distributed; 
when data were skewed, the non-parametric Mann-Whitney U test was used instead. In 
order to compare percentages of participants taking supplementation versus those non-
supplemented and their respective Vitamin D level categories (deficient versus 
nondeficient), Fisher’s exact test or Pearson’s chi-square for categorical variables or 
Wilcoxon rank sum were used for continuous variables.  
Moreover, RQ2 used ANCOVA to test group difference post–pre in CD4 
count/percent changes. Supplementation was considered the design factor, the pretest 
(baseline score) as the covariate (to eliminate between-subject variability from 
supplementation effect), while the posttest measurement was the response variable. In 
other words, to control the effect of baseline pretest Vitamin D on response to 
supplementation, baseline measurement or pre-test was treated as a potential confounding 
variable. Generally, ANCOVA has the potential of producing a significant treatment 
effect, especially if there is some kind of uncontrolled pre-existing differences between 
groups to start with. Comparing the difference between Vitamin D levels pre–post in the 
supplemented group was done using paired t test. In order to display variations and 
differences within the supplemented group, the participants’ pre and post 25(OH)D 
levels, and the immune function parameters across time (T0, T1, & T2) were compared 
using repeated measures ANOVA.  
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The between-subjects comparison between supplemented group versus non-
supplemented on the same variables was done through ANCOVA model. In looking for 
confounding variables for the ANCOVA model, univariate and successive multivariate 
analysis (when applicable) checked factors that were associated with 25(OH)D level or 
with Vitamin D status (group allocation as fixed effect). The confounding variables that 
were hypothesized to affect Vitamin D were: baseline 25(OH)D level, age, season of 
measurement, ART, smoking, diabetes, history of AIDS, BMI, and other variables 
provided that they showed significant correlation with Vitamin D levels in univariate 
analysis. ANCOVA would allow to examine if the change in 25(OH)D level induced by 
supplementation would translate into significant impact on CD4 count, percent, and viral 
load- after adjusting for the aforementioned variables. Box plot was used to show the 
increase in Vitamin D level at different time frames compared with baseline. Descriptive 
analysis was run to compare proportions of subjects in the deficiency group at baseline 
and after supplementation, to see how many subjects achieved Vitamin D sufficiency.  
Consideration for the Rights of Human Subjects 
 The data that was used in this analysis were retrieved from medical charts at 
ACCESS clinic in Dearborn, Michigan. Upon receipt of special permission from the 
department of community health and research at the clinic, and upon signing HIPAA 
patient safety and privacy rule forms, the researcher was allowed to access the medical 
charts and to retrieve de-identified data and to make sure that no personal identifying 
information was collected or reported, and that patient confidentiality was honored. Data 
collection process took place at the clinic with the use of the researcher’s personal 
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computer and SPSS database. All charts were given numbers and data was coded to avoid 
retaining personal identifiers. Upon analysis, all data was presented in statistical forms. 
Since this study was retrospective in nature and only dealt with medical charts, there was 
no contact with participants. Therefore, informed consent was not requested from any 
patient included in the sample and in the analysis. In accordance with an earlier contact 
with the Institutional Review Board at Walden University, the IRB member expressed the 
lack of necessity to obtain consent forms from study participants.  
Conclusion 
This chapter described in detail the proposed methodology, the research variables, 
and the corresponding statistical plan for the study. This study aimed to expand our 
understanding of the controversial relationship between Vitamin D and CD4 in the 
context of impact on immune function of HIV patients with Vitamin D deficiency. After 
data collection and analysis, the results and the conclusions were presented and discussed 











Chapter 4: Results  
Introduction 
This chapter presented the results of the study about the relationship between 
Vitamin D level and the immune function of HIV patients as depicted by CD4 
count/percent, CD8 percent, CD4/CD8 ratio, and viral load. It also reported the findings 
about the effect of Vitamin D supplementation on the aforementioned immune function 
parameters in Vitamin D deficient HIV patients. The chapter began with a presentation of 
major descriptive statistics, including sample demographics and variables studied. The 
chapter discussed in details the research questions and hypotheses, as well as illustrated 
the assumptions for the selected statistical tests used in the analyses. The chapter 
concluded with a summary of the data analysis procedures and a general assessment of 
the findings.  
Data Collection 
The data for this analysis is based on medical chart abstraction that took place 
after IRB approval between January 8, 2015 and February 20, 2015. The sample 
consisted of 70 African American, HIV-infected male patients who presented between 
2010 and 2014 to an HIV specialty clinic (ACCESS) located in the city of Dearborn in 
southeast Michigan. This sample size is smaller than the sample size estimated originally 
in the principal proposal (100 participants). Despite the difference in sample size to what 
was originally proposed (N = 70 versus N = 100), a retesting of power analysis for the 
correlation analysis would still demonstrate at least 80% chance of finding a potential 
medium effect (Cohen’s medium effect of 0.5). Despite the abundance in the number of 
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HIV-infected, African American patients that seek medical services at the clinic and that 
meet the basic inclusion criteria for the study based on an initial sample frame (N = 125), 
the thorough review during the data abstraction process resulted in disqualification of a 
sizable number of medical charts. To a great extent, the retrospective and the longitudinal 
nature of collected data displayed some inconsistencies in measuring the main variables 
under study with every routine visit or at follow-up visits whenever Vitamin D 
supplementation was administered.  
Descriptive Statistics 
All data were entered electronically into SPSS (version 21.0) and the statistical 
analyses were completed through SPSS software version 21.0 as well (SPSS, Chicago, 
IL, USA). The sample included 70 male African American, HIV-infected patients who 
attended an underserved HIV clinic in southeast Michigan between 2010 and 2014. They 
range in age from 21 to 57 years (Mean age = 37.6 years, standard deviation [SD] = 
11.3). The general characteristics of the total study sample are presented in Table 4. Of 
the 70 participants, the majority (80%) were MSM (men who have sex with men), 57% 
were smokers, 8.6% had type II diabetes, 1.4% had history of injection drug use, 3% had 
hepatitis C, almost 49% had normal body mass index (BMI) and 11% were considered 
obese. Moreover, only one patient (1%) had a history of contracting HIV through 
injection drug use (IDU), about 90% were on ART at admission, and 18.6% had 
experienced AIDS (defined as a CD4 count below 200 ng/mL or prior AIDS defining 
event). Approximately, 26% of the participants had undetectable HIV plasma RNA or 
viral load in their blood at baseline, reflecting a good adherence to ART. A viral load 
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value of “0” denoted undetectable level < 48 copies/mL. Table 4 portrayed the 
descriptive characteristics of the study population.  
Table 4  
Baseline Descriptive and Demographic Characteristics of Study Population 













Smoking 40 57.1 












ART on Admission 

















At baseline, of the 70 participants, 40 percent (n = 28) had sufficient or normal 
Vitamin D level (25(OH)D ≥ 30 ng/μL), while 60% (n = 42) had Vitamin D insufficiency 
and deficiency (25(OH)D < 30 ng/μL) – of which 14.3% (n = 10) have severe Vitamin D 
deficiency (25(OH)D < 10 ng/μL). The study sample was split into two main groups: (1) 
Vitamin D deficient group and (2) Vitamin D sufficient group (internal comparison). 
Only patients in the deficient group received supplementation and were followed for at 
least one year with repeated measurements of Vitamin D levels and corresponding HIV-




Moreover, an independent t test was run to compare the baseline age and BMI 
characteristics (both normally distributed variables) between the Vitamin D deficient 
group (n = 42) and the Vitamin D sufficient group (n = 28). As per Levene’s test for 
equality of variances for the two variables in both groups, the assumption for the t test 
was met in these continuous scaled variables. The mean age of participants in the 
deficient group (M = 37.40, SD = 11.13) was comparable to that in the sufficient group 
(M = 38.00, SD = 11.80), t(68) = -0.214, p = 0.831. The distribution of HIV duration 
since diagnosis was found skewed, therefore, Mann-Whitney U test was used to compare 
the mean ranks HIV duration in both deficient and sufficient groups. As a result, both 
groups did not differ on HIV duration since diagnosis (ranged from one year to 26 years); 
the deficient participants had a higher mean rank of 38.3 (median = 7, IQR = 8, range = 1 
– 22) as compared to 31.3 (median = 4.3, IQR = 7, range = 1–26) for the participants in 
the sufficient group (U(68) = 470.0, Z = -1.419, p = 0.156). The means for HIV duration 
in years were also comparable M = 8.10, SD = 5.70 versus M = 7.11, SD = 7.13, in 
deficient and sufficient group, respectively. Similarly, BMI in the deficient group (M = 
25.70, SD = 4.71) and in the sufficient group (M = 25.54, SD = 4.57) did not differ 
significantly at baseline, t(68) = 0.138, p = 0.890. 
Baseline categorically scaled variables were compared between both groups using 
Chi-square test to determine differences in proportions or nonparametric Fisher’s exact 
test (whenever appropriate, i.e., for expected cell sizes with less than 5 cases). These 
results are depicted in Table 5. Both groups were comparable on all these variables 
except for diabetes. Diabetes was only present in six patients in the deficient group and 
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none have diabetes in the sufficient group. Fisher’s exact test has showed that the two 
groups differed significantly in having diabetes at baseline (p = 0.040). 
Table 5 
Group Comparison on Baseline Categorical Variables 
 Vitamin D 
Deficient 
(n = 42) 
n (%) 
  Vitamin D            
   Sufficient 













χ² (1, N = 70) = 0.972 









 28 (100) 
 
Fisher’s exact test 
p = 0.040* 







 5 (18) 
23 (82) 
 
χ² (1, N = 70) = 0.016 











χ² (1, N = 70) = 0.134 
p = 0.714 








 27 (96.4) 
 
Fisher’s exact test 








      9 (32.1) 
     19 (67.9) 
 
χ² (1, N = 70) = 0.011 
p = 0.917 




     36 (86) 
      6 (14) 
 
     27 (96.4) 
     1 (3.6) 
 
Fisher’s exact test 
p = 0.145 
*Significance = p ≤ 0.05 
 
 
Prior to running inferential analysis, a bivariate logistic regression model using 
SPSS was conducted to assess which independent variables at baseline can be useful in 
predicting the probability or likelihood of having a Vitamin D deficiency status 
(deficiency versus sufficiency) in the sample. The candidate risk factors for the logistic 
model were selected based on the literature review that showed the major predictors of 
deficient Vitamin D levels. For this analysis, the goal was to test whether the proportion 
132 
 
of the variance in Vitamin D deficiency status (deficiency status being the indicator 
variable) can be explained by the following independent variables: Age ≥ 40 years old, 
smoking, having AIDS, being MSM, high BMI, being on ART, and Vitamin D measured 
in winter months. All independent variables were dummy coded (using 0 and 1) before 
running the analysis. Before running the logistic model, a preliminary bivariate 
correlation analysis was done separately for each independent factor with the categorical 
dependent variable, that is, with Vitamin D status (deficiency versus sufficiency) before 
inputting the significant correlations into the binary logistic regression model.  
 The results from bivariate correlation analyses and later from the binary logistic 
regression model run on SPSS for all the variables combined showed that none of the 
aforementioned variables have demonstrated a significant relationship with Vitamin D 
status (deficiency status as an indicator) or Vitamin D levels. Neither the logistic 
regression model has produced a significant prediction of the outcome of Vitamin D 
deficiency status at baseline (Omnibus test showed a p = 0.555, that means that the model 
is not a good predictor; the Hosmer & Lemeshow test has a p = 0.744, which could have 
indicated a good model but all the B coefficients and Wald chi-square statistics have p 
values > 0.05, χ² (8) = 5.13, p = 0.744 (p > 0.05), R2 = 0.042 (Cox and Snell) and 0.057 
(Nagelkerke); in other words, in best case scenario, a significant model could have 
predicted 4.2% to 5.7% of the outcome. As no significant correlations have presented in 
the bivariate and the binary logistic regression, the multivariate analysis of predictors of 
Vitamin D deficiency was deemed unnecessary.  
A preliminary evaluation of Vitamin D level and the HIV immune function 
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laboratory data at baseline included running a total sample analysis and then a 
comparative analysis between Vitamin D deficient and sufficient groups on the following 
parameters: 25(OH)D level, CD4 count, CD4 percent, CD8 percent, CD4/CD8 ratio, and 
viral load. Before proceeding with analysis and fitting data into statistical models and 
tests, it was essential to explore these main outcome variables and examine the spread 
and dispersion of their values and frequency in the distribution. For the sake of avoiding 
inaccuracies in results and flaws in hypothesis testing, normality of distribution check 
through plotting histograms and using Shapiro-Wilk tests of normality was imperative 
before deciding on the use of parametric or non-parametric tests. Consequently, 
descriptive statistics (kurtosis and skewness) and histograms (plus Q-Q and P-P plots), in 
addition to normality tests were performed on all data at baseline (using SPSS) for the 
aforementioned variables. 
The findings indicated that Vitamin D levels, CD4 count, CD4/CD8 ratio, and 
viral load data were not normally distributed (as per histograms and the Shapiro-Wilk test 
significant p values < 0.05) in the study population. On the other hand, CD4%, and 
CD8% data are normally distributed (Shapiro-Wilk test p values > 0.05). For non-
normally distributed variables, median and IQR were used instead of mean and standard 
deviation, and the latter statistics were considered for normally distributed variables. 
Table 6 describes a summary of the baseline Vitamin D and immune parameters 





Baseline Vitamin D Level and HIV Immune Function Markers of Study Population 
 Mean (SD) Median (IQR) Range 
CD4 count                     542.93 (286.34)       539.5 (370.0) 108 - 1503 
CD4%          26.93 (10.90) 28.00 (14.0) 5 – 54 
CD8%                  45.80 (12.64) 45.86 (13.2) 21 – 74 







0 – 506000 
5 – 70 
 
Prior to comparative analysis, separate descriptive statistics were explored in a 
split file for each group (deficient versus sufficient) in order to check for normal 
distribution. The findings indicated that Vitamin D levels, CD4/CD8 ratio, and viral load 
data were not normally distributed (as per histograms and the Shapiro-Wilk test 
significant p values < 0.05) in either deficient or sufficient group. On the other hand, CD4 
count, CD4%, and CD8% data were found normally distributed in both groups (Shapiro-
Wilk test p values > 0.05) and they also met the homogeneity of variance assumption for 
t test (as per Levene’s test p values > 0.05). The baseline comparative analysis findings 
are presented in Table 7.  
The mean difference in serum 25(OH)D levels between Vitamin D deficient 
group (M = 15.83, SD = 7.3) and Vitamin D sufficient group (M = 39.93, SD= 9.7) as 
calculated using independent t test showed a statistically significant difference at baseline 
with t(68) = -11.88, p = 0.000. However, since Vitamin D level variable did not meet 
normal distribution assumption based on the shape of the histograms and the Shapiro-
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Wilk normality tests (deficient group p = 0.010 and sufficient group p = 0.000), the non-
parametric Mann–Whitney U test was used instead of student t test to compare the 
medians and mean ranks of the two independent groups. The median levels of 25(OH)D 
was 15.5 ng/μL (IQR = 12, range 5 – 28) and 36 ng/μL (IQR = 11, range 30 - 70) for 
deficient and sufficient groups, respectively; there was an evidence that the groups 
differed significantly with higher mean rank of 56.5 in the sufficient group as compared 
to a mean rank of 21.5 in the deficient group (U = 0.000, Z = -7.055, p = 0.000). Mann-
Whitney U test was also used to compare CD4/CD8 ratio in both groups.  
Table 7 
Baseline HIV Immune Function Markers by Vitamin D Group 
 Vitamin D 
Deficient 
(n = 42) 
Vitamin D  
Sufficient 
(n = 28) 
Sig. 
p value 
CD4 count (cells/μL)Ŧ 529.14 (266.16) 563.61 (318.151) 0.625 
CD4%Ŧ 27.43 (10.13) 26.18 (12.12) 0.642 
CD8%Ŧ 45.83 (12.42) 45.75 (13.20) 0.979 
CD4/CD8 ratio§ 0.61 (0.46) 0.51 (0.55) 0.513 
Viral load (< 5000)† 22 (52.4%) 22 (78.6%)  0.026* 
Ŧ Mean ± standard deviation (SD). Independent t-test. 
§ Median (IQR). Mann-Whitney test. 
† n (%). Chi-square utilized to compare proportions by Vitamin D status group.  
*Significance = p ≤ 0.05 
 
It should be noted that based on the frequency distribution analysis for viral load 
level and the corresponding wide dispersion of data, the scaled variable was transformed 
into a dichotomous nominal variable with two main categories: (1) HIV plasma RNA 
level below 5000 copies/mL and (2) HIV plasma RNA level above 5000 copies/mL. Chi-
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square test was used to compare proportions between both groups with the characteristic 
of interest viral load level < 5000 copies/mL. The results of Table 7 revealed that the 
immune function parameters between deficient and sufficient groups did not differ 
significantly at baseline, except for viral load (χ²(1, N = 70) = 4.936, p = 0.026). 
Univariate analysis indicated that 76.9% of those with viral load > 5000 copies/mL were 
more likely to be Vitamin D deficient as compared to only 23.1% in the sufficient people.  
Research Questions and Hypotheses 
The first research question was developed based on conflicting results in the 
existing literature about the association between Vitamin D level and CD4 count/percent.  
Research Question 1: Do Vitamin D levels significantly correlate with CD4 count and 
CD4 percent in Vitamin D deficient group versus sufficient group?  
H0: There is no statistically significant correlation between Vitamin D levels and 
CD4 count or percent in Vitamin D deficient group versus sufficient group.  
H1: There is statistically significant correlation between Vitamin D levels and 
CD4 count, or CD4 percent in Vitamin D deficient group versus sufficient group.  
 In order to answer this research question and to test the hypothesis, a bivariate 
linear correlation was carried out with both parametric and non-parametric correlation 
coefficients, Pearson’s r and Spearman rho (rs), respectively. However, since Pearson’s 
correlation was sensitive to normal distribution, and based on lack of meeting normality 
assumptions for Vitamin D and CD4/CD8 ratio, Spearman rho (rs) was used to rank the 
data and to provide better correlation coefficient estimates.  
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At baseline, there was no significant correlation between Vitamin D levels and 
CD4 count in all participants (N = 70), rs = 0.090, p = .0.458. Moreover, CD4 count was 
not significantly related to Vitamin D levels in either Vitamin D groups, deficient and 
sufficient (rs = 0.107 versus rs = 0.132, p > 0.05, respectively). The negative correlation 
between Vitamin D levels and CD4 percent for the whole sample did not reach statistical 
significance as well on Spearman rho correlation (rs = -0.035, p = 0.776). The bivariate 
correlation analysis failed to show sufficient evidence of significant negative correlation 
between baseline Vitamin D level and each of the following: CD8 percent, CD4/CD8 
ratio and viral load for all study participants at baseline. Table 8 summarizes the bivariate 
correlations analyses between Vitamin D level and each of the immune parameters.  
A binary logistic regression analysis was not needed as not all immune variables 
had statistically significant correlations with Vitamin D levels. A linear regression 
analysis was performed to examine any association between the aforementioned variables 
and Vitamin D levels at baseline, especially to define whether CD4 count or CD4 percent 
were associated with Vitamin D levels. The model failed to show significant relationship 
for the entire sample (R = 0.271, p = 0.285) whereby all variables accounted for 7.3% of 
the variation in Vitamin D levels (R2 = 0.073). However, only CD4 percent had a weak 
but significant negative relationship with Vitamin D level (β = -0.852, p = 0.044). That 
meant that every one-unit increase in CD4% corresponded with 8.5 units decrease in 
Vitamin D levels.  
In order to test the hypothesis whether Vitamin D levels and CD4 count and CD4 
percent were equally correlated or the same in deficient versus sufficient group (Vitamin 
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D status), bivariate correlations for each group were performed and later a Fisher’s Z-
transformation test was calculated to test the significance of the difference between the 
correlations in both groups (see Table 8). Fisher’s Z-transformation calculator was used 
to reduce skewness and convert the correlation coefficients into a Z score, that is, a 
normally distributed Z statistic. 
Table 8 
 
Baseline Comparison of Bivariate Correlations Between 25(OH)D Levels and Immune 
Function Variables 
 
 Vitamin D 
Deficient 
(n = 42) 
Spearman rs (sig.) 
Vitamin D  
Sufficient 
(n = 28) 





CD4 count  .107 (0.502) .132 (0.504) -0.1 (0.920) 
CD4 percent  -.084 (0.598) .204 (0.298) -1.14 (0.254) 










Overall, the difference between correlations for both groups did not reach 
statistical significance (p > 0.05) in any of the immune parameters with Vitamin D levels 
(the sample sizes were too small to detect a significant difference). At the same time, 
multivariate analysis (MANOVA) failed to provide evidence of a statistical difference in 
the means of the combination of dependent variables (CD4 count, CD4%, CD4/CD8 
ratio, & CD8%) between both Vitamin D groups; in other words, there was no effect of 
Vitamin D status on all the immune variables as a group in the model (all ps > 0.05). In 
conclusion, correlation testing for the first research question has resulted in accepting the 
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null hypothesis for CD4 count and CD4 percent. Moreover, both Vitamin D groups did 
not differ in their correlations with the immune parameters when Fisher Z-transformation 
was applied. Only viral load and CD4 % at baseline were significantly predictive of 
Vitamin D deficiency in logistic regression. 
Research Question 2: Does Vitamin D supplementation have a statistically significant 
effect on CD4 count/percent in HIV-infected African American adult men in this study?  
H0: There is no statistically significant effect of Vitamin D supplementation on 
CD4 count/percent in HIV-infected African American men in this study. 
H1: There is a statistically significant effect of Vitamin D supplementation on 
CD4 count/percent in HIV-infected African American men in this study. 
Vitamin D. After evaluating baseline Vitamin D levels, all HIV-infected patients 
in the deficiency group (n = 42) were prescribed Vitamin D supplementation (oral 50000 
IU cholecalciferol once per week) and were followed-up for a time frame period that 
stretched up to 14 months from date of entry. A T0 denotes baseline visit, while T1 (up to 
6 months from baseline) and T2 (up to 8 months from T1) denote follow-up visits, 
respectively. Of these 42 patients, only 28.6% (n = 12) normalized their Vitamin D levels 
by 6 months (i.e., 25(OH)D ≥ 30 ng/μL) and 71.4% remained deficient. The proportion of 
patients achieving Vitamin D sufficiency increased considerably by T2, whereby 21 






Figure 7. Change in 25(OH)D level from pre- to post-supplementation in deficient group. 
 
Since Vitamin D levels were not normally distributed at baseline and follow-up 
visits (as per the histograms, Q-Q plots, P-P plots, and the Shapiro-Wilk tests of 
normality, p < 0.05), nonparametric Wilcoxon signed rank test are carried out to analyze 
presupplementation and postsupplementation Vitamin D levels. The Wilcoxon signed 
rank test showed that Vitamin D supplementation produced statistically significant 
changes in Vitamin D levels in the deficient patients at T1 (Z = -2.256, p = 0.024) and T2 
(Z = -4.916, p = 0.000). The median 25(OH)D level at baseline is 15.50 (IQR = 12, range 
= 5–28) as compared to 18 (IQR = 28, range = 7–68) and 29 (IQR = 17, range = 6–66) in 
T1 and T2 visits, respectively. Moreover, Wilcoxon Rank’s table had shown that from 
baseline T0 to T1, 14 participants out of 42 had lower Vitamin D levels at T1 than at 
presupplementation T0, while 25 participants had improved and normalized their Vitamin 
D levels at T1 post-supplementation (only 3 participants have no change in their levels).  
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From baseline to T2, 6 participants failed to normalize their Vitamin D levels as 
compared to 36 participants who significantly increased their levels postsupplementation 
(of which 21 achieved sufficiency by T2).  
Overall, in comparing the Vitamin D level measurements on the same participants 
at three different time variables (T0, T1, and T2), the nonparametric Friedman test was 
used as an alternative to one-way ANOVA with repeated measures; the test compared the 
mean ranks to examine how the groups differed on their medians too. There was a 
statistically significant difference in Vitamin D levels after Vitamin D supplementation, 
χ²(2) = 23.263, p =0.000. For post hoc analysis aiming to check where the differences 
really occurred among the related groups, the Wilcoxon signed-rank tests were used on 
multiple comparisons (T0 versus T1; T0 versus T2; and T1 versus T2) using Bonferroni 
adjustment on the p values obtained in the results. Consequently, a Bonferroni-adjusted 
significance level (known as Bonferroni correction) was set at 0.017, whereby the 
original significant p value of 0.05 was divided by number of comparisons, or by 3 in this 
case. Based on the results (presented in Table 9), the groups differed in their median 
Vitamin D levels (see values above) most significantly between baseline T0 and T2 (p = 
0.000, < Bonferroni p of 0.017) and between T1 and T2 (p = 0.004, also less than 0.017). 
In other words, the increase in Vitamin D level was most significant between T0 to T2 
and between T1 to T2. Statistically, the Wilcoxon median posttest ranks were 






Vitamin D Levels Pre-Post Supplementation Changes: Wilcoxon Signed-Rank Test 
 
 Vitamin D level at 
T1 - Vitamin D 
level at T0 
Vitamin D level at 
T2 - Vitamin D 
level at T0 
Vitamin D level at 
T2 - Vitamin D 
level at T1 
Z -2.256* -4.916* -2.905* 
Asymp. Sig. (2-tailed) .024 .000 .004 
* Based on negative ranks. 
 
HIV immune parameters. In order to check whether there was any effect of 
Vitamin D supplementation on CD4 count and percent, and the rest of the immune 
variables, a univariate analysis was run to determine the changes in levels at T1 and T2 
before conducting comparative analysis. Moreover, a correlation analysis was performed 
between postsupplementation Vitamin D levels and postsupplementation CD4 
count/percent. Univariate results show that CD4 count, CD4 percent, and CD8 percent 
were normally distributed (Shapiro-Wilk p values > 0.05) at baseline, T1, and T2, and 
accordingly, changes in their levels were examined through parametric tests such as 
paired t test and repeated measures ANOVA. CD4/CD8 ratio data lacked normal 
distribution, therefore, nonparametric tests such as Wilcoxon signed test and Friedman 
test were used.  
In the normally distributed immune variables, the data were checked for outliers 
prior to comparing their means in order to reduce any effect of these values on the 
significance results (although they did not skew the distribution, means would remain 
sensitive to extreme values). For CD4 count, there were three outliers (one case at T0, 
and 2 cases at T1). Transformations of these outlier scores did not guarantee more robust 
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results nor did case removal due to small sample size. However, as per good practice 
guidelines suggested by Field (2007), the outlier scores have been changed and 
recalculated based on the mean value plus two times the standard deviation. Paired t–test 
before transformed outliers showed non-significant results (p > 0.05), and after adjusting 
the outliers, the paired t–test results remained non-significant. CD4 count, CD4 percent, 
and CD8 percent values with repeated measures remained normally distributed. Table 10 
and Table 11 depict the immune parameters changes from pre- to post- supplementation 
at T1 and T2.  
Table 10 
 
HIV Immune Parameters Changes: Pre–and Post–Supplementation (T0 –T1)  
 
  T0 
(Presupplementation) 




n = 42 
Mean (SD) 
     P value 
CD4 count 529.14 (266.16) 550.02 (257.52) 0.438 
CD4 percent 27.26 (9.73) 28.10 (10.36) 0.449 
CD8 percent 45.83 (12.42) 42.69 (12.11)    0.013* 
CD4/CD8 ratio† 0.614 (0.47) 0.680 (0.55)  0.276 
† Median (IQR), Wilcoxon signed rank test.  
* Significant p < 0.05, based on paired t test. 
 
The findings of the paired t–test for the within-group analysis of pre–post changes 
in Tables 10 and 11 suggested that after Vitamin D supplementation and up to the first 
follow-up period (T1), there was a significant change in the CD8 percent (p = 0.013) 
only. More importantly, these findings did not confirm any significant influence of 
Vitamin D supplementation on the main HIV immune parameters presented in the 
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hypothesis, which are CD4 count and CD4 percent. Despite a statistically significant 
increase in Vitamin D levels from baseline to follow-up visits, there was no 
corresponding influence of Vitamin D supplementation on the immune markers - which 




HIV Immune Parameters Changes: Pre–and Post–Supplementation (T0 –T2) 
 T0 
(Presupplementation) 




n = 42 
Mean (SD) 
     P value 
CD4 count 529.14 (266.16) 586.48 (280.40) 0.084 
CD4 percent 27.26 (9.73) 29.02 (10.79) 0.101 
CD8 percent 45.83 (12.42) 44.26 (12.25) 0.380 
CD4/CD8 ratio† 0.614 (0.47) 0.659 (0.56) 0.107 
† Median (IQR), Wilcoxon signed rank test. 
 
Repeated measures ANOVA were performed to examine the effect of Vitamin D 
supplementation on the immune variables, that is, to test the hypothesis whether there 
was any overall significant change in the CD4 count, CD4 percent, and CD8 percent 
values within subjects and across the three different time periods (T0, T1, and T2). All 
assumptions for the test were met except for Mauchly’s sphericity (this assumption was 
violated, p = 0.009); therefore, in order to avoid distorted results, the Greenhouse-Geisser 
correction in the SPSS for within-subjects output table was reported instead. As a result, 
the ANOVA with repeated measures with Greenhouse-Geisser correction indicated that 
the mean values for CD4 count were not statistically significant; there was no significant 
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effect of supplementation on CD4 count, F(1.654, 67.808) = 2.278, p = 0.119 (Wilk’s 
Lambda = 0.915, F (2, 40) = 1.867, p = 0.168). The strength of the relationship between 
Vitamin D supplementation and the change in the CD4 count scores as assessed by partial 
eta squared (i.e., effect size), was weak, with supplementation accounting for only 5.3% 
of the variance of the dependent variable, CD4 count.  
Similarly, Vitamin D supplementation had no effect on CD4 percent change 
across baseline, T1, and T2. However, Mauchly’s sphericity assumption was met for CD4 
percent (p = 0.963). The repeated measures ANOVA again failed to demonstrate a 
significant effect of Vitamin D supplementation on CD4 percent, Wilk’s Lambda = 
0.936, F (2, 40) = 1.379, p = 0.264. Partial eta squared or effect size was also weak, with 
supplementation accounting for only 6.4% of the variance in CD4 percent. Post-hoc 
pairwise differences among the means of CD4 percent with the use of Bonferroni 
correction coincided with the earlier results of paired t–tests, and accordingly, have failed 
to elicit significant changes postsupplementation.  
As for CD8 percent, supplementation did not produce statistically significant 
changes in the mean levels from baseline to postsupplementation, but it had elicited a 
significant reduction in mean value from baseline to T1 (p = 0.038). On the other hand, 
the nonparametric Friedman test of differences in medians among repeated measures for 
CD4/CD8 ratio was conducted and rendered a χ²(2, n = 42) of 1.280, which was not 
significant (p = 0.527). Beside repeated measures, bivariate Pearson’s correlations 
between Vitamin D levels and postsupplementation CD4 count, CD4 percent, and CD8% 
at T1 and T2, failed to yield significant results (all p values > 0.05).  
146 
 
Supplemented versus nonsupplemented. Although the intention of this study 
was to follow-up only on Vitamin D deficient participants, as the abstractor, I did collect 
data on Vitamin D and the corresponding immune parameters from sufficient subjects 
with subsequent visits that took place within six months of baseline. Only 18 (64%) 
nonsupplemented Vitamin D sufficient participants out of 28 had complete data for T1. 
Bivariate Spearman correlations between T1 Vitamin D levels and CD4 count and 
percent after supplementation also remained non-significant. Paired t–test analysis for the 
nonsupplemented group revealed no statistical difference between T0 and T1 (all p values 
> 0.05) for the immune parameters. Only Vitamin D levels for the sufficient group have 
failed the normality assumption, and a comparison of their median Vitamin D levels at 
T0 and T1 showed a statistically significant difference with Wilcoxon signed rank test (Z 
= -2.288, p = 0.022). According to the negative ranks, fourteen participants had higher 
levels at baseline than at T1, and four had higher levels at T1 without supplementation. 
T1 median = 30 (IQR = 21, range = 18–72) compared to T0 median = 36 (IQR = 11, 
range = 30–70), p = 0.022.  
Mann-Whitney U test was performed to examine group difference in Vitamin D 
levels between supplemented and nonsupplemented group at T0 and T1. The result of 
Mann-Whitney revealed that compared to the supplemented group, the nonsupplemented 
group still had higher medians and mean ranks at T0 and T1 (mean ranks: 50.5 versus 
21.5, and 42.4 versus 25.4, at T0 and T1, respectively). Most importantly, the group 
difference in Vitamin D levels at T1 was highly significant, U(60) = 163.5, Z = -3.463, p 
= 0.001.  
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As for viral load, the proportion of participants in the supplemented group 
belonging to the undetectable to the very low viral load category (0–1000 copies/mL) had 
increased postsupplementation from 50% at T0 to 69% at T1, as compared to 83% for the 
nonsupplemented group at T0 to 89% at T1. Fisher’s exact test showed that there was no 
difference postsupplementation at T1 (p = 0.192) between both groups, unlike at T0 (p = 
0.021). Mann-Whitney median and mean ranks comparison between groups at T0 and 
T1, indicated a significant difference in viral load at baseline only (U(60) = 252.000, Z = 
-2.395, p = 0.017) with higher viral load mean ranks for the deficient group, but did not 
yield any significant difference in viral load between both groups postsupplementation 
(U(60) = 303.000, Z = -1.613, p = 0.107).  
In order to examine the effect of supplementation on the HIV immune parameters, 
the last statistical analysis consisted of running ANCOVA to compare changes in post–
pre mean scores for these parameters, while treating their presupplementation or baseline 
scores as time-varying covariate and as a confounding variable, and the 
postsupplementation scores as the response. Group allocation to supplementation was 
considered the fixed effect. All ANCOVA assumptions were considered and were met 
(Levene’s test of sphericity p = 0.145; homogeneity of regression slopes p = 0.302). The 
findings (see Table 12) revealed that there was no statistically significant effect of 
Vitamin D supplementation on CD4 counts at postsupplementation after controlling for 
baseline Vitamin D levels (F(1, 56) = 1.563, p = 0.216). Even after adjusting the means 
for CD4 count following the removal of the effect of the covariate (the mean had 
increased for the nonsupplemented group to 714.5, and to 566.07 for the supplemented 
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group), the F ratio remained nonsignificant, F(1, 56) = 1.039, p = 0.312. If the covariance 
were significant, the increase in the adjusted means would have indicated a possible 
positive covariance between CD4 count and supplementation status (group allocation), 
especially in the nonsupplemented group. The results failed to reject the null hypothesis 
of significant effect of supplementation on CD4 count. 
 
Table 12 
Changes in Vitamin D Levels and Immune Parameters in Supplemented Group Versus 
Nonsupplemented Group: Baseline to T1. 
 
Parameter Supplemented Group 
(n = 42) 
Nonsupplemented Group 
(n = 18) 
Sig. †  
(p Value) 
Baseline T1 Baseline T1  
25(OH)D level 15.83 ± 7.3 21.88 ± 13.9 40.83 ± 10.7 35.61 ± 15.2 0.001* 
CD4 count 529.14 ± 266.2 550.02 ± 257.5 566.9 ± 349.5 590.2 ± 335.2  0.216 
CD4 percent 27.26 ± 9.7 28.10 ± 10.4 26.22 ± 13.1 27.22 ± 10.7 0.918 
CD8 percent 45.83 ± 12.4 42.69 ± 12.1 43.83 ± 12.8 43.00 ± 11.7 0.367 
† P value calculated based on Analysis of Covariance (ANCOVA). 
* Significance p < 0.05. Based on Mann-Whitney U test.  
 
ANCOVA results for CD4 percent showed a statistically non-significant 
relationship between baseline Vitamin D levels and CD4 percent within the groups, F(1, 
56) = 0.011, p = 0.918). The covariate did not contribute at all to the variance of the CD4 
percent. The adjusted means have shown a reduction in CD4 percent in the 
nonsupplemented group as compared to an increase in CD4 percent in the supplemented 
group; however, these adjustments remained non-significant, F(1, 56) = 0.055, p = 0.816. 
Again, this result failed to reject null hypothesis of no statistically significant effect of 
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Vitamin D supplementation on CD4 percent. Similar to the results for CD4 count and 
CD4 percent, supplementation has failed to exert any significant influence on CD8 
percent, F(1, 56) = 0.829, p = 0.367. 
Summary and Conclusion 
This chapter has displayed the statistical analyses of this retrospective chart 
review study that ranged from descriptive to inferential and hypotheses testing. All 
statistical tests have been performed using SPSS 21. The chapter has provided detailed 
presentation of all the analyses and the results related to two main research questions and 
their corresponding hypotheses. The first research question examined the presence of 
correlation between Vitamin D level and CD4 count/percent levels. The results have 
failed to reject the null hypothesis of no correlation between Vitamin D levels and CD4 
count/percent. The second research question evaluateed the effect of Vitamin D 
supplementation on CD4 count and CD4 percent, in addition to comparing the difference 
in Vitamin D levels between the deficient/supplemented group and the nonsupplemented 
group (like a placebo group). Despite a significant increase in Vitamin D levels 
postsupplementation, again, the effect of Vitamin D supplementation was not evident on 
the CD4 count and CD4 percent levels; the study has failed to reject the null hypothesis 
of no significant impact of supplementation on these main HIV immune markers. Chapter 
5 presents a detailed interpretation of all findings in this chapter, along with an 





Chapter 5: Discussion, Conclusions, and Recommendations 
Overview 
The purpose of this quantitative, observational retrospective chart review study 
was to examine if any association between Vitamin D deficiency and CD4 exists in HIV 
positive persons and to then evaluate the impact of Vitamin D supplementation. The 
literature has shown that Vitamin D is an immunomodulator that regulates immune target 
cell function, especially CD4 T cells that express Vitamin D receptors, the fact which 
might enable Vitamin D to influence their immune responses against the invading 
pathogens (Cantorna, 2011). The immune influence of Vitamin D deficiency remains 
understudied in HIV and is rather controversial, especially with regard to the conflicting 
results in the literature that support or reject such influence. Moreover, there is scarce 
knowledge about the impact of Vitamin D supplementation on immune function in the 
field of HIV. 
The relationship between Vitamin D and CD4 T cells constituted the conceptual 
framework for this study. The proposed conceptual framework suggests that Vitamin D 
in its active form in the body binds to the Vitamin D receptors (VDR) on the immune 
cells, especially the CD4 T cells and B lymphocytes. This leads to an activation of the 
CD4 and to an increase in the number of VDR that is translated into enhanced 
modulating effects of Vitamin D on CD4 cells (Baeke et al., 2010c; Beard et al., 2011; 
Deluca & Cantorna, 2001; Kamen & Tangpricha, 2010; Mahon et al., 2003), followed by 
a regulation of immune responses to pathogens (e.g., increasing the production of 
antimicrobial peptides – cathelicidin) (Baeke et al., 2007; Heany, 2008; Kamen & 
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Tangpricha, 2010; Liu et al., 2006; Liu et al., 2007; Wang et al., 2004; Wolff et al., 2008) 
and of cytokines production (Kamen & Tangpricha, 2010; Lake & Adams, 2011). Since 
HIV is characterized by a general pro-inflammatory condition, restoration of Vitamin D 
enhances the cytokine production that favors an anti-inflammatory milieu at the immune 
level, and improves CD4 count, which eventually slows progression towards AIDS (Lake 
& Adams, 2011). 
In the context of framework, this study speculated that restoring Vitamin D to 
normal levels after supplementation would ensue in a simultaneous increase in CD4 
count/percent, which in turn would enhance the overall immune health of HIV patients. 
This study addressed the gap in the literature through framing two research questions that 
were also directly relevant to the framework: the first examined the correlation between 
Vitamin D level and CD4 count/percent, and the second question evaluated the impact of 
Vitamin D supplementation as depicted by improvements in Vitamin D levels and the 
corresponding changes in CD4 count/percent in a group of Vitamin D deficient HIV-
infected African American patients.  
In order to answer these research questions, data was collected from a 
convenience cohort of 70 African American HIV-infected male participants (aged 21 
years and up) who attended a specialized underserved HIV clinic in Southeast Michigan. 
The cohort was split into two groups based on first Vitamin D level at study entry: 1- 
Vitamin D deficient group (n = 42), and 2- Vitamin D sufficient (n = 28). The deficient 
group was followed up for more than a year retrospectively, and the participants’ clinical 
parameters pertaining to Vitamin D and immune function were assessed at three points in 
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time: baseline (T0), T1 (up to 6 months), and T2 (up to 14 months). The sufficient group 
was mainly assessed at T0, and only 18 participants had follow-up data at T1. The 
researcher used chart review to abstract data and entered it into an electronic database 
using SPSS 21.0 software. Chapter 4 discussed the data analyses processes in details and 
presented the results. This chapter scrutinizes and interprets the main findings of the 
study, upon which conclusions, social change implications, and recommendations are 
furnished.  
Interpretation of the Findings 
It is well documented that there is a high prevalence of Vitamin D deficiency 
among HIV-infected patients of Vitamin D deficiency that can range from 70 percent to 
more than 90 percent (Bang et al., 2010; Dao et al., 2011; Vescini et al., 2011; Viard et 
al., 2011). As the study population consisted solely of African Americans, who have an 
assumed innate susceptibility to Vitamin D deficiency, 60 percent (n = 42) of the total 
study population were Vitamin D deficient at study entry; however, this prevalence could 
have constituted a vast majority if most of the 125 charts reviewed by the researcher and 
pertaining to HIV African American patients seen at the clinic had complete data on 
Vitamin D at subsequent visits within one year time frame from first baseline Vitamin D 
level. It was interesting to find that 40 percent of the total sample (n = 28) had sufficient 
Vitamin D levels, despite the applicable factors that constitute some known predisposing 
factors to Vitamin D deficiency with residual confounding effect such as, black 
race/ethnicity, geographic location and northern latitude, inadequate sunlight exposure, 
and low Vitamin D diet. The number of patients who had history of AIDS in the study 
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population was low (13 patients total, 8 in the deficient group and 5 in the sufficient 
group), but this was not associated with Vitamin D deficiency in the bivariate correlation 
or in the logistic model, unlike the findings by Mueller et al. (2010).  
The results from the present study have shown that deficient and sufficient groups 
differed on baseline Vitamin D levels. The sufficient group had higher Vitamin D level 
mean rank (56.5) and median (36 ng/μL) as compared to the mean rank (21.5) and 
median (15.5 ng/μL) of Vitamin D level in the deficient group. Both groups were 
comparable at baseline on almost all characteristics that are commonly considered 
significant predictors of Vitamin D deficiency and that are accounted for in this study, 
accordingly: Age, BMI, HIV duration, smoking, history of AIDS, transmission mode, 
having hepatitis C, being on ART, and Vitamin D level measurement season. Upon 
examining if these risk factors constituted predictors of Vitamin D deficiency levels 
and/or Vitamin D status (deficiency being an indicator) in this study population, the 
bivariate logistic regression model failed to show significant results with any of these 
factors, in contrast to most findings in the literature. Most likely, this could be due to the 
inability to infer significant and stable correlations from a small sample size (Schonbrodt 
& Perugini, 2013). It should be noted that both groups differed on diabetes only, whereby 
none of the participants in the sufficient group had diabetes as compared to six 
participants in the deficient group. Despite the study small sample size, this finding on 
diabetes is consistent with what the literature highlights about the inverse association 
between low Vitamin D levels and higher incidence of type II diabetes, secondary to a 
propensity to have an increase in insulin resistance in Vitamin D deficient people 
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(Forouhi et al., 2012); however, a causal relationship between Vitamin D deficiency and 
type II diabetes is still far from being confirmed and, thus, constitutes a fertile area to 
investigate (Baz-Hecht & Goldfine, 2010; Tai, Need, Horowitz, & Chapman, 2008).  
At baseline, both groups did not differ significantly on CD4 count, CD4 percent, 
CD8 percent, CD4/CD8 ratio, and viral load. Although group comparability at baseline 
could provide an unbiased platform upon which it would be easier to assess changes in 
Vitamin D and the immune parameters over the follow-up period, this could influence the 
whole analysis, which is based on baseline Vitamin D and on presumed difference in the 
main immune parameters, specifically CD4 count and CD4 percent. Such comparability 
reflected some considerable degree of immune competence as depicted by high means of 
CD4 count in both groups (M = 529 ± 266.16 versus M = 563.61 ± 318.15, in deficient 
and sufficient groups, respectively). The fact that 90 percent of the total participants were 
on ART at time of entry into study could imply that these participants have some degree 
of preserved immunity. Another possible reason for this enhanced immunity could be 
explained by the closeness of follow-up visits, hence the seeking of medical care those 
participants from both groups initiated. Conversely, being on ART did not seem to have 
an influential effect on Vitamin D level in this study population because of lack of 
evident correlation between ART and Vitamin D deficiency status, unlike other studies 
that found a high correlation between Vitamin D deficiency and ART (Childs et al., 2012; 
Conesa-Botella et al., 2010; Dao et al., 2011; Giusti et al., 2011; Griffin & Arnold, 2012; 
Mueller et al., 2010; Rodriguez et al., 2009; Van Den Bout- Van Den Beukel et al., 2008; 
Viard et al., 2011). However, adherence to ART was partially reflected by low or 
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undetectable levels of viral load in both groups, but more pronounced in the sufficient 
group. This study did not consider the type of ART or the duration of receiving ART to 
avoid methodological complexity issues with data collection and analysis, especially in 
view of the small study sample size, and this not being one of the objectives of the study. 
Research Question 1. This study was conducted to emphasize the role of 
Vitamin D as an immune-modulator and as an immune response enhancer based on the 
HIV literature that discussed the unique Vitamin D characteristic that enables it of 
regulating the immune cells functions, mainly the CD4 T cells. Therefore, the first 
research question in this study examined the correlation between Vitamin D level and 
CD4 count and CD4 percent in both deficient and sufficient groups. At baseline, 
Spearman rho correlation coefficient, for the total sample, did not show significant 
correlation between Vitamin D levels and CD4 count (p = 0.458) or with CD4 percent (p 
= 0.776). Similarly, there was no correlation between Vitamin D levels and either of the 
group’s CD4 count/percent, at baseline or at T1. Results of bivariate correlations, 
MANOVA, and linear regression model analyses, could not find a significant relationship 
between Vitamin D levels and the immune parameters: CD4 count, CD4 percent, CD8 
percent, CD4/CD8 ratio, and viral load. In concordance with previous studies (Bang et 
al., 2010; Bearden et al., 2013; Gedala et al., 2013; Kim et al., 2011; Mehta et al., 2009, 
2010; Sudfeld et al., 2012; Turett et al., 2013; Van Den Bout- Van Den Beukel et al., 
2008; Viard et al., 2011; Wasserman & Rubin, 2010), this study could not provide 
evidence of any significant relationship, correlation or association, between Vitamin D 
levels and CD4 count or CD4 percent, unlike the findings of the studies done by De Luis 
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et al. (2002), Egan et al., 2008; Giusti et al., 2011, Haug et al. (1994, 1998), Legeai et al. 
(2013), Ross et al. (2011), Stein et al. (2010), Theodorou et al. (2013), and Welz et al. 
(2010). However, in most of these studies, the observed correlation was mostly between 
Vitamin D deficiency status and low CD4 counts, as compared to this study that sought to 
find any correlation between Vitamin D levels and CD4 count/percent mostly irrespective 
of categorization for parameters (knowing that the study population has preserved 
immune function). This explanation is in agreement with Sudfeld et al. (2012) who 
viewed the results of these studies (Haug et al., 1998; Rustein et al., 2011; Stein et al., 
2010; Welz et al., 2010) as proving a “biologically plausible” (p. 5) phenomenon that 
patients with low CD4 counts are more likely to be Vitamin D deficient secondary to 
increased risk for opportunistic infections that is accompanied by high immune cells 
activation and a corresponding high use of Vitamin D by these cells. This explanation is 
in agreement with the studies that correlated Vitamin D deficiency with greater risk for 
HIV disease progression and mortality (Mehta et al., 2010, 2011; Sudfeld et al., 2012; 
Viard et al., 2011) and yet could not find a correlation between Vitamin D levels and 
CD4 counts. 
The study finding that there is no correlation could be indicative of 
methodological limitation; whereby, the analysis was based on the available data (for 
both groups) at baseline, thus, could be viewed as similar to using a cross-sectional 
approach that could not account for longitudinal data when testing for correlation. Even, 
when the correlation analysis was run at a consecutive follow-up visit (T1), still, the 
study failed to establish a correlation between Vitamin D levels and CD4 count/percent in 
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view of the limited or insignificant changes in the parameters at T1 under the context of 
Vitamin D supplementation. The small sample size of the deficient group and the 
baseline comparability between both deficient and sufficient groups in most 
characteristics, especially in the immune parameters, could partly explain the inability to 
find a plausible correlation.  
Research Question 2. The second research question investigated the effect of 
Vitamin D supplementation (50,000 IU once weekly) on CD4 count and CD4 percent in 
Vitamin D deficient group at six months (T1) and at one year (T2), and in Vitamin D 
sufficient group at T1. Changes in Vitamin D levels, CD4 count, and CD4 percent were 
compared between deficient/supplemented group and sufficient/nonsupplemented group. 
The nonsupplemented group consisted of 18 participants out of 28 sufficient participants 
and who had complete follow-up data at T1. This group was treated as a placebo or 
control group against the supplemented group. Taking the deficient group alone (n =48), 
28.6 percent normalized their Vitamin D levels by T1, and 50 percent by T2 on post-
supplementation analysis. A total of 36 (86%) participants improved their Vitamin D 
levels post-supplementation. There was a statistically significant increase in Vitamin D 
levels from a median of 15.5 ng/μL at T0, to 18 and 29 ng/μL at T1 and T2, respectively. 
The results of the Friedman test that compared the changes in Vitamin D levels across 
time confirmed that median posttest ranks were significantly higher than median pretest 
ranks (p = 0.000), with most pronounced increase taking place between T0 and T2 and 
between T1 and T2, as compared to between T0 and T1, as shown in post-hoc analysis. 
The increase in serum Vitamin D postsupplementation is consistent with findings from 
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Arpadi et al. (2009), Giacomet et al. (2013), Kakalia et al. (2011), and Van Den Bout- 
Van Den Beukel et al. (2008).  
Post-supplementation, paired t test was performed to assess changes in the 
immune parameters (CD4 count, CD4 percent, CD8 percent, and CD4/CD8 ratio) from 
baseline to T1, and from baseline to T2 (for the deficient/supplemented group only). The 
findings showed no statistically significant changes in the parameters at T1, except for a 
lower CD8 percent (p = 0.013). In general, a lower CD8 percent could be indicative of 
either an ongoing non-HIV related infection or to an increased risk for HIV progression 
or even for higher risk for mortality (Hellebergh et al., 2014). The mean CD4 count 
increased from 529.14 cells/μL at T0 to 550.02 cells/μL at T1 (p = 0.438). From baseline 
to T2, the increase in CD4 count was more evident by 57 units but failed to be 
statistically significant (CD4 count at T2: 586.48 cells/μL, p = 0.084). Similarly, the 
supplemented group did not show significant improvement in the CD4 percent, whereby 
the increase in CD4 percent from baseline was by one unit at each follow-up, T1 (28.10 ± 
10.36) and T2 (29.02 ± 10.79) postsupplementation (p > 0.05). A repeated measure 
ANOVA was conducted to test the overall change in the parameters within the 
supplemented subjects and across time (T0, T1, and T2). The findings indicated that 
Vitamin D supplementation had no effect on the immune parameters in question, CD4 
count (p = 0.168) and CD4 percent (p = 0.264), in the supplemented group.  
Upon comparing the supplemented group versus the nonsupplemented group, they 
still differed significantly on their Vitamin D level at T0 and at T1. Surprisingly, the 
nonsupplemented group showed better results in their Vitamin D medians and mean 
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ranks than the supplemented group at T1 (T0 mean ranks: 50.5 versus 21.5, and T1 mean 
ranks: 42.4 versus 25.4; p = 0.001). As for viral load, there was an increase in the 
proportion of participants who lowered their viral load to undetectable level or less than 
1000 copies/mL among the supplemented (from 50% at T0 to 69% at T1) as well as 
among the nonsupplemented (from 83% at T0 to 89% at T1); both groups differed at 
baseline, but did not differ statistically on viral load change at T1, p = 0.107. Lastly, 
ANCOVA test was performed to examine the effect of supplementation on HIV immune 
parameters through comparing changes in post-pre scores between supplemented and 
nonsupplemented groups, after controlling for baseline Vitamin D levels. The 
nonsupplemented group (n = 18) at T1 showed no statistically significant difference in 
their CD4 count and CD4 percent compared to baseline. Actually, 14 subjects (78%) of 
the nonsupplemented had a significant drop in their CD4 count at T1 from a median of 36 
(IQR = 11, range = 30 -70) at baseline to a median of 30 (IQR = 21, range = 18 -72) at 
T1, p = 0.022. However, the nonsupplemented group had an increase in their mean scores 
of CD4 count from 566.9 cells/μL (SD = 349.5) at baseline to 590.2 (SD = 335.2), which 
was not statistically significant (p = 0.216). Likewise, the increase in CD4 percent scores 
in the nonsupplemented group from 26.22 (SD = 13.1) to 27.22 (SD =10.7) at T1 did not 
yield statistical significance (p = 0.918). Overall, the results of ANCOVA failed to reject 
the null hypothesis of no statistically significant effect of Vitamin D supplementation on 
the main parameters of immune function, CD4 count and CD4 percent, in both groups.  
 The study hypothesized an improvement in the immune function of Vitamin D 
deficient HIV- infected participants following supplementation. However, the reported 
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findings of no effect on immune parameters resonate with results from previous studies, 
despite some differences in the methodological approaches. Kakalia et al. (2011) 
evaluated the impact of Vitamin D supplementation on CD4 count in 54 children with 
HIV (3-18 years old, mean age = 10.3 ± 3.9) in a randomized, non-blinded, controlled 
clinical trial. About 85% were deficient and 15% were sufficient; the majority was on 
ART, and had some preserved immunity (baseline mean CD4 count = 927 cells/μL ± 
468). The authors randomized the study population to three groups: placebo Group 1 (no 
supplementation), and two supplemented groups (800 IU/day for Group 2, and 1600 
IU/day for Group 3). Similar to the findings from the present study, supplementation 
significantly improved Vitamin D levels in supplemented groups (Vitamin D 
normalization increased from 17% to 39% in Group 2 and from 6% to 67% in Group 3) 
but not in the placebo group. However, the mean change in vitamin level from baseline to 
six months was not statistically significant in Group 3. On the other hand, similar to this 
study finding, Kakalia et al. (2011) failed to provide evidence of a significant impact of 
Vitamin D supplementation on CD4 count, CD4 percent, or viral load. The authors 
argued that because the study population had some preserved immunity at baseline, it was 
less likely for Vitamin D supplementation would exert more significant changes in their 
immune parameters; besides, the findings could not be generalized to a population with 
advanced HIV disease and more immune-compromised status. This explanation is also 




 Arpadi et al. (2009) evaluated a 12-month Vitamin D supplementation 
intervention in a randomized controlled study that recruited 56 HIV-infected children and 
split them into two groups: placebo (Vitamin D sufficient n = 27) and supplemented 
(Vitamin D deficient n = 9). Although the objective of the study was to evaluate the 
effect of bimonthly supplementation of 100,000 IU of Vitamin D on bone mass, the 
authors assessed changes in CD4 count and viral load and found no impact of 
supplementation on these parameters. Giacomet et al. (2013) also could not find 
significant changes in CD4 counts after supplementing a group of Vitamin D deficient 
children (n = 26) with 100,000 IU D3 administered every three months against a placebo 
group (n = 26) with comparable immune function and Vitamin D profiles at baseline. Just 
in keeping with Kakalia et al. (2011) and the present study, the fact that the study 
populations had some degree of preserved immunity could have underpowered the 
impact of supplementation on CD4 count/percent.  
Poowuttikul et al. (2013) study remains the closest to the present study in terms of 
design (retrospective chart review), population (N = 160 dark skinned HIV-infected 
patients with low Vitamin D), and geographic location (Detroit, Michigan). However, 
their study population was younger and consisted of children and young adults aged 2 to 
26 years who were recruited as part of routine clinical care. The authors used a cutoff 
point for Vitamin D deficiency/insufficiency at ≤ 35 ng/μL, where 152 had Vitamin D 
deficiency and received Vitamin D3 supplementation 1000 IU/day. Similar to this study, 
Poowuttikul et al. (2013) aimed to evaluate whether Vitamin D supplementation in HIV 
patients would improve the disease immune markers such as, CD4 count, CD4 percent, 
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and viral load. The changes in Vitamin D levels post-supplementation were statistically 
significant in the supplemented groups, whereby 39.5 percent (n = 60) reached 
normalization. On the other hand, the changes in CD4 count, CD4 percent, or viral load 
failed to reflect any significant effect of Vitamin D supplementation. A plausible 
explanation for this lack of supplementation effect could be that the study population had 
high pre-supplementation CD4 counts (M = 734 cells/μL ± 469.9) that did not 
significantly change post-supplementation (M = 702.3 cells/μL ± 446.7), p = 0.26. This is 
applicable to CD4 percent pre-post absolute change (p = 0.60) and to viral load (p = 
0.31). This study by Poowuttikul et al. (2013) provided similar insights concerning the 
effect of Vitamin D supplementation on the immune function of HIV patients. The 
following section discusses the limitations of the present study, some of which could be 
pertinent to the above-mentioned studies dealing with Vitamin D supplementation in 
HIV. 
Limitations of the Study 
There are some limitations that can explain why the study findings could not 
reach the intended statistical significance. First and foremost, the present study is 
observational and retrospective in nature; thus, it brings along some typical limitations 
that are applicable to this kind of design, such as: lacking control over the included 
variables; introducing selection bias (threat to internal validity) by including only patients 
with complete data; presenting threat to external validity through inability to generalize 
results to other subpopulations; failing to control for compliance issues; and lacking the 
ability to account for exposure variables (e.g., Vitamin D intake through diet or sunlight 
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exposure, or even using a multivitamin with Vitamin D). The sample consists of a 
convenience sample and it comes from a single-site clinic; the sample size could have 
been too small to have statistical power that can demonstrate the intended effect. Besides, 
this study, being retrospective and longitudinal, could not provide any guarantee with 
compliance to the supplementation regimen, the fact that could have influenced 
considerably the findings. Despite prescribing the same supplementation regimen (50,000 
IU/weekly of cholecalciferol or D3) to all study participants, it is hard to assume that all 
participants dispensed the same Vitamin D type (i.e., D3), especially that D2 is more 
commonly used in prescriptions but is less potent and has higher degradation than D3. It 
is noteworthy to mention that Vitamin D testing is expensive and this can impede routine 
checking for Vitamin D in clinical settings with poor resources (similar to the clinic in 
this study). This was evident in the inability of the researcher to include more patients in 
the sample size due to Vitamin D testing limitations and despite the high prevalence of 
Vitamin D deficiency among the HIV patients attending the clinic. Last but not least, this 
study did not account for the type of ART, knowing that some ART types are negatively 
implicated in Vitamin D deficiency (e.g., Efavirenz). It remains unclear though whether 
accounting for ART could have influenced the findings related to immune parameters. 
Recommendations 
Given the findings of this study, there is a need for large prospective longitudinal 
studies that take into account all the above-mentioned limitations. Multicenter studies 
could provide even more insights concerning the different HIV populations with high 
prevalence of Vitamin D deficiency. Randomized controlled trials (RCTs) that use 
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Vitamin D supplementation with appropriate doses (controlled intervention) are the only 
designs that can provide unbiased, evidence-based, and generalizable results pertained to 
the potential effect of supplementation on Vitamin D levels or immune function 
parameters in HIV. The controversial issue concerning the correlation between Vitamin 
D levels and CD4 count remains unsolved. Therefore, more studies should be undertaken 
to clearly establish the relationship between Vitamin D deficiency and CD4 not only in 
the context of evaluating supplementation but also in the context of highlighting the 
immune impact of Vitamin D, the potent immune-modulator targeting the CD4 cells in 
HIV. There are many studies that have demonstrated the overall health benefits of normal 
Vitamin D levels for general health and in multitude of diseases (Bischoff-Ferrari et al., 
2006; Holick, 2004, 2006, 2007; Holick et al., 2011; Holick & Chen, 2008; Hossein-
Nezhad & Holick, 2013). However, the variety in the recommendations for Vitamin D 
supplementation regimen could be responsible for the lack of consensus on the clinical 
efficacy of correcting Vitamin D deficiency in some populations, including HIV, and 
therefore, present an ongoing gap in the literature that need to be addressed in future 
studies. 
Implications 
This study recognized the importance of acknowledging and treating Vitamin D 
deficiency, a very common issue that is highly prevalent in the general population 
worldwide, as well as in the HIV subpopulation. The negative implications of Vitamin D 
deficiency in various chronic diseases discussed in the vast medical literature, besides 
HIV, have pinpointed to the importance of addressing and managing this easily 
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preventable condition. A general purpose of this study is to provide an eye-opener to an 
often-overlooked problem in routine HIV care, that of high prevalence of Vitamin D 
deficiency in African American HIV-infected patients. African Americans, being dark-
skinned, have an inherent biologic tendency to be Vitamin D deficient, the fact that puts 
them at a disadvantage and more prone for health problems as compared to other racial 
groups.  
In the context of HIV, Vitamin D has proved to be an immune-modulator and an 
immune response booster, and therefore, public health efforts should seek to educate the 
patients, the clinicians, the health policy makers, and the public on the significance of 
screening for and correcting the deficiency status, especially in view of the studies that 
linked Vitamin D deficiency to greater risk for disease progression or mortality. Although 
the evidence about the benefits or efficacy of Vitamin D supplementation on the immune 
function of HIV patients is still controversial, the knowledge on the risk factors and the 
negatives outcomes associated with Vitamin D deficiency in HIV are known and provide 
a solid platform to embrace good practices to manage this epidemic. A social change 
implication secondary to the findings of the study (whether significant or not) would be 
to acknowledge the need to modify the clinical approach in caring for HIV patients, in a 
way that make clinicians more aware of factors that contribute to HIV disease process 
(i.e., Vitamin D deficiency), notably in highly-impacted and high-risk populations such 
as African American patients. Vitamin D deficiency supplementation is a both cost-
effective and easy strategy that can dramatically impact the general health of the 
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population; needless to say, this overhaul encompasses healthy individuals to reach 
patients from all walks of life, including those with HIV.  
Conclusion 
Vitamin D deficiency remains a worldwide health problem that is often 
overlooked, and yet merits special acknowledgment in the health field because of its 
association with a variety of chronic diseases, including HIV. The literature has shown 
that, as compared to the general population, the HIV population seems to be more 
susceptible to Vitamin D deficiency and to its adverse effects. More specifically, the 
discovered immune-modulatory role of Vitamin D has kindled a series of studies that 
targeted HIV populations in an attempt to reduce HIV disease burden and halt disease 
progression towards AIDS. Since CD4 count presents an important immune function 
parameter in HIV, this retrospective observational study opted to examine the 
relationship between Vitamin D levels and CD4 count/percent and to examine the impact 
of Vitamin D supplementation (as part of routine care) on CD4 count/percent. The fact 
that this study could not find significant results should be viewed with some caution 
because it may imply that the study had inadequate power to test the relationship or to 
find an effect of Vitamin D supplementation on CD4. This remains an observational 
study with non-generalizable results secondary to selection bias of study population and 
to the inadequate sample size due to low eligibility of participants at study entrance; these 
limitations led to low statistical power that could have undermined the possibility of 
detecting any effect, besides potential increased type II error and inflated variance in the 
variables under study that could have influenced the results. However, while the data may 
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not be statistically significant in this current study, the theoretical framework should not 
be rejected altogether, rather should provide a valuable insight to be tested in large 
prospective longitudinal studies and RCTs that take into consideration feasibility and 
limitation issues to maximize their methodological rigor and extend an evidence-based 
knowledge in the field. The findings from this study could not establish enough bases for 
clinical relevance to market implementing Vitamin D testing and supplementation in 
routine HIV care; yet, this remains a challenge that is incumbent on future public health 
research endeavors to draw on all findings and limitations in order to tailor better suited 
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